date generated: 2024-02-26
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
x | |
---|---|
5_8S_rRNA | 3.8928494 |
7SK | 0.4717721 |
A1BG | 1.6651353 |
A1BG.AS1 | 0.1794742 |
A2M | 0.7123567 |
A2M.AS1 | 1.0831002 |
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genesets | 2612 |
num_genes_in_profile | 16432 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 8188 |
num_profile_genes_not_in_sets | 8244 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Here are some metrics about the gene sets used:
GMT file of genesets: ReactomePathways_2023-09-01.gmtGene sets metrics | |
---|---|
num_genesets | 2612 |
num_genesets_excluded | 1148 |
num_genesets_included | 1464 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Top N= 50 gene sets
## Warning in kable_styling(., "hover", full_width = FALSE): Please specify format
## in kable. kableExtra can customize either HTML or LaTeX outputs. See
## https://haozhu233.github.io/kableExtra/ for details.
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Eukaryotic Translation Elongation | 91 | 1.75e-32 | 0.719 | 5.13e-30 |
Peptide chain elongation | 87 | 1.19e-30 | 0.713 | 1.75e-28 |
Viral mRNA Translation | 87 | 4.76e-30 | 0.705 | 6.34e-28 |
Formation of a pool of free 40S subunits | 99 | 4.49e-32 | 0.685 | 8.21e-30 |
SARS-CoV-1 modulates host translation machinery | 36 | 1.35e-12 | 0.682 | 4.60e-11 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 1.43e-29 | 0.677 | 1.74e-27 |
Eukaryotic Translation Termination | 91 | 1.13e-28 | 0.673 | 1.18e-26 |
Formation of tubulin folding intermediates by CCT/TriC | 20 | 2.11e-07 | 0.670 | 3.40e-06 |
Selenocysteine synthesis | 91 | 3.37e-28 | 0.667 | 2.90e-26 |
L13a-mediated translational silencing of Ceruloplasmin expression | 109 | 2.15e-33 | 0.667 | 1.05e-30 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 110 | 7.05e-33 | 0.658 | 2.58e-30 |
Folding of actin by CCT/TriC | 10 | 3.84e-04 | 0.648 | 2.67e-03 |
SRP-dependent cotranslational protein targeting to membrane | 110 | 1.21e-31 | 0.645 | 1.96e-29 |
Prefoldin mediated transfer of substrate to CCT/TriC | 24 | 6.78e-08 | 0.636 | 1.38e-06 |
Formation of the ternary complex, and subsequently, the 43S complex | 51 | 4.10e-15 | 0.635 | 1.54e-13 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 99 | 1.17e-27 | 0.633 | 9.49e-26 |
Cap-dependent Translation Initiation | 117 | 3.73e-32 | 0.631 | 7.80e-30 |
Eukaryotic Translation Initiation | 117 | 3.73e-32 | 0.631 | 7.80e-30 |
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | 12 | 1.57e-04 | 0.630 | 1.21e-03 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 27 | 1.56e-08 | 0.629 | 3.81e-07 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 2.82e-16 | 0.615 | 1.18e-14 |
Translation initiation complex formation | 58 | 8.92e-16 | 0.610 | 3.53e-14 |
Ribosomal scanning and start codon recognition | 58 | 1.34e-15 | 0.606 | 5.17e-14 |
Josephin domain DUBs | 10 | 9.34e-04 | 0.604 | 5.88e-03 |
Selenoamino acid metabolism | 113 | 1.56e-28 | 0.603 | 1.52e-26 |
Glycogen synthesis | 12 | 4.83e-04 | 0.582 | 3.27e-03 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 4.79e-25 | 0.562 | 3.19e-23 |
Nonsense-Mediated Decay (NMD) | 113 | 4.79e-25 | 0.562 | 3.19e-23 |
TP53 Regulates Transcription of Death Receptors and Ligands | 10 | 2.52e-03 | 0.552 | 1.40e-02 |
Transport of connexons to the plasma membrane | 13 | 6.92e-04 | 0.543 | 4.52e-03 |
SARS-CoV-2 modulates host translation machinery | 49 | 1.07e-10 | 0.533 | 3.48e-09 |
Regulation of expression of SLITs and ROBOs | 162 | 4.60e-29 | 0.509 | 5.19e-27 |
Downregulation of ERBB2:ERBB3 signaling | 13 | 1.50e-03 | 0.508 | 8.73e-03 |
Keratan sulfate biosynthesis | 26 | 9.09e-06 | 0.503 | 9.17e-05 |
Membrane binding and targetting of GAG proteins | 14 | 1.25e-03 | 0.498 | 7.47e-03 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 1.25e-03 | 0.498 | 7.47e-03 |
E3 ubiquitin ligases ubiquitinate target proteins | 43 | 1.68e-08 | 0.497 | 4.03e-07 |
Diseases associated with glycosaminoglycan metabolism | 38 | 3.78e-07 | 0.476 | 5.33e-06 |
Chondroitin sulfate biosynthesis | 16 | 1.04e-03 | 0.474 | 6.37e-03 |
Ubiquitin-dependent degradation of Cyclin D | 50 | 1.11e-08 | 0.467 | 2.86e-07 |
Pexophagy | 11 | 7.34e-03 | 0.467 | 3.61e-02 |
ABC transporters in lipid homeostasis | 12 | 5.18e-03 | -0.466 | 2.72e-02 |
Assembly Of The HIV Virion | 16 | 1.28e-03 | 0.465 | 7.62e-03 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression | 11 | 7.88e-03 | 0.463 | 3.82e-02 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 6.33e-03 | -0.455 | 3.15e-02 |
Cellular response to starvation | 148 | 2.05e-21 | 0.452 | 1.11e-19 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 5.92e-08 | 0.452 | 1.22e-06 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 69 | 8.45e-11 | 0.452 | 2.81e-09 |
HSF1 activation | 25 | 1.04e-04 | 0.449 | 8.19e-04 |
Translation | 290 | 2.82e-39 | 0.447 | 4.13e-36 |
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Eukaryotic Translation Elongation | 91 | 1.75e-32 | 0.719000 | 5.13e-30 |
Peptide chain elongation | 87 | 1.19e-30 | 0.713000 | 1.75e-28 |
Viral mRNA Translation | 87 | 4.76e-30 | 0.705000 | 6.34e-28 |
Formation of a pool of free 40S subunits | 99 | 4.49e-32 | 0.685000 | 8.21e-30 |
SARS-CoV-1 modulates host translation machinery | 36 | 1.35e-12 | 0.682000 | 4.60e-11 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 1.43e-29 | 0.677000 | 1.74e-27 |
Eukaryotic Translation Termination | 91 | 1.13e-28 | 0.673000 | 1.18e-26 |
Formation of tubulin folding intermediates by CCT/TriC | 20 | 2.11e-07 | 0.670000 | 3.40e-06 |
Selenocysteine synthesis | 91 | 3.37e-28 | 0.667000 | 2.90e-26 |
L13a-mediated translational silencing of Ceruloplasmin expression | 109 | 2.15e-33 | 0.667000 | 1.05e-30 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 110 | 7.05e-33 | 0.658000 | 2.58e-30 |
Folding of actin by CCT/TriC | 10 | 3.84e-04 | 0.648000 | 2.67e-03 |
SRP-dependent cotranslational protein targeting to membrane | 110 | 1.21e-31 | 0.645000 | 1.96e-29 |
Prefoldin mediated transfer of substrate to CCT/TriC | 24 | 6.78e-08 | 0.636000 | 1.38e-06 |
Formation of the ternary complex, and subsequently, the 43S complex | 51 | 4.10e-15 | 0.635000 | 1.54e-13 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 99 | 1.17e-27 | 0.633000 | 9.49e-26 |
Cap-dependent Translation Initiation | 117 | 3.73e-32 | 0.631000 | 7.80e-30 |
Eukaryotic Translation Initiation | 117 | 3.73e-32 | 0.631000 | 7.80e-30 |
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | 12 | 1.57e-04 | 0.630000 | 1.21e-03 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 27 | 1.56e-08 | 0.629000 | 3.81e-07 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 2.82e-16 | 0.615000 | 1.18e-14 |
Translation initiation complex formation | 58 | 8.92e-16 | 0.610000 | 3.53e-14 |
Ribosomal scanning and start codon recognition | 58 | 1.34e-15 | 0.606000 | 5.17e-14 |
Josephin domain DUBs | 10 | 9.34e-04 | 0.604000 | 5.88e-03 |
Selenoamino acid metabolism | 113 | 1.56e-28 | 0.603000 | 1.52e-26 |
Glycogen synthesis | 12 | 4.83e-04 | 0.582000 | 3.27e-03 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 4.79e-25 | 0.562000 | 3.19e-23 |
Nonsense-Mediated Decay (NMD) | 113 | 4.79e-25 | 0.562000 | 3.19e-23 |
TP53 Regulates Transcription of Death Receptors and Ligands | 10 | 2.52e-03 | 0.552000 | 1.40e-02 |
Transport of connexons to the plasma membrane | 13 | 6.92e-04 | 0.543000 | 4.52e-03 |
SARS-CoV-2 modulates host translation machinery | 49 | 1.07e-10 | 0.533000 | 3.48e-09 |
Regulation of expression of SLITs and ROBOs | 162 | 4.60e-29 | 0.509000 | 5.19e-27 |
Downregulation of ERBB2:ERBB3 signaling | 13 | 1.50e-03 | 0.508000 | 8.73e-03 |
Keratan sulfate biosynthesis | 26 | 9.09e-06 | 0.503000 | 9.17e-05 |
Membrane binding and targetting of GAG proteins | 14 | 1.25e-03 | 0.498000 | 7.47e-03 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 1.25e-03 | 0.498000 | 7.47e-03 |
E3 ubiquitin ligases ubiquitinate target proteins | 43 | 1.68e-08 | 0.497000 | 4.03e-07 |
Diseases associated with glycosaminoglycan metabolism | 38 | 3.78e-07 | 0.476000 | 5.33e-06 |
Chondroitin sulfate biosynthesis | 16 | 1.04e-03 | 0.474000 | 6.37e-03 |
Ubiquitin-dependent degradation of Cyclin D | 50 | 1.11e-08 | 0.467000 | 2.86e-07 |
Pexophagy | 11 | 7.34e-03 | 0.467000 | 3.61e-02 |
ABC transporters in lipid homeostasis | 12 | 5.18e-03 | -0.466000 | 2.72e-02 |
Assembly Of The HIV Virion | 16 | 1.28e-03 | 0.465000 | 7.62e-03 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression | 11 | 7.88e-03 | 0.463000 | 3.82e-02 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 6.33e-03 | -0.455000 | 3.15e-02 |
Cellular response to starvation | 148 | 2.05e-21 | 0.452000 | 1.11e-19 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 5.92e-08 | 0.452000 | 1.22e-06 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 69 | 8.45e-11 | 0.452000 | 2.81e-09 |
HSF1 activation | 25 | 1.04e-04 | 0.449000 | 8.19e-04 |
Translation | 290 | 2.82e-39 | 0.447000 | 4.13e-36 |
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 48 | 9.13e-08 | 0.446000 | 1.76e-06 |
Influenza Viral RNA Transcription and Replication | 134 | 5.14e-19 | 0.446000 | 2.69e-17 |
Response of EIF2AK1 (HRI) to heme deficiency | 14 | 3.98e-03 | 0.444000 | 2.11e-02 |
PINK1-PRKN Mediated Mitophagy | 21 | 4.50e-04 | 0.442000 | 3.09e-03 |
Aggrephagy | 34 | 8.21e-06 | 0.442000 | 8.46e-05 |
Syndecan interactions | 26 | 9.74e-05 | 0.442000 | 7.79e-04 |
Autodegradation of the E3 ubiquitin ligase COP1 | 49 | 9.26e-08 | 0.441000 | 1.76e-06 |
ATF6 (ATF6-alpha) activates chaperones | 12 | 8.25e-03 | 0.440000 | 3.92e-02 |
AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 3.31e-08 | 0.439000 | 7.57e-07 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 64 | 1.88e-09 | 0.434000 | 5.38e-08 |
Defective CFTR causes cystic fibrosis | 58 | 1.08e-08 | 0.434000 | 2.81e-07 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 4.64e-08 | 0.434000 | 1.03e-06 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 49 | 1.51e-07 | 0.434000 | 2.57e-06 |
p53-Independent DNA Damage Response | 49 | 1.51e-07 | 0.434000 | 2.57e-06 |
p53-Independent G1/S DNA damage checkpoint | 49 | 1.51e-07 | 0.434000 | 2.57e-06 |
Gap junction assembly | 20 | 8.04e-04 | 0.433000 | 5.14e-03 |
Vif-mediated degradation of APOBEC3G | 52 | 7.05e-08 | 0.432000 | 1.41e-06 |
Regulation of ornithine decarboxylase (ODC) | 48 | 2.40e-07 | 0.431000 | 3.75e-06 |
Signaling by ROBO receptors | 201 | 7.20e-26 | 0.430000 | 5.27e-24 |
Major pathway of rRNA processing in the nucleolus and cytosol | 179 | 3.36e-23 | 0.430000 | 1.97e-21 |
ATF6 (ATF6-alpha) activates chaperone genes | 10 | 1.93e-02 | 0.427000 | 7.79e-02 |
Hh mutants are degraded by ERAD | 53 | 7.35e-08 | 0.427000 | 1.45e-06 |
DARPP-32 events | 21 | 7.00e-04 | 0.427000 | 4.55e-03 |
Hh mutants abrogate ligand secretion | 55 | 4.58e-08 | 0.426000 | 1.03e-06 |
Attenuation phase | 22 | 5.54e-04 | 0.425000 | 3.72e-03 |
rRNA processing in the nucleus and cytosol | 189 | 6.77e-24 | 0.425000 | 4.31e-22 |
Negative regulation of NOTCH4 signaling | 54 | 8.44e-08 | 0.421000 | 1.65e-06 |
Vpu mediated degradation of CD4 | 50 | 3.42e-07 | 0.417000 | 5.06e-06 |
Assembly and cell surface presentation of NMDA receptors | 30 | 8.12e-05 | 0.416000 | 6.57e-04 |
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 52 | 2.18e-07 | 0.416000 | 3.47e-06 |
Free fatty acids regulate insulin secretion | 10 | 2.32e-02 | -0.415000 | 8.89e-02 |
Regulation of RUNX3 expression and activity | 55 | 1.11e-07 | 0.414000 | 2.06e-06 |
Degradation of DVL | 54 | 1.57e-07 | 0.413000 | 2.64e-06 |
rRNA processing | 199 | 1.33e-23 | 0.412000 | 8.14e-22 |
Suppression of phagosomal maturation | 13 | 1.02e-02 | 0.411000 | 4.65e-02 |
Metabolism of polyamines | 56 | 1.18e-07 | 0.409000 | 2.14e-06 |
Packaging Of Telomere Ends | 12 | 1.41e-02 | 0.409000 | 6.10e-02 |
Synthesis, secretion, and deacylation of Ghrelin | 10 | 2.52e-02 | 0.409000 | 9.31e-02 |
Hedgehog ligand biogenesis | 60 | 4.85e-08 | 0.407000 | 1.06e-06 |
Influenza Infection | 153 | 3.82e-18 | 0.407000 | 1.86e-16 |
PI-3K cascade:FGFR3 | 12 | 1.55e-02 | 0.403000 | 6.57e-02 |
Stabilization of p53 | 54 | 2.95e-07 | 0.403000 | 4.50e-06 |
Dectin-1 mediated noncanonical NF-kB signaling | 58 | 1.13e-07 | 0.403000 | 2.07e-06 |
Formation of ATP by chemiosmotic coupling | 16 | 5.58e-03 | 0.400000 | 2.91e-02 |
Translesion Synthesis by POLH | 18 | 3.29e-03 | 0.400000 | 1.76e-02 |
Regulation of Apoptosis | 51 | 7.78e-07 | 0.400000 | 1.01e-05 |
Diseases associated with glycosylation precursor biosynthesis | 15 | 7.39e-03 | 0.400000 | 3.62e-02 |
Mucopolysaccharidoses | 11 | 2.21e-02 | -0.399000 | 8.59e-02 |
PI-3K cascade:FGFR4 | 11 | 2.26e-02 | 0.397000 | 8.74e-02 |
Protein ubiquitination | 63 | 5.14e-08 | 0.397000 | 1.09e-06 |
NIK–>noncanonical NF-kB signaling | 57 | 2.41e-07 | 0.396000 | 3.75e-06 |
STAT3 nuclear events downstream of ALK signaling | 10 | 3.09e-02 | 0.394000 | 1.09e-01 |
Cholesterol biosynthesis | 26 | 5.64e-04 | 0.391000 | 3.77e-03 |
Degradation of GLI2 by the proteasome | 57 | 3.51e-07 | 0.390000 | 5.08e-06 |
GLI3 is processed to GLI3R by the proteasome | 57 | 3.78e-07 | 0.389000 | 5.33e-06 |
Cellular response to hypoxia | 71 | 1.97e-08 | 0.385000 | 4.65e-07 |
SHC-mediated cascade:FGFR3 | 12 | 2.09e-02 | 0.385000 | 8.29e-02 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs | 69 | 3.27e-08 | 0.385000 | 7.57e-07 |
SCF-beta-TrCP mediated degradation of Emi1 | 53 | 1.48e-06 | 0.382000 | 1.80e-05 |
Budding and maturation of HIV virion | 27 | 5.91e-04 | 0.382000 | 3.93e-03 |
TP53 Regulates Transcription of Caspase Activators and Caspases | 10 | 3.73e-02 | -0.380000 | 1.25e-01 |
Mitochondrial translation elongation | 88 | 7.03e-10 | 0.380000 | 2.10e-08 |
Negative regulation of FGFR3 signaling | 23 | 1.62e-03 | 0.380000 | 9.34e-03 |
Keratan sulfate/keratin metabolism | 32 | 2.03e-04 | 0.380000 | 1.52e-03 |
Cross-presentation of soluble exogenous antigens (endosomes) | 46 | 8.93e-06 | 0.379000 | 9.13e-05 |
Regulation of BACH1 activity | 11 | 2.98e-02 | 0.378000 | 1.07e-01 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 15 | 1.13e-02 | 0.378000 | 5.04e-02 |
SHC-mediated cascade:FGFR4 | 11 | 3.04e-02 | 0.377000 | 1.08e-01 |
GRB2 events in EGFR signaling | 10 | 3.90e-02 | -0.377000 | 1.29e-01 |
SCF(Skp2)-mediated degradation of p27/p21 | 59 | 5.63e-07 | 0.377000 | 7.57e-06 |
Interleukin-7 signaling | 19 | 4.56e-03 | 0.376000 | 2.40e-02 |
Negative regulation of FGFR4 signaling | 22 | 2.30e-03 | 0.375000 | 1.30e-02 |
N-Glycan antennae elongation | 13 | 1.94e-02 | 0.375000 | 7.80e-02 |
Zinc transporters | 10 | 4.06e-02 | 0.374000 | 1.32e-01 |
Synthesis of PIPs at the Golgi membrane | 15 | 1.25e-02 | -0.372000 | 5.47e-02 |
TRAF3-dependent IRF activation pathway | 13 | 2.07e-02 | -0.371000 | 8.22e-02 |
TRAF6 mediated IRF7 activation | 15 | 1.30e-02 | -0.370000 | 5.65e-02 |
Mitophagy | 28 | 7.24e-04 | 0.369000 | 4.69e-03 |
Degradation of GLI1 by the proteasome | 57 | 1.57e-06 | 0.368000 | 1.88e-05 |
Mitochondrial translation termination | 88 | 2.49e-09 | 0.368000 | 7.00e-08 |
Degradation of AXIN | 53 | 3.67e-06 | 0.368000 | 4.07e-05 |
Interconversion of nucleotide di- and triphosphates | 27 | 1.01e-03 | 0.366000 | 6.25e-03 |
Activation of NF-kappaB in B cells | 65 | 3.55e-07 | 0.365000 | 5.09e-06 |
Degradation of beta-catenin by the destruction complex | 82 | 1.18e-08 | 0.364000 | 2.98e-07 |
NF-kB is activated and signals survival | 13 | 2.30e-02 | 0.364000 | 8.85e-02 |
Platelet Adhesion to exposed collagen | 11 | 3.81e-02 | 0.361000 | 1.27e-01 |
Keratan sulfate degradation | 13 | 2.42e-02 | 0.361000 | 9.07e-02 |
Endosomal Sorting Complex Required For Transport (ESCRT) | 30 | 6.26e-04 | 0.361000 | 4.13e-03 |
Orc1 removal from chromatin | 67 | 3.48e-07 | 0.360000 | 5.08e-06 |
FGFR2 mutant receptor activation | 23 | 2.82e-03 | 0.360000 | 1.55e-02 |
Sealing of the nuclear envelope (NE) by ESCRT-III | 23 | 2.91e-03 | 0.359000 | 1.58e-02 |
Purine catabolism | 13 | 2.54e-02 | 0.358000 | 9.34e-02 |
Mitochondrial translation initiation | 88 | 6.66e-09 | 0.358000 | 1.77e-07 |
Regulation of RUNX2 expression and activity | 69 | 2.91e-07 | 0.357000 | 4.48e-06 |
Downstream TCR signaling | 78 | 5.16e-08 | 0.357000 | 1.09e-06 |
Transcriptional regulation by RUNX3 | 93 | 2.90e-09 | 0.356000 | 8.01e-08 |
Asymmetric localization of PCP proteins | 61 | 1.50e-06 | 0.356000 | 1.82e-05 |
Intrinsic Pathway of Fibrin Clot Formation | 12 | 3.27e-02 | 0.356000 | 1.13e-01 |
SLBP independent Processing of Histone Pre-mRNAs | 10 | 5.25e-02 | 0.354000 | 1.58e-01 |
Regulation of PTEN stability and activity | 67 | 5.59e-07 | 0.354000 | 7.57e-06 |
Crosslinking of collagen fibrils | 14 | 2.20e-02 | 0.354000 | 8.58e-02 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 4.24e-02 | 0.353000 | 1.37e-01 |
Collagen chain trimerization | 36 | 2.70e-04 | 0.351000 | 1.97e-03 |
Selective autophagy | 71 | 3.23e-07 | 0.351000 | 4.83e-06 |
HSF1-dependent transactivation | 31 | 7.60e-04 | 0.349000 | 4.90e-03 |
Processing and activation of SUMO | 10 | 5.58e-02 | 0.349000 | 1.63e-01 |
Nuclear events mediated by NFE2L2 | 76 | 1.42e-07 | 0.349000 | 2.51e-06 |
Mitochondrial translation | 94 | 5.83e-09 | 0.348000 | 1.58e-07 |
Glycogen storage diseases | 13 | 3.08e-02 | 0.346000 | 1.09e-01 |
Collagen biosynthesis and modifying enzymes | 58 | 6.22e-06 | 0.343000 | 6.70e-05 |
Negative regulation of FGFR2 signaling | 24 | 3.77e-03 | 0.342000 | 2.01e-02 |
Smooth Muscle Contraction | 35 | 4.79e-04 | 0.341000 | 3.26e-03 |
Autodegradation of Cdh1 by Cdh1:APC/C | 64 | 2.40e-06 | 0.341000 | 2.75e-05 |
APC/C:Cdc20 mediated degradation of Securin | 66 | 1.71e-06 | 0.341000 | 1.98e-05 |
Integrin cell surface interactions | 70 | 8.73e-07 | 0.340000 | 1.12e-05 |
p53-Dependent G1 DNA Damage Response | 62 | 3.67e-06 | 0.340000 | 4.07e-05 |
p53-Dependent G1/S DNA damage checkpoint | 62 | 3.67e-06 | 0.340000 | 4.07e-05 |
Late endosomal microautophagy | 32 | 9.35e-04 | 0.338000 | 5.88e-03 |
Activation of AMPK downstream of NMDARs | 20 | 9.00e-03 | 0.337000 | 4.21e-02 |
ABC transporter disorders | 68 | 1.64e-06 | 0.336000 | 1.92e-05 |
Regulation of FZD by ubiquitination | 15 | 2.48e-02 | 0.335000 | 9.22e-02 |
TRP channels | 20 | 9.76e-03 | -0.334000 | 4.47e-02 |
Glycogen metabolism | 23 | 5.72e-03 | 0.333000 | 2.94e-02 |
SHC1 events in EGFR signaling | 11 | 5.61e-02 | -0.333000 | 1.64e-01 |
PI-3K cascade:FGFR2 | 13 | 3.87e-02 | 0.331000 | 1.28e-01 |
MASTL Facilitates Mitotic Progression | 10 | 6.97e-02 | 0.331000 | 1.95e-01 |
Signaling by FGFR2 IIIa TM | 18 | 1.50e-02 | 0.331000 | 6.42e-02 |
G1/S DNA Damage Checkpoints | 63 | 5.50e-06 | 0.331000 | 5.96e-05 |
RAS processing | 21 | 8.74e-03 | 0.331000 | 4.10e-02 |
Post-chaperonin tubulin folding pathway | 17 | 1.86e-02 | 0.330000 | 7.60e-02 |
Dectin-2 family | 14 | 3.30e-02 | -0.329000 | 1.13e-01 |
Metalloprotease DUBs | 19 | 1.30e-02 | 0.329000 | 5.65e-02 |
Lysine catabolism | 11 | 5.89e-02 | -0.329000 | 1.70e-01 |
Somitogenesis | 50 | 5.83e-05 | 0.329000 | 4.93e-04 |
Defective B3GALT6 causes EDSP2 and SEMDJL1 | 17 | 1.91e-02 | 0.328000 | 7.73e-02 |
Downstream signaling events of B Cell Receptor (BCR) | 78 | 6.26e-07 | 0.326000 | 8.33e-06 |
Transcriptional regulation of pluripotent stem cells | 16 | 2.40e-02 | 0.326000 | 9.06e-02 |
rRNA modification in the nucleus and cytosol | 59 | 1.57e-05 | 0.325000 | 1.49e-04 |
COPI-mediated anterograde transport | 89 | 1.26e-07 | 0.324000 | 2.25e-06 |
Chaperone Mediated Autophagy | 20 | 1.24e-02 | 0.323000 | 5.44e-02 |
Activation of Matrix Metalloproteinases | 21 | 1.04e-02 | 0.323000 | 4.72e-02 |
Cristae formation | 29 | 2.67e-03 | 0.322000 | 1.48e-02 |
Defective Intrinsic Pathway for Apoptosis | 21 | 1.07e-02 | 0.322000 | 4.81e-02 |
Anchoring fibril formation | 11 | 6.56e-02 | 0.321000 | 1.86e-01 |
MAPK6/MAPK4 signaling | 83 | 5.02e-07 | 0.319000 | 6.87e-06 |
The canonical retinoid cycle in rods (twilight vision) | 10 | 8.08e-02 | -0.319000 | 2.14e-01 |
Non-integrin membrane-ECM interactions | 53 | 6.00e-05 | 0.319000 | 5.04e-04 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 82 | 6.69e-07 | 0.318000 | 8.82e-06 |
Collagen degradation | 50 | 1.03e-04 | 0.317000 | 8.19e-04 |
Defective B4GALT7 causes EDS, progeroid type | 17 | 2.36e-02 | 0.317000 | 8.99e-02 |
CS/DS degradation | 11 | 6.90e-02 | 0.317000 | 1.93e-01 |
Beta-catenin phosphorylation cascade | 17 | 2.40e-02 | 0.316000 | 9.06e-02 |
SHC-mediated cascade:FGFR2 | 13 | 4.98e-02 | 0.314000 | 1.54e-01 |
Complex I biogenesis | 51 | 1.05e-04 | 0.314000 | 8.26e-04 |
Translesion synthesis by REV1 | 16 | 2.98e-02 | 0.314000 | 1.07e-01 |
Defective B3GAT3 causes JDSSDHD | 17 | 2.53e-02 | 0.313000 | 9.31e-02 |
The phototransduction cascade | 18 | 2.15e-02 | 0.313000 | 8.40e-02 |
NGF-stimulated transcription | 35 | 1.36e-03 | 0.313000 | 7.99e-03 |
Assembly of the pre-replicative complex | 88 | 4.32e-07 | 0.312000 | 5.97e-06 |
Cleavage of the damaged purine | 15 | 3.66e-02 | 0.312000 | 1.23e-01 |
Depurination | 15 | 3.66e-02 | 0.312000 | 1.23e-01 |
Recognition and association of DNA glycosylase with site containing an affected purine | 15 | 3.66e-02 | 0.312000 | 1.23e-01 |
Gluconeogenesis | 27 | 5.24e-03 | 0.310000 | 2.74e-02 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 3.28e-03 | 0.310000 | 1.76e-02 |
CDK-mediated phosphorylation and removal of Cdc6 | 70 | 7.30e-06 | 0.310000 | 7.74e-05 |
Collagen formation | 78 | 2.50e-06 | 0.308000 | 2.83e-05 |
Cytochrome c-mediated apoptotic response | 13 | 5.45e-02 | -0.308000 | 1.62e-01 |
ERBB2 Activates PTK6 Signaling | 11 | 7.74e-02 | -0.307000 | 2.10e-01 |
RHO GTPases activate IQGAPs | 23 | 1.07e-02 | 0.307000 | 4.81e-02 |
Synthesis of PE | 12 | 6.62e-02 | -0.306000 | 1.87e-01 |
MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 3.48e-02 | 0.305000 | 1.18e-01 |
COPI-independent Golgi-to-ER retrograde traffic | 44 | 4.79e-04 | 0.304000 | 3.26e-03 |
Phase 4 - resting membrane potential | 11 | 8.17e-02 | 0.303000 | 2.16e-01 |
FRS-mediated FGFR3 signaling | 14 | 4.97e-02 | 0.303000 | 1.54e-01 |
Mitochondrial iron-sulfur cluster biogenesis | 13 | 5.88e-02 | 0.303000 | 1.70e-01 |
Regulation of RAS by GAPs | 65 | 2.50e-05 | 0.302000 | 2.28e-04 |
Formation of Fibrin Clot (Clotting Cascade) | 19 | 2.27e-02 | 0.302000 | 8.77e-02 |
Interleukin-4 and Interleukin-13 signaling | 86 | 1.31e-06 | 0.302000 | 1.63e-05 |
GAB1 signalosome | 14 | 5.07e-02 | -0.302000 | 1.54e-01 |
Inhibition of DNA recombination at telomere | 26 | 8.03e-03 | 0.300000 | 3.85e-02 |
Downregulation of TGF-beta receptor signaling | 26 | 8.20e-03 | 0.300000 | 3.92e-02 |
Assembly of collagen fibrils and other multimeric structures | 52 | 2.00e-04 | 0.298000 | 1.50e-03 |
Translation of Replicase and Assembly of the Replication Transcription Complex 9679504 | 12 | 7.50e-02 | 0.297000 | 2.04e-01 |
MECP2 regulates neuronal receptors and channels | 14 | 5.48e-02 | 0.297000 | 1.62e-01 |
Cargo concentration in the ER | 28 | 6.77e-03 | 0.296000 | 3.35e-02 |
Post-translational protein phosphorylation | 74 | 1.11e-05 | 0.296000 | 1.10e-04 |
Cytosolic tRNA aminoacylation | 24 | 1.23e-02 | 0.295000 | 5.39e-02 |
KEAP1-NFE2L2 pathway | 101 | 2.99e-07 | 0.295000 | 4.51e-06 |
Incretin synthesis, secretion, and inactivation | 12 | 7.83e-02 | 0.294000 | 2.11e-01 |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 12 | 7.83e-02 | 0.294000 | 2.11e-01 |
Inactivation, recovery and regulation of the phototransduction cascade | 17 | 3.71e-02 | 0.292000 | 1.25e-01 |
Protein methylation | 15 | 5.03e-02 | 0.292000 | 1.54e-01 |
FCERI mediated NF-kB activation | 79 | 7.51e-06 | 0.292000 | 7.86e-05 |
Pausing and recovery of Tat-mediated HIV elongation | 30 | 5.72e-03 | 0.292000 | 2.94e-02 |
Tat-mediated HIV elongation arrest and recovery | 30 | 5.72e-03 | 0.292000 | 2.94e-02 |
Respiratory electron transport | 93 | 1.31e-06 | 0.290000 | 1.63e-05 |
LGI-ADAM interactions | 10 | 1.12e-01 | -0.290000 | 2.61e-01 |
FRS-mediated FGFR4 signaling | 13 | 7.03e-02 | 0.290000 | 1.96e-01 |
Antimicrobial peptides | 23 | 1.65e-02 | 0.289000 | 6.83e-02 |
Metabolism of amino acids and derivatives | 311 | 2.42e-18 | 0.288000 | 1.22e-16 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 4.00e-02 | 0.288000 | 1.31e-01 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 4.00e-02 | 0.288000 | 1.31e-01 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 70 | 3.60e-05 | 0.286000 | 3.14e-04 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 70 | 3.60e-05 | 0.286000 | 3.14e-04 |
Synthesis of PIPs at the early endosome membrane | 16 | 4.81e-02 | -0.285000 | 1.51e-01 |
Transcriptional regulation by RUNX2 | 112 | 1.85e-07 | 0.285000 | 3.04e-06 |
Pentose phosphate pathway | 13 | 7.50e-02 | 0.285000 | 2.04e-01 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 71 | 3.28e-05 | 0.285000 | 2.89e-04 |
Switching of origins to a post-replicative state | 88 | 3.84e-06 | 0.285000 | 4.23e-05 |
ECM proteoglycans | 58 | 1.85e-04 | 0.284000 | 1.40e-03 |
TCF dependent signaling in response to WNT | 155 | 1.20e-09 | 0.283000 | 3.50e-08 |
Chaperonin-mediated protein folding | 76 | 2.02e-05 | 0.283000 | 1.86e-04 |
Spry regulation of FGF signaling | 16 | 5.01e-02 | 0.283000 | 1.54e-01 |
Initiation of Nuclear Envelope (NE) Reformation | 19 | 3.32e-02 | 0.282000 | 1.14e-01 |
APC/C:Cdc20 mediated degradation of mitotic proteins | 72 | 3.68e-05 | 0.281000 | 3.18e-04 |
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 21 | 2.57e-02 | 0.281000 | 9.44e-02 |
Metal ion SLC transporters | 18 | 3.97e-02 | 0.280000 | 1.31e-01 |
p75NTR signals via NF-kB | 16 | 5.28e-02 | 0.280000 | 1.59e-01 |
ER to Golgi Anterograde Transport | 138 | 1.48e-08 | 0.279000 | 3.68e-07 |
Gastrin-CREB signalling pathway via PKC and MAPK | 16 | 5.35e-02 | -0.279000 | 1.60e-01 |
Assembly of active LPL and LIPC lipase complexes | 11 | 1.10e-01 | 0.278000 | 2.59e-01 |
Gamma carboxylation, hypusine formation and arylsulfatase activation | 32 | 6.51e-03 | 0.278000 | 3.23e-02 |
Signaling by NOTCH4 | 81 | 1.57e-05 | 0.278000 | 1.49e-04 |
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 10 | 1.29e-01 | 0.277000 | 2.94e-01 |
Translesion synthesis by POLK | 17 | 4.84e-02 | 0.277000 | 1.51e-01 |
Cyclin E associated events during G1/S transition | 81 | 1.72e-05 | 0.276000 | 1.61e-04 |
PCP/CE pathway | 86 | 9.69e-06 | 0.276000 | 9.72e-05 |
Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 11 | 1.13e-01 | 0.276000 | 2.63e-01 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 113 | 4.16e-07 | 0.276000 | 5.81e-06 |
Mitochondrial protein import | 63 | 1.55e-04 | 0.276000 | 1.20e-03 |
Metabolism of fat-soluble vitamins | 32 | 7.13e-03 | 0.275000 | 3.51e-02 |
UCH proteinases | 85 | 1.22e-05 | 0.275000 | 1.19e-04 |
Biosynthesis of DHA-derived SPMs | 12 | 1.01e-01 | -0.274000 | 2.45e-01 |
Hedgehog ‘on’ state | 82 | 1.93e-05 | 0.273000 | 1.80e-04 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 11 | 1.18e-01 | 0.273000 | 2.71e-01 |
TICAM1-dependent activation of IRF3/IRF7 | 12 | 1.03e-01 | 0.272000 | 2.49e-01 |
Translation of Replicase and Assembly of the Replication Transcription Complex 9694676 | 13 | 9.22e-02 | 0.270000 | 2.32e-01 |
Metabolism of Angiotensinogen to Angiotensins | 13 | 9.27e-02 | 0.269000 | 2.32e-01 |
ERBB2 Regulates Cell Motility | 13 | 9.33e-02 | -0.269000 | 2.33e-01 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 73 | 7.35e-05 | 0.268000 | 6.12e-04 |
Interleukin-1 signaling | 107 | 1.64e-06 | 0.268000 | 1.92e-05 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 18 | 4.90e-02 | 0.268000 | 1.52e-01 |
Neurodegenerative Diseases | 18 | 4.90e-02 | 0.268000 | 1.52e-01 |
SARS-CoV-1-host interactions | 94 | 7.24e-06 | 0.268000 | 7.74e-05 |
Formation of the beta-catenin:TCF transactivating complex | 35 | 6.16e-03 | 0.268000 | 3.10e-02 |
Inwardly rectifying K+ channels | 22 | 2.99e-02 | 0.267000 | 1.07e-01 |
Mismatch Repair | 14 | 8.38e-02 | 0.267000 | 2.19e-01 |
Caspase-mediated cleavage of cytoskeletal proteins | 12 | 1.10e-01 | -0.267000 | 2.58e-01 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 32 | 9.23e-03 | 0.266000 | 4.29e-02 |
Iron uptake and transport | 53 | 8.80e-04 | 0.264000 | 5.60e-03 |
SARS-CoV-2 modulates autophagy | 11 | 1.31e-01 | -0.263000 | 2.97e-01 |
Inactivation of CSF3 (G-CSF) signaling | 24 | 2.65e-02 | 0.262000 | 9.68e-02 |
Regulation of mRNA stability by proteins that bind AU-rich elements | 87 | 2.59e-05 | 0.261000 | 2.34e-04 |
NPAS4 regulates expression of target genes | 18 | 5.58e-02 | 0.260000 | 1.63e-01 |
Association of TriC/CCT with target proteins during biosynthesis | 35 | 7.75e-03 | 0.260000 | 3.77e-02 |
Response of Mtb to phagocytosis | 23 | 3.09e-02 | 0.260000 | 1.09e-01 |
Elastic fibre formation | 40 | 4.45e-03 | 0.260000 | 2.35e-02 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 3.10e-02 | 0.260000 | 1.09e-01 |
The activation of arylsulfatases | 10 | 1.57e-01 | 0.258000 | 3.37e-01 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane | 27 | 2.06e-02 | 0.257000 | 8.21e-02 |
Cyclin A:Cdk2-associated events at S phase entry | 83 | 5.11e-05 | 0.257000 | 4.38e-04 |
HIV elongation arrest and recovery | 32 | 1.18e-02 | 0.257000 | 5.22e-02 |
Pausing and recovery of HIV elongation | 32 | 1.18e-02 | 0.257000 | 5.22e-02 |
Senescence-Associated Secretory Phenotype (SASP) | 55 | 9.77e-04 | 0.257000 | 6.09e-03 |
Autophagy | 138 | 1.91e-07 | 0.257000 | 3.10e-06 |
DNA Replication Pre-Initiation | 102 | 7.52e-06 | 0.257000 | 7.86e-05 |
Chondroitin sulfate/dermatan sulfate metabolism | 44 | 3.22e-03 | 0.257000 | 1.73e-02 |
Lewis blood group biosynthesis | 10 | 1.60e-01 | 0.257000 | 3.42e-01 |
CLEC7A (Dectin-1) signaling | 95 | 1.62e-05 | 0.256000 | 1.53e-04 |
Unwinding of DNA | 11 | 1.42e-01 | 0.256000 | 3.15e-01 |
TNFR2 non-canonical NF-kB pathway | 85 | 5.69e-05 | 0.253000 | 4.84e-04 |
Activation of BAD and translocation to mitochondria | 15 | 9.16e-02 | 0.252000 | 2.32e-01 |
NFE2L2 regulating anti-oxidant/detoxification enzymes | 14 | 1.03e-01 | 0.252000 | 2.49e-01 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 13 | 1.17e-01 | 0.251000 | 2.70e-01 |
TCR signaling | 97 | 2.00e-05 | 0.251000 | 1.85e-04 |
Metabolism of cofactors | 18 | 6.60e-02 | 0.250000 | 1.87e-01 |
Signaling by FGFR4 | 32 | 1.51e-02 | 0.248000 | 6.44e-02 |
CLEC7A (Dectin-1) induces NFAT activation | 11 | 1.55e-01 | 0.248000 | 3.33e-01 |
Protein folding | 82 | 1.09e-04 | 0.247000 | 8.55e-04 |
COPI-dependent Golgi-to-ER retrograde traffic | 85 | 8.19e-05 | 0.247000 | 6.59e-04 |
FRS-mediated FGFR2 signaling | 15 | 9.76e-02 | 0.247000 | 2.41e-01 |
Cellular responses to stimuli | 696 | 2.20e-28 | 0.247000 | 2.01e-26 |
CTNNB1 S33 mutants aren’t phosphorylated | 15 | 9.85e-02 | 0.246000 | 2.41e-01 |
CTNNB1 S37 mutants aren’t phosphorylated | 15 | 9.85e-02 | 0.246000 | 2.41e-01 |
CTNNB1 S45 mutants aren’t phosphorylated | 15 | 9.85e-02 | 0.246000 | 2.41e-01 |
CTNNB1 T41 mutants aren’t phosphorylated | 15 | 9.85e-02 | 0.246000 | 2.41e-01 |
Signaling by CTNNB1 phospho-site mutants | 15 | 9.85e-02 | 0.246000 | 2.41e-01 |
Signaling by GSK3beta mutants | 15 | 9.85e-02 | 0.246000 | 2.41e-01 |
Pyrimidine salvage | 10 | 1.77e-01 | 0.246000 | 3.70e-01 |
Hedgehog ‘off’ state | 105 | 1.39e-05 | 0.246000 | 1.33e-04 |
Dopamine Neurotransmitter Release Cycle | 19 | 6.43e-02 | 0.245000 | 1.83e-01 |
Signaling by ALK | 27 | 2.76e-02 | 0.245000 | 1.00e-01 |
Signaling by FGFR3 in disease | 16 | 9.04e-02 | 0.245000 | 2.29e-01 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 33 | 1.60e-02 | -0.242000 | 6.70e-02 |
Calnexin/calreticulin cycle | 26 | 3.26e-02 | 0.242000 | 1.13e-01 |
Peroxisomal lipid metabolism | 26 | 3.27e-02 | -0.242000 | 1.13e-01 |
Translesion synthesis by POLI | 17 | 8.42e-02 | 0.242000 | 2.19e-01 |
Transport to the Golgi and subsequent modification | 163 | 1.07e-07 | 0.241000 | 2.00e-06 |
Cellular responses to stress | 687 | 7.54e-27 | 0.241000 | 5.81e-25 |
Extracellular matrix organization | 242 | 1.26e-10 | 0.240000 | 3.91e-09 |
Signaling by FGFR3 | 34 | 1.55e-02 | 0.240000 | 6.57e-02 |
RNA Polymerase III Chain Elongation | 18 | 7.91e-02 | 0.239000 | 2.13e-01 |
Processing of Intronless Pre-mRNAs | 20 | 6.47e-02 | -0.239000 | 1.84e-01 |
Macroautophagy | 124 | 4.80e-06 | 0.238000 | 5.25e-05 |
Regulation of APC/C activators between G1/S and early anaphase | 78 | 2.88e-04 | 0.238000 | 2.08e-03 |
PTEN Regulation | 137 | 1.62e-06 | 0.238000 | 1.92e-05 |
Biosynthesis of specialized proresolving mediators (SPMs) | 14 | 1.25e-01 | -0.237000 | 2.86e-01 |
Retinoid metabolism and transport | 29 | 2.76e-02 | 0.236000 | 1.00e-01 |
Formation of paraxial mesoderm | 63 | 1.18e-03 | 0.236000 | 7.16e-03 |
NR1H2 and NR1H3-mediated signaling | 40 | 9.73e-03 | -0.236000 | 4.47e-02 |
Ras activation upon Ca2+ influx through NMDA receptor | 14 | 1.26e-01 | 0.236000 | 2.89e-01 |
Negative regulation of FGFR1 signaling | 25 | 4.16e-02 | 0.235000 | 1.35e-01 |
Alpha-protein kinase 1 signaling pathway | 11 | 1.77e-01 | 0.235000 | 3.70e-01 |
Scavenging of heme from plasma | 10 | 2.00e-01 | 0.234000 | 4.01e-01 |
Golgi-to-ER retrograde transport | 118 | 1.12e-05 | 0.234000 | 1.11e-04 |
A tetrasaccharide linker sequence is required for GAG synthesis | 21 | 6.36e-02 | 0.234000 | 1.81e-01 |
mTORC1-mediated signalling | 24 | 4.79e-02 | 0.233000 | 1.50e-01 |
Signaling by the B Cell Receptor (BCR) | 107 | 3.14e-05 | 0.233000 | 2.79e-04 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 13 | 1.46e-01 | 0.233000 | 3.21e-01 |
ER-Phagosome pathway | 79 | 3.53e-04 | 0.233000 | 2.48e-03 |
Gastrulation | 85 | 2.17e-04 | 0.232000 | 1.60e-03 |
Cyclin D associated events in G1 | 47 | 6.13e-03 | 0.231000 | 3.10e-02 |
G1 Phase | 47 | 6.13e-03 | 0.231000 | 3.10e-02 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 1.81e-02 | 0.231000 | 7.43e-02 |
NRIF signals cell death from the nucleus | 16 | 1.10e-01 | 0.231000 | 2.59e-01 |
TGF-beta receptor signaling activates SMADs | 45 | 7.43e-03 | 0.231000 | 3.62e-02 |
Infection with Mycobacterium tuberculosis | 27 | 3.86e-02 | 0.230000 | 1.28e-01 |
TICAM1, RIP1-mediated IKK complex recruitment | 19 | 8.33e-02 | 0.230000 | 2.18e-01 |
Dissolution of Fibrin Clot | 10 | 2.09e-01 | 0.229000 | 4.11e-01 |
Paracetamol ADME | 19 | 8.41e-02 | -0.229000 | 2.19e-01 |
Receptor-type tyrosine-protein phosphatases | 12 | 1.71e-01 | 0.228000 | 3.59e-01 |
Gap junction trafficking | 31 | 2.81e-02 | 0.228000 | 1.01e-01 |
Transcriptional regulation by RUNX1 | 159 | 7.21e-07 | 0.228000 | 9.42e-06 |
AKT phosphorylates targets in the nucleus | 10 | 2.14e-01 | 0.227000 | 4.14e-01 |
EGR2 and SOX10-mediated initiation of Schwann cell myelination | 23 | 6.02e-02 | 0.226000 | 1.73e-01 |
Signaling by FGFR2 in disease | 33 | 2.47e-02 | 0.226000 | 9.22e-02 |
Downstream signaling of activated FGFR3 | 19 | 8.84e-02 | 0.226000 | 2.26e-01 |
Nervous system development | 499 | 7.33e-18 | 0.226000 | 3.46e-16 |
Asparagine N-linked glycosylation | 276 | 1.19e-10 | 0.226000 | 3.78e-09 |
Long-term potentiation | 17 | 1.08e-01 | 0.225000 | 2.54e-01 |
Sema4D induced cell migration and growth-cone collapse | 19 | 8.89e-02 | 0.225000 | 2.26e-01 |
Regulation of localization of FOXO transcription factors | 12 | 1.77e-01 | 0.225000 | 3.70e-01 |
Unfolded Protein Response (UPR) | 90 | 2.28e-04 | 0.225000 | 1.67e-03 |
Uptake and function of anthrax toxins | 11 | 1.97e-01 | 0.225000 | 3.96e-01 |
Regulation of TP53 Expression and Degradation | 36 | 1.97e-02 | 0.225000 | 7.92e-02 |
Cellular response to chemical stress | 183 | 1.71e-07 | 0.224000 | 2.84e-06 |
Axon guidance | 479 | 5.69e-17 | 0.224000 | 2.45e-15 |
FOXO-mediated transcription of cell cycle genes | 15 | 1.34e-01 | 0.224000 | 3.01e-01 |
The citric acid (TCA) cycle and respiratory electron transport | 160 | 1.14e-06 | 0.223000 | 1.44e-05 |
IRAK2 mediated activation of TAK1 complex | 10 | 2.24e-01 | 0.222000 | 4.29e-01 |
RHO GTPases activate PKNs | 36 | 2.14e-02 | 0.222000 | 8.40e-02 |
Apoptotic factor-mediated response | 20 | 8.80e-02 | -0.220000 | 2.26e-01 |
Formation of WDR5-containing histone-modifying complexes | 42 | 1.39e-02 | -0.219000 | 6.01e-02 |
Nucleotide salvage | 21 | 8.26e-02 | 0.219000 | 2.17e-01 |
Formation of apoptosome | 11 | 2.10e-01 | -0.218000 | 4.11e-01 |
Regulation of the apoptosome activity | 11 | 2.10e-01 | -0.218000 | 4.11e-01 |
MET activates PTK2 signaling | 30 | 3.87e-02 | 0.218000 | 1.28e-01 |
IRE1alpha activates chaperones | 49 | 8.31e-03 | 0.218000 | 3.94e-02 |
Beta-oxidation of very long chain fatty acids | 10 | 2.34e-01 | -0.218000 | 4.39e-01 |
SARS-CoV-1 Infection | 136 | 1.29e-05 | 0.217000 | 1.26e-04 |
Signaling by FLT3 ITD and TKD mutants | 15 | 1.47e-01 | 0.216000 | 3.21e-01 |
Laminin interactions | 27 | 5.19e-02 | 0.216000 | 1.57e-01 |
Gap junction trafficking and regulation | 33 | 3.20e-02 | 0.216000 | 1.11e-01 |
Transport of Ribonucleoproteins into the Host Nucleus | 32 | 3.48e-02 | -0.216000 | 1.18e-01 |
COPII-mediated vesicle transport | 63 | 3.11e-03 | 0.215000 | 1.68e-02 |
Mitotic G1 phase and G1/S transition | 143 | 8.98e-06 | 0.215000 | 9.13e-05 |
Regulation of TP53 Degradation | 35 | 2.77e-02 | 0.215000 | 1.00e-01 |
Metabolism of nucleotides | 80 | 9.01e-04 | 0.215000 | 5.71e-03 |
Detoxification of Reactive Oxygen Species | 33 | 3.30e-02 | 0.215000 | 1.13e-01 |
Synthesis of DNA | 116 | 6.73e-05 | 0.214000 | 5.63e-04 |
Transferrin endocytosis and recycling | 27 | 5.45e-02 | 0.214000 | 1.62e-01 |
Base-Excision Repair, AP Site Formation | 22 | 8.26e-02 | 0.214000 | 2.17e-01 |
Acyl chain remodelling of PI | 10 | 2.42e-01 | 0.214000 | 4.47e-01 |
Nuclear Pore Complex (NPC) Disassembly | 36 | 2.70e-02 | -0.213000 | 9.83e-02 |
NS1 Mediated Effects on Host Pathways | 40 | 1.99e-02 | -0.213000 | 7.98e-02 |
GRB2 events in ERBB2 signaling | 14 | 1.69e-01 | -0.212000 | 3.56e-01 |
Downstream signaling of activated FGFR4 | 18 | 1.19e-01 | 0.212000 | 2.74e-01 |
IL-6-type cytokine receptor ligand interactions | 12 | 2.03e-01 | 0.212000 | 4.06e-01 |
Cellular hexose transport | 13 | 1.86e-01 | -0.212000 | 3.83e-01 |
Formation of RNA Pol II elongation complex | 56 | 6.18e-03 | 0.212000 | 3.10e-02 |
RNA Polymerase II Transcription Elongation | 56 | 6.18e-03 | 0.212000 | 3.10e-02 |
RHO GTPases activate PAKs | 20 | 1.02e-01 | 0.211000 | 2.46e-01 |
Trafficking and processing of endosomal TLR | 12 | 2.07e-01 | -0.210000 | 4.11e-01 |
Cleavage of the damaged pyrimidine | 20 | 1.05e-01 | 0.209000 | 2.51e-01 |
Depyrimidination | 20 | 1.05e-01 | 0.209000 | 2.51e-01 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 20 | 1.05e-01 | 0.209000 | 2.51e-01 |
Nuclear Envelope (NE) Reassembly | 67 | 3.08e-03 | 0.209000 | 1.67e-02 |
Negative regulation of MAPK pathway | 41 | 2.13e-02 | 0.208000 | 8.39e-02 |
Transport of bile salts and organic acids, metal ions and amine compounds | 45 | 1.59e-02 | 0.208000 | 6.69e-02 |
Heme biosynthesis | 13 | 1.95e-01 | 0.207000 | 3.95e-01 |
Signaling by Hedgehog | 139 | 2.51e-05 | 0.207000 | 2.28e-04 |
Interleukin-6 family signaling | 18 | 1.29e-01 | 0.207000 | 2.94e-01 |
XBP1(S) activates chaperone genes | 47 | 1.42e-02 | 0.207000 | 6.13e-02 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 31 | 4.70e-02 | -0.206000 | 1.48e-01 |
Regulation of Glucokinase by Glucokinase Regulatory Protein | 31 | 4.70e-02 | -0.206000 | 1.48e-01 |
RNA Polymerase II Pre-transcription Events | 77 | 1.83e-03 | 0.206000 | 1.04e-02 |
TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 2.39e-01 | 0.205000 | 4.43e-01 |
NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 4.48e-02 | -0.205000 | 1.43e-01 |
Peptide hormone metabolism | 52 | 1.06e-02 | 0.205000 | 4.78e-02 |
Repression of WNT target genes | 13 | 2.01e-01 | 0.205000 | 4.03e-01 |
Maturation of spike protein 9694548 | 37 | 3.12e-02 | 0.205000 | 1.09e-01 |
APC/C-mediated degradation of cell cycle proteins | 83 | 1.30e-03 | 0.204000 | 7.67e-03 |
Regulation of mitotic cell cycle | 83 | 1.30e-03 | 0.204000 | 7.67e-03 |
Signaling by FGFR2 | 60 | 6.28e-03 | 0.204000 | 3.14e-02 |
Insulin receptor recycling | 25 | 7.82e-02 | 0.204000 | 2.11e-01 |
DNA Replication | 127 | 7.57e-05 | 0.204000 | 6.19e-04 |
N-glycan antennae elongation in the medial/trans-Golgi | 20 | 1.16e-01 | 0.203000 | 2.68e-01 |
Nuclear Events (kinase and transcription factor activation) | 57 | 7.99e-03 | 0.203000 | 3.85e-02 |
PI-3K cascade:FGFR1 | 13 | 2.05e-01 | 0.203000 | 4.08e-01 |
Regulation of CDH11 function | 10 | 2.68e-01 | 0.202000 | 4.73e-01 |
IRAK1 recruits IKK complex | 14 | 1.92e-01 | 0.201000 | 3.91e-01 |
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 14 | 1.92e-01 | 0.201000 | 3.91e-01 |
Sema4D in semaphorin signaling | 23 | 9.47e-02 | 0.201000 | 2.36e-01 |
Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 2.41e-02 | 0.201000 | 9.06e-02 |
HIV Transcription Elongation | 42 | 2.41e-02 | 0.201000 | 9.06e-02 |
Tat-mediated elongation of the HIV-1 transcript | 42 | 2.41e-02 | 0.201000 | 9.06e-02 |
Interleukin-12 family signaling | 46 | 1.87e-02 | 0.200000 | 7.62e-02 |
RUNX3 regulates p14-ARF | 10 | 2.73e-01 | 0.200000 | 4.78e-01 |
Beta-catenin independent WNT signaling | 131 | 8.11e-05 | 0.200000 | 6.57e-04 |
Transport of the SLBP independent Mature mRNA | 35 | 4.13e-02 | -0.199000 | 1.34e-01 |
G1/S Transition | 125 | 1.26e-04 | 0.199000 | 9.79e-04 |
Signaling by BMP | 23 | 9.95e-02 | 0.198000 | 2.42e-01 |
Sialic acid metabolism | 28 | 7.10e-02 | 0.197000 | 1.97e-01 |
Separation of Sister Chromatids | 173 | 7.93e-06 | 0.197000 | 8.23e-05 |
Translation of Structural Proteins 9683701 | 29 | 6.66e-02 | 0.197000 | 1.88e-01 |
Unblocking of NMDA receptors, glutamate binding and activation | 15 | 1.88e-01 | 0.197000 | 3.85e-01 |
NOTCH2 Activation and Transmission of Signal to the Nucleus | 22 | 1.11e-01 | 0.196000 | 2.60e-01 |
Regulation of RUNX1 Expression and Activity | 18 | 1.49e-01 | 0.196000 | 3.24e-01 |
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 11 | 2.60e-01 | 0.196000 | 4.68e-01 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 33 | 5.12e-02 | 0.196000 | 1.55e-01 |
FLT3 signaling in disease | 27 | 7.98e-02 | 0.195000 | 2.14e-01 |
Oncogene Induced Senescence | 33 | 5.31e-02 | 0.195000 | 1.59e-01 |
Telomere Extension By Telomerase | 21 | 1.23e-01 | 0.194000 | 2.82e-01 |
Adrenaline,noradrenaline inhibits insulin secretion | 23 | 1.08e-01 | 0.194000 | 2.54e-01 |
Signaling by CSF3 (G-CSF) | 29 | 7.08e-02 | 0.194000 | 1.97e-01 |
Viral Infection Pathways | 655 | 3.61e-17 | 0.194000 | 1.60e-15 |
Metabolism of proteins | 1614 | 1.35e-37 | 0.193000 | 9.89e-35 |
APC truncation mutants have impaired AXIN binding | 14 | 2.10e-01 | 0.193000 | 4.11e-01 |
AXIN missense mutants destabilize the destruction complex | 14 | 2.10e-01 | 0.193000 | 4.11e-01 |
Signaling by AMER1 mutants | 14 | 2.10e-01 | 0.193000 | 4.11e-01 |
Signaling by APC mutants | 14 | 2.10e-01 | 0.193000 | 4.11e-01 |
Signaling by AXIN mutants | 14 | 2.10e-01 | 0.193000 | 4.11e-01 |
Truncations of AMER1 destabilize the destruction complex | 14 | 2.10e-01 | 0.193000 | 4.11e-01 |
Signaling by Leptin | 10 | 2.91e-01 | 0.193000 | 4.98e-01 |
G2/M Checkpoints | 124 | 2.10e-04 | 0.193000 | 1.56e-03 |
Interleukin-1 family signaling | 134 | 1.20e-04 | 0.193000 | 9.32e-04 |
Synthesis of PIPs at the late endosome membrane | 11 | 2.69e-01 | -0.192000 | 4.74e-01 |
Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 9.68e-02 | 0.192000 | 2.40e-01 |
RHOBTB2 GTPase cycle | 23 | 1.12e-01 | 0.192000 | 2.61e-01 |
Mitotic Anaphase | 216 | 1.35e-06 | 0.191000 | 1.66e-05 |
Glycosaminoglycan metabolism | 108 | 6.16e-04 | 0.191000 | 4.08e-03 |
BBSome-mediated cargo-targeting to cilium | 21 | 1.31e-01 | 0.190000 | 2.97e-01 |
DNA methylation | 10 | 2.98e-01 | 0.190000 | 5.04e-01 |
Activation of BH3-only proteins | 28 | 8.41e-02 | 0.189000 | 2.19e-01 |
Assembly of the ORC complex at the origin of replication | 14 | 2.22e-01 | 0.189000 | 4.25e-01 |
Uptake and actions of bacterial toxins | 25 | 1.03e-01 | 0.188000 | 2.49e-01 |
Mitotic Metaphase and Anaphase | 217 | 1.88e-06 | 0.188000 | 2.16e-05 |
Diseases associated with O-glycosylation of proteins | 55 | 1.60e-02 | -0.188000 | 6.69e-02 |
Downstream signaling of activated FGFR2 | 20 | 1.46e-01 | 0.188000 | 3.21e-01 |
Vpr-mediated nuclear import of PICs | 34 | 5.89e-02 | -0.187000 | 1.70e-01 |
MET promotes cell motility | 40 | 4.05e-02 | 0.187000 | 1.32e-01 |
GABA synthesis, release, reuptake and degradation | 12 | 2.62e-01 | 0.187000 | 4.71e-01 |
ERKs are inactivated | 13 | 2.44e-01 | 0.187000 | 4.50e-01 |
Constitutive Signaling by NOTCH1 HD Domain Mutants | 15 | 2.13e-01 | 0.186000 | 4.13e-01 |
Signaling by NOTCH1 HD Domain Mutants in Cancer | 15 | 2.13e-01 | 0.186000 | 4.13e-01 |
SHC-mediated cascade:FGFR1 | 13 | 2.46e-01 | 0.186000 | 4.51e-01 |
Regulation of TP53 Activity through Association with Co-factors | 10 | 3.09e-01 | 0.186000 | 5.17e-01 |
Activation of G protein gated Potassium channels | 19 | 1.62e-01 | 0.185000 | 3.43e-01 |
G protein gated Potassium channels | 19 | 1.62e-01 | 0.185000 | 3.43e-01 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 19 | 1.62e-01 | 0.185000 | 3.43e-01 |
Transport of the SLBP Dependant Mature mRNA | 36 | 5.58e-02 | -0.184000 | 1.63e-01 |
ABC-family proteins mediated transport | 91 | 2.41e-03 | 0.184000 | 1.34e-02 |
Signaling by WNT | 236 | 1.14e-06 | 0.184000 | 1.44e-05 |
MET activates RAS signaling | 11 | 2.90e-01 | -0.184000 | 4.98e-01 |
mRNA 3’-end processing | 57 | 1.65e-02 | -0.184000 | 6.83e-02 |
ER Quality Control Compartment (ERQC) | 21 | 1.45e-01 | 0.184000 | 3.21e-01 |
Removal of the Flap Intermediate from the C-strand | 17 | 1.90e-01 | 0.183000 | 3.89e-01 |
Fc epsilon receptor (FCERI) signaling | 128 | 3.47e-04 | 0.183000 | 2.45e-03 |
Pyruvate metabolism | 27 | 1.00e-01 | 0.183000 | 2.44e-01 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 22 | 1.39e-01 | 0.182000 | 3.11e-01 |
PERK regulates gene expression | 32 | 7.48e-02 | 0.182000 | 2.04e-01 |
Synthesis of substrates in N-glycan biosythesis | 58 | 1.66e-02 | 0.182000 | 6.83e-02 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 42 | 4.17e-02 | 0.182000 | 1.35e-01 |
Deactivation of the beta-catenin transactivating complex | 38 | 5.32e-02 | 0.181000 | 1.59e-01 |
Developmental Biology | 769 | 1.91e-17 | 0.181000 | 8.73e-16 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 36 | 6.09e-02 | 0.181000 | 1.75e-01 |
Formation of HIV elongation complex in the absence of HIV Tat | 44 | 3.86e-02 | 0.180000 | 1.28e-01 |
G-protein beta:gamma signalling | 27 | 1.06e-01 | -0.180000 | 2.51e-01 |
Signaling by PDGFRA extracellular domain mutants | 12 | 2.82e-01 | 0.179000 | 4.88e-01 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 2.82e-01 | 0.179000 | 4.88e-01 |
RORA activates gene expression | 18 | 1.88e-01 | -0.179000 | 3.85e-01 |
Degradation of the extracellular matrix | 105 | 1.52e-03 | 0.179000 | 8.81e-03 |
Nuclear events stimulated by ALK signaling in cancer | 19 | 1.76e-01 | 0.179000 | 3.70e-01 |
Negative regulation of NMDA receptor-mediated neuronal transmission | 14 | 2.46e-01 | 0.179000 | 4.51e-01 |
Transcription of the HIV genome | 67 | 1.14e-02 | 0.179000 | 5.08e-02 |
Methylation | 12 | 2.85e-01 | 0.178000 | 4.92e-01 |
Processive synthesis on the C-strand of the telomere | 19 | 1.79e-01 | 0.178000 | 3.72e-01 |
Signaling by FGFR | 69 | 1.06e-02 | 0.178000 | 4.78e-02 |
Norepinephrine Neurotransmitter Release Cycle | 14 | 2.51e-01 | 0.177000 | 4.58e-01 |
Carboxyterminal post-translational modifications of tubulin | 30 | 9.40e-02 | 0.177000 | 2.34e-01 |
Amyloid fiber formation | 41 | 5.07e-02 | 0.176000 | 1.54e-01 |
DNA Double Strand Break Response | 43 | 4.56e-02 | 0.176000 | 1.45e-01 |
Nephrin family interactions | 17 | 2.09e-01 | 0.176000 | 4.11e-01 |
Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 9.93e-03 | -0.176000 | 4.53e-02 |
Caspase activation via Death Receptors in the presence of ligand | 15 | 2.40e-01 | -0.175000 | 4.43e-01 |
DNA Damage/Telomere Stress Induced Senescence | 33 | 8.27e-02 | 0.175000 | 2.17e-01 |
Formation of the cornified envelope | 23 | 1.48e-01 | 0.174000 | 3.21e-01 |
Keratinization | 23 | 1.48e-01 | 0.174000 | 3.21e-01 |
Receptor Mediated Mitophagy | 11 | 3.17e-01 | 0.174000 | 5.26e-01 |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 2.60e-01 | -0.174000 | 4.68e-01 |
Formation of definitive endoderm | 10 | 3.44e-01 | 0.173000 | 5.52e-01 |
SUMOylation of ubiquitinylation proteins | 39 | 6.21e-02 | -0.173000 | 1.78e-01 |
AKT phosphorylates targets in the cytosol | 14 | 2.63e-01 | 0.173000 | 4.71e-01 |
ADP signalling through P2Y purinoceptor 12 | 16 | 2.33e-01 | 0.172000 | 4.39e-01 |
Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 5.40e-02 | -0.172000 | 1.61e-01 |
Translation of Structural Proteins 9694635 | 57 | 2.51e-02 | 0.172000 | 9.31e-02 |
PIWI-interacting RNA (piRNA) biogenesis | 22 | 1.64e-01 | 0.171000 | 3.47e-01 |
PI3K events in ERBB2 signaling | 14 | 2.67e-01 | -0.171000 | 4.73e-01 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 3.26e-01 | -0.171000 | 5.36e-01 |
Signaling by FGFR1 | 40 | 6.15e-02 | 0.171000 | 1.76e-01 |
Plasma lipoprotein assembly | 11 | 3.27e-01 | -0.171000 | 5.36e-01 |
Peptide ligand-binding receptors | 77 | 9.70e-03 | 0.171000 | 4.46e-02 |
Attachment and Entry 9694614 | 16 | 2.39e-01 | 0.170000 | 4.43e-01 |
C-type lectin receptors (CLRs) | 122 | 1.19e-03 | 0.170000 | 7.17e-03 |
SUMOylation of immune response proteins | 11 | 3.29e-01 | 0.170000 | 5.36e-01 |
Export of Viral Ribonucleoproteins from Nucleus | 33 | 9.25e-02 | -0.169000 | 2.32e-01 |
Molecules associated with elastic fibres | 33 | 9.27e-02 | 0.169000 | 2.32e-01 |
Blood group systems biosynthesis | 13 | 2.93e-01 | 0.168000 | 5.00e-01 |
RNA Polymerase III Transcription Termination | 23 | 1.65e-01 | 0.167000 | 3.49e-01 |
Generation of second messenger molecules | 16 | 2.48e-01 | -0.167000 | 4.54e-01 |
Maturation of nucleoprotein 9683610 | 11 | 3.39e-01 | -0.166000 | 5.47e-01 |
Signaling by TGFB family members | 112 | 2.38e-03 | 0.166000 | 1.34e-02 |
Negative regulation of FLT3 | 13 | 3.00e-01 | 0.166000 | 5.07e-01 |
PIP3 activates AKT signaling | 240 | 1.01e-05 | 0.166000 | 1.00e-04 |
Metabolism of RNA | 692 | 1.41e-13 | 0.166000 | 5.05e-12 |
Regulation of PTEN gene transcription | 59 | 2.81e-02 | 0.165000 | 1.01e-01 |
STING mediated induction of host immune responses | 15 | 2.68e-01 | -0.165000 | 4.73e-01 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 30 | 1.19e-01 | 0.165000 | 2.73e-01 |
S Phase | 157 | 3.91e-04 | 0.164000 | 2.71e-03 |
VLDLR internalisation and degradation | 15 | 2.72e-01 | 0.164000 | 4.78e-01 |
Defects in cobalamin (B12) metabolism | 12 | 3.26e-01 | 0.164000 | 5.36e-01 |
Signaling by Interleukins | 376 | 5.38e-08 | 0.164000 | 1.12e-06 |
DNA Damage Recognition in GG-NER | 38 | 8.11e-02 | 0.164000 | 2.14e-01 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 73 | 1.58e-02 | 0.163000 | 6.67e-02 |
Integration of energy metabolism | 87 | 8.72e-03 | 0.163000 | 4.10e-02 |
HIV Infection | 221 | 3.14e-05 | 0.163000 | 2.79e-04 |
Transcriptional regulation of granulopoiesis | 33 | 1.06e-01 | 0.163000 | 2.51e-01 |
Hyaluronan metabolism | 16 | 2.60e-01 | -0.163000 | 4.68e-01 |
RHO GTPases Activate ROCKs | 18 | 2.33e-01 | 0.162000 | 4.39e-01 |
Interleukin-35 Signalling | 10 | 3.75e-01 | 0.162000 | 5.79e-01 |
Meiotic recombination | 26 | 1.54e-01 | 0.162000 | 3.31e-01 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 39 | 8.12e-02 | 0.161000 | 2.14e-01 |
Infectious disease | 826 | 4.60e-15 | 0.161000 | 1.68e-13 |
Initial triggering of complement | 20 | 2.12e-01 | -0.161000 | 4.12e-01 |
Tie2 Signaling | 15 | 2.80e-01 | 0.161000 | 4.88e-01 |
Chemokine receptors bind chemokines | 32 | 1.15e-01 | 0.161000 | 2.68e-01 |
Formation of the Early Elongation Complex | 33 | 1.12e-01 | 0.160000 | 2.61e-01 |
Formation of the HIV-1 Early Elongation Complex | 33 | 1.12e-01 | 0.160000 | 2.61e-01 |
Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 6.98e-02 | -0.160000 | 1.95e-01 |
EPHA-mediated growth cone collapse | 23 | 1.85e-01 | 0.160000 | 3.82e-01 |
Antigen processing-Cross presentation | 92 | 8.21e-03 | 0.160000 | 3.92e-02 |
Regulation of IFNG signaling | 13 | 3.19e-01 | 0.160000 | 5.29e-01 |
Apoptosis | 161 | 5.02e-04 | 0.159000 | 3.39e-03 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 29 | 1.39e-01 | 0.159000 | 3.10e-01 |
Oxidative Stress Induced Senescence | 69 | 2.28e-02 | 0.159000 | 8.78e-02 |
Rev-mediated nuclear export of HIV RNA | 35 | 1.05e-01 | -0.158000 | 2.51e-01 |
RAB geranylgeranylation | 55 | 4.25e-02 | 0.158000 | 1.37e-01 |
Signaling by PDGF | 53 | 4.67e-02 | 0.158000 | 1.48e-01 |
Caspase activation via extrinsic apoptotic signalling pathway | 23 | 1.92e-01 | -0.157000 | 3.91e-01 |
Signaling by NOTCH | 173 | 3.99e-04 | 0.156000 | 2.75e-03 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 23 | 1.95e-01 | 0.156000 | 3.95e-01 |
Class I peroxisomal membrane protein import | 19 | 2.39e-01 | 0.156000 | 4.43e-01 |
TNFs bind their physiological receptors | 17 | 2.66e-01 | -0.156000 | 4.72e-01 |
GPER1 signaling | 38 | 9.64e-02 | 0.156000 | 2.39e-01 |
Mitochondrial Fatty Acid Beta-Oxidation | 34 | 1.16e-01 | 0.156000 | 2.68e-01 |
Regulation of TP53 Activity through Acetylation | 29 | 1.47e-01 | 0.156000 | 3.21e-01 |
G2/M Transition | 184 | 2.86e-04 | 0.155000 | 2.07e-03 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 14 | 3.15e-01 | 0.155000 | 5.24e-01 |
Defective EXT2 causes exostoses 2 | 14 | 3.15e-01 | 0.155000 | 5.24e-01 |
SUMOylation of DNA methylation proteins | 16 | 2.83e-01 | 0.155000 | 4.89e-01 |
SUMOylation of SUMOylation proteins | 35 | 1.14e-01 | -0.155000 | 2.64e-01 |
Transport of Mature Transcript to Cytoplasm | 81 | 1.63e-02 | -0.154000 | 6.78e-02 |
Muscle contraction | 138 | 1.78e-03 | 0.154000 | 1.02e-02 |
Interleukin-12 signaling | 40 | 9.18e-02 | 0.154000 | 2.32e-01 |
HIV Transcription Initiation | 45 | 7.40e-02 | 0.154000 | 2.03e-01 |
RNA Polymerase II HIV Promoter Escape | 45 | 7.40e-02 | 0.154000 | 2.03e-01 |
RNA Polymerase II Promoter Escape | 45 | 7.40e-02 | 0.154000 | 2.03e-01 |
RNA Polymerase II Transcription Initiation | 45 | 7.40e-02 | 0.154000 | 2.03e-01 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 7.40e-02 | 0.154000 | 2.03e-01 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 7.40e-02 | 0.154000 | 2.03e-01 |
Late SARS-CoV-2 Infection Events | 66 | 3.07e-02 | 0.154000 | 1.09e-01 |
Amine ligand-binding receptors | 10 | 4.00e-01 | 0.154000 | 6.01e-01 |
CTLA4 inhibitory signaling | 18 | 2.60e-01 | 0.153000 | 4.68e-01 |
Protein localization | 154 | 1.05e-03 | 0.153000 | 6.41e-03 |
Metabolism of carbohydrates | 253 | 3.05e-05 | 0.153000 | 2.74e-04 |
Signaling by ALK fusions and activated point mutants | 55 | 5.07e-02 | 0.152000 | 1.54e-01 |
Signaling by ALK in cancer | 55 | 5.07e-02 | 0.152000 | 1.54e-01 |
Acyl chain remodelling of PE | 18 | 2.63e-01 | -0.152000 | 4.71e-01 |
Ion homeostasis | 40 | 9.56e-02 | 0.152000 | 2.38e-01 |
Mitotic G2-G2/M phases | 186 | 3.49e-04 | 0.152000 | 2.46e-03 |
Programmed Cell Death | 188 | 3.25e-04 | 0.152000 | 2.31e-03 |
Other interleukin signaling | 20 | 2.39e-01 | -0.152000 | 4.43e-01 |
Processing of SMDT1 | 15 | 3.09e-01 | 0.152000 | 5.17e-01 |
RHO GTPases activate CIT | 18 | 2.65e-01 | 0.152000 | 4.71e-01 |
Ub-specific processing proteases | 156 | 1.09e-03 | 0.152000 | 6.63e-03 |
Disorders of transmembrane transporters | 137 | 2.24e-03 | 0.151000 | 1.27e-02 |
rRNA processing in the mitochondrion | 10 | 4.08e-01 | 0.151000 | 6.09e-01 |
Physiological factors | 10 | 4.09e-01 | 0.151000 | 6.10e-01 |
Visual phototransduction | 56 | 5.13e-02 | 0.151000 | 1.55e-01 |
RHOG GTPase cycle | 70 | 3.08e-02 | 0.149000 | 1.09e-01 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 12 | 3.71e-01 | -0.149000 | 5.78e-01 |
Prostacyclin signalling through prostacyclin receptor | 14 | 3.35e-01 | 0.149000 | 5.42e-01 |
Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 10 | 4.15e-01 | 0.149000 | 6.17e-01 |
Cardiogenesis | 19 | 2.63e-01 | 0.148000 | 4.71e-01 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 31 | 1.53e-01 | 0.148000 | 3.30e-01 |
Platelet degranulation | 105 | 9.14e-03 | 0.147000 | 4.26e-02 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 5.88e-02 | 0.147000 | 1.70e-01 |
mRNA Splicing - Minor Pathway | 50 | 7.16e-02 | 0.147000 | 1.98e-01 |
Branched-chain amino acid catabolism | 21 | 2.46e-01 | -0.146000 | 4.51e-01 |
Activation of the AP-1 family of transcription factors | 10 | 4.24e-01 | 0.146000 | 6.23e-01 |
Neddylation | 223 | 1.76e-04 | 0.146000 | 1.35e-03 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 22 | 2.36e-01 | 0.146000 | 4.42e-01 |
p75NTR recruits signalling complexes | 13 | 3.63e-01 | 0.146000 | 5.72e-01 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 1.32e-01 | 0.145000 | 2.97e-01 |
Classical antibody-mediated complement activation | 10 | 4.27e-01 | -0.145000 | 6.26e-01 |
Metabolism of folate and pterines | 16 | 3.15e-01 | 0.145000 | 5.24e-01 |
VEGFR2 mediated cell proliferation | 19 | 2.75e-01 | 0.145000 | 4.80e-01 |
Resolution of D-Loop Structures | 33 | 1.50e-01 | -0.145000 | 3.25e-01 |
IRS-related events triggered by IGF1R | 37 | 1.30e-01 | 0.144000 | 2.95e-01 |
Acetylcholine Neurotransmitter Release Cycle | 12 | 3.88e-01 | 0.144000 | 5.90e-01 |
Serotonin Neurotransmitter Release Cycle | 14 | 3.53e-01 | 0.143000 | 5.62e-01 |
Bacterial Infection Pathways | 65 | 4.59e-02 | 0.143000 | 1.45e-01 |
IGF1R signaling cascade | 38 | 1.27e-01 | 0.143000 | 2.90e-01 |
Host Interactions of HIV factors | 125 | 5.97e-03 | 0.143000 | 3.06e-02 |
Metabolism of porphyrins | 21 | 2.58e-01 | 0.142000 | 4.67e-01 |
NOTCH3 Activation and Transmission of Signal to the Nucleus | 25 | 2.19e-01 | 0.142000 | 4.22e-01 |
Glycogen breakdown (glycogenolysis) | 13 | 3.75e-01 | 0.142000 | 5.79e-01 |
Fatty acyl-CoA biosynthesis | 29 | 1.86e-01 | 0.142000 | 3.83e-01 |
Signaling by TGF-beta Receptor Complex | 90 | 2.04e-02 | 0.142000 | 8.13e-02 |
Purine salvage | 12 | 3.96e-01 | 0.141000 | 5.98e-01 |
Early SARS-CoV-2 Infection Events | 33 | 1.62e-01 | 0.141000 | 3.43e-01 |
Signaling by WNT in cancer | 28 | 1.99e-01 | 0.140000 | 3.99e-01 |
LDL clearance | 18 | 3.04e-01 | -0.140000 | 5.11e-01 |
Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 1.46e-01 | 0.140000 | 3.21e-01 |
Metabolism | 1716 | 1.93e-21 | 0.140000 | 1.09e-19 |
Interactions of Vpr with host cellular proteins | 37 | 1.41e-01 | -0.140000 | 3.14e-01 |
Response to elevated platelet cytosolic Ca2+ | 109 | 1.18e-02 | 0.140000 | 5.22e-02 |
Metabolism of steroid hormones | 20 | 2.81e-01 | -0.139000 | 4.88e-01 |
Synthesis of IP2, IP, and Ins in the cytosol | 12 | 4.03e-01 | -0.139000 | 6.04e-01 |
Growth hormone receptor signaling | 20 | 2.81e-01 | 0.139000 | 4.88e-01 |
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | 13 | 3.85e-01 | 0.139000 | 5.86e-01 |
Constitutive Signaling by AKT1 E17K in Cancer | 26 | 2.20e-01 | 0.139000 | 4.22e-01 |
CD28 dependent Vav1 pathway | 10 | 4.46e-01 | -0.139000 | 6.45e-01 |
Leading Strand Synthesis | 14 | 3.68e-01 | -0.139000 | 5.77e-01 |
Polymerase switching | 14 | 3.68e-01 | -0.139000 | 5.77e-01 |
Intracellular signaling by second messengers | 276 | 7.46e-05 | 0.139000 | 6.17e-04 |
Cellular Senescence | 131 | 6.15e-03 | 0.139000 | 3.10e-02 |
Signaling by MET | 75 | 3.82e-02 | 0.138000 | 1.27e-01 |
Metabolic disorders of biological oxidation enzymes | 23 | 2.53e-01 | 0.138000 | 4.60e-01 |
Nucleotide catabolism | 23 | 2.53e-01 | 0.138000 | 4.60e-01 |
G alpha (z) signalling events | 38 | 1.43e-01 | 0.137000 | 3.17e-01 |
DAP12 signaling | 25 | 2.35e-01 | -0.137000 | 4.41e-01 |
Estrogen-dependent gene expression | 90 | 2.48e-02 | 0.137000 | 9.22e-02 |
Signaling by ERBB2 TMD/JMD mutants | 20 | 2.93e-01 | -0.136000 | 4.99e-01 |
FRS-mediated FGFR1 signaling | 15 | 3.62e-01 | 0.136000 | 5.72e-01 |
Intraflagellar transport | 48 | 1.04e-01 | 0.136000 | 2.49e-01 |
Sphingolipid de novo biosynthesis | 37 | 1.53e-01 | 0.136000 | 3.31e-01 |
FGFR2 alternative splicing | 24 | 2.50e-01 | 0.136000 | 4.57e-01 |
mRNA Capping | 29 | 2.06e-01 | 0.136000 | 4.10e-01 |
RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 2.15e-01 | 0.136000 | 4.16e-01 |
Acyl chain remodelling of PC | 19 | 3.09e-01 | -0.135000 | 5.17e-01 |
Cytosolic iron-sulfur cluster assembly | 13 | 4.00e-01 | -0.135000 | 6.01e-01 |
Pre-NOTCH Processing in Golgi | 18 | 3.23e-01 | 0.134000 | 5.34e-01 |
Class B/2 (Secretin family receptors) | 49 | 1.04e-01 | 0.134000 | 2.49e-01 |
Regulation of NPAS4 gene expression | 12 | 4.21e-01 | -0.134000 | 6.21e-01 |
Signaling by NTRK1 (TRKA) | 108 | 1.62e-02 | 0.134000 | 6.76e-02 |
Miscellaneous transport and binding events | 21 | 2.88e-01 | 0.134000 | 4.96e-01 |
Deposition of new CENPA-containing nucleosomes at the centromere | 30 | 2.05e-01 | 0.134000 | 4.08e-01 |
Nucleosome assembly | 30 | 2.05e-01 | 0.134000 | 4.08e-01 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 3.54e-01 | -0.134000 | 5.63e-01 |
Interleukin-15 signaling | 13 | 4.04e-01 | 0.134000 | 6.04e-01 |
HCMV Infection | 98 | 2.25e-02 | 0.133000 | 8.74e-02 |
Constitutive Signaling by EGFRvIII | 15 | 3.71e-01 | -0.133000 | 5.78e-01 |
Signaling by EGFRvIII in Cancer | 15 | 3.71e-01 | -0.133000 | 5.78e-01 |
Termination of O-glycan biosynthesis | 14 | 3.88e-01 | 0.133000 | 5.90e-01 |
activated TAK1 mediates p38 MAPK activation | 23 | 2.71e-01 | 0.133000 | 4.77e-01 |
Signaling by FGFR in disease | 52 | 9.85e-02 | 0.132000 | 2.41e-01 |
FCGR activation | 15 | 3.75e-01 | -0.132000 | 5.79e-01 |
MAPK family signaling cascades | 265 | 2.12e-04 | 0.132000 | 1.57e-03 |
PI Metabolism | 78 | 4.36e-02 | -0.132000 | 1.40e-01 |
TP53 Regulates Metabolic Genes | 80 | 4.15e-02 | 0.132000 | 1.35e-01 |
RAF/MAP kinase cascade | 225 | 6.65e-04 | 0.132000 | 4.37e-03 |
Signaling by Insulin receptor | 63 | 7.13e-02 | 0.131000 | 1.98e-01 |
RNA Pol II CTD phosphorylation and interaction with CE | 27 | 2.39e-01 | 0.131000 | 4.43e-01 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 2.39e-01 | 0.131000 | 4.43e-01 |
HS-GAG biosynthesis | 24 | 2.67e-01 | 0.131000 | 4.73e-01 |
Late Phase of HIV Life Cycle | 132 | 9.68e-03 | 0.131000 | 4.46e-02 |
tRNA Aminoacylation | 42 | 1.44e-01 | 0.130000 | 3.19e-01 |
Glutamate and glutamine metabolism | 11 | 4.55e-01 | 0.130000 | 6.52e-01 |
Glutathione synthesis and recycling | 10 | 4.76e-01 | -0.130000 | 6.70e-01 |
Potential therapeutics for SARS | 92 | 3.11e-02 | 0.130000 | 1.09e-01 |
Regulation of IFNA/IFNB signaling | 12 | 4.35e-01 | 0.130000 | 6.33e-01 |
Creation of C4 and C2 activators | 13 | 4.17e-01 | -0.130000 | 6.18e-01 |
Glucagon-type ligand receptors | 17 | 3.55e-01 | 0.130000 | 5.63e-01 |
Cell surface interactions at the vascular wall | 106 | 2.13e-02 | 0.130000 | 8.39e-02 |
Adenylate cyclase activating pathway | 10 | 4.79e-01 | -0.129000 | 6.72e-01 |
PKMTs methylate histone lysines | 42 | 1.47e-01 | -0.129000 | 3.21e-01 |
Regulation of insulin secretion | 60 | 8.36e-02 | 0.129000 | 2.18e-01 |
SUMOylation of DNA replication proteins | 45 | 1.34e-01 | -0.129000 | 3.02e-01 |
PLC beta mediated events | 45 | 1.34e-01 | -0.129000 | 3.02e-01 |
Diseases of mitotic cell cycle | 38 | 1.69e-01 | 0.129000 | 3.56e-01 |
MAPK1/MAPK3 signaling | 230 | 7.93e-04 | 0.129000 | 5.09e-03 |
Metabolism of vitamins and cofactors | 156 | 5.66e-03 | 0.129000 | 2.94e-02 |
Intra-Golgi and retrograde Golgi-to-ER traffic | 185 | 2.66e-03 | 0.128000 | 1.48e-02 |
Nuclear import of Rev protein | 34 | 1.96e-01 | -0.128000 | 3.96e-01 |
Signaling by Erythropoietin | 24 | 2.78e-01 | -0.128000 | 4.85e-01 |
O-linked glycosylation of mucins | 41 | 1.56e-01 | 0.128000 | 3.35e-01 |
Disease | 1460 | 7.99e-16 | 0.127000 | 3.25e-14 |
Mitotic Telophase/Cytokinesis | 13 | 4.27e-01 | -0.127000 | 6.26e-01 |
Toll Like Receptor 3 (TLR3) Cascade | 102 | 2.64e-02 | 0.127000 | 9.68e-02 |
Transport of vitamins, nucleosides, and related molecules | 29 | 2.36e-01 | 0.127000 | 4.41e-01 |
Adherens junctions interactions | 43 | 1.50e-01 | 0.127000 | 3.24e-01 |
Aquaporin-mediated transport | 36 | 1.88e-01 | 0.127000 | 3.85e-01 |
Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 10 | 4.87e-01 | 0.127000 | 6.79e-01 |
Ovarian tumor domain proteases | 35 | 1.95e-01 | 0.127000 | 3.95e-01 |
Deubiquitination | 227 | 1.03e-03 | 0.127000 | 6.36e-03 |
Activation of gene expression by SREBF (SREBP) | 42 | 1.60e-01 | 0.125000 | 3.42e-01 |
Post-translational protein modification | 1177 | 8.07e-13 | 0.125000 | 2.81e-11 |
Platelet sensitization by LDL | 17 | 3.74e-01 | 0.125000 | 5.79e-01 |
FGFR1 mutant receptor activation | 25 | 2.82e-01 | 0.124000 | 4.88e-01 |
Phase 2 - plateau phase | 10 | 4.96e-01 | 0.124000 | 6.88e-01 |
The NLRP3 inflammasome | 16 | 3.90e-01 | 0.124000 | 5.92e-01 |
Cardiac conduction | 88 | 4.48e-02 | 0.124000 | 1.43e-01 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 32 | 2.27e-01 | -0.123000 | 4.31e-01 |
P2Y receptors | 11 | 4.80e-01 | -0.123000 | 6.73e-01 |
Activation of GABAB receptors | 32 | 2.28e-01 | 0.123000 | 4.33e-01 |
GABA B receptor activation | 32 | 2.28e-01 | 0.123000 | 4.33e-01 |
Interleukin-10 signaling | 31 | 2.37e-01 | 0.123000 | 4.43e-01 |
Telomere Maintenance | 69 | 7.93e-02 | 0.122000 | 2.13e-01 |
Ca-dependent events | 33 | 2.25e-01 | -0.122000 | 4.30e-01 |
Phase I - Functionalization of compounds | 66 | 8.76e-02 | 0.122000 | 2.26e-01 |
Azathioprine ADME | 18 | 3.72e-01 | 0.122000 | 5.78e-01 |
Signaling by ERBB2 in Cancer | 24 | 3.03e-01 | -0.121000 | 5.11e-01 |
mitochondrial fatty acid beta-oxidation of saturated fatty acids | 10 | 5.06e-01 | 0.121000 | 6.95e-01 |
TRAF6 mediated NF-kB activation | 22 | 3.26e-01 | -0.121000 | 5.36e-01 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 14 | 4.33e-01 | -0.121000 | 6.30e-01 |
Downstream signaling of activated FGFR1 | 21 | 3.38e-01 | 0.121000 | 5.45e-01 |
MAP kinase activation | 63 | 9.93e-02 | 0.120000 | 2.42e-01 |
Olfactory Signaling Pathway | 27 | 2.81e-01 | 0.120000 | 4.88e-01 |
Signaling by KIT in disease | 19 | 3.66e-01 | 0.120000 | 5.76e-01 |
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 19 | 3.66e-01 | 0.120000 | 5.76e-01 |
Activation of IRF3, IRF7 mediated by TBK1, IKBKE | 17 | 3.93e-01 | 0.120000 | 5.95e-01 |
DAP12 interactions | 33 | 2.35e-01 | -0.119000 | 4.41e-01 |
Fanconi Anemia Pathway | 35 | 2.22e-01 | -0.119000 | 4.25e-01 |
Activation of NMDA receptors and postsynaptic events | 74 | 7.66e-02 | 0.119000 | 2.08e-01 |
MHC class II antigen presentation | 96 | 4.48e-02 | 0.119000 | 1.43e-01 |
Cytosolic sulfonation of small molecules | 19 | 3.71e-01 | 0.119000 | 5.78e-01 |
Cell Cycle Checkpoints | 238 | 1.69e-03 | 0.118000 | 9.70e-03 |
Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 3.85e-01 | -0.118000 | 5.86e-01 |
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 13 | 4.61e-01 | 0.118000 | 6.60e-01 |
ROS and RNS production in phagocytes | 30 | 2.64e-01 | 0.118000 | 4.71e-01 |
PI3K Cascade | 30 | 2.64e-01 | 0.118000 | 4.71e-01 |
ALK mutants bind TKIs | 12 | 4.80e-01 | 0.118000 | 6.73e-01 |
Diseases of signal transduction by growth factor receptors and second messengers | 387 | 7.52e-05 | 0.118000 | 6.18e-04 |
Triglyceride catabolism | 16 | 4.16e-01 | 0.117000 | 6.17e-01 |
Activation of kainate receptors upon glutamate binding | 23 | 3.30e-01 | 0.117000 | 5.36e-01 |
Erythropoietin activates RAS | 13 | 4.64e-01 | -0.117000 | 6.61e-01 |
TAK1-dependent IKK and NF-kappa-B activation | 42 | 1.90e-01 | 0.117000 | 3.89e-01 |
O-glycosylation of TSR domain-containing proteins | 35 | 2.32e-01 | -0.117000 | 4.39e-01 |
Interactions of Rev with host cellular proteins | 37 | 2.20e-01 | -0.117000 | 4.22e-01 |
Meiotic synapsis | 31 | 2.62e-01 | 0.116000 | 4.71e-01 |
MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 2.66e-01 | 0.115000 | 4.73e-01 |
APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 3.29e-01 | 0.115000 | 5.36e-01 |
IKK complex recruitment mediated by RIP1 | 23 | 3.41e-01 | 0.115000 | 5.49e-01 |
Vitamin B5 (pantothenate) metabolism | 16 | 4.28e-01 | -0.114000 | 6.27e-01 |
IRF3-mediated induction of type I IFN | 12 | 4.93e-01 | -0.114000 | 6.85e-01 |
HIV Life Cycle | 145 | 1.78e-02 | 0.114000 | 7.31e-02 |
RAF activation | 33 | 2.57e-01 | 0.114000 | 4.66e-01 |
NOTCH1 Intracellular Domain Regulates Transcription | 47 | 1.78e-01 | 0.114000 | 3.70e-01 |
CD209 (DC-SIGN) signaling | 20 | 3.79e-01 | 0.114000 | 5.81e-01 |
APC-Cdc20 mediated degradation of Nek2A | 25 | 3.27e-01 | 0.113000 | 5.36e-01 |
Synaptic adhesion-like molecules | 18 | 4.07e-01 | 0.113000 | 6.08e-01 |
Tryptophan catabolism | 10 | 5.39e-01 | -0.112000 | 7.24e-01 |
TP53 Regulates Transcription of DNA Repair Genes | 61 | 1.31e-01 | 0.112000 | 2.97e-01 |
ESR-mediated signaling | 152 | 1.88e-02 | 0.110000 | 7.67e-02 |
Signaling by NOTCH2 | 30 | 2.96e-01 | 0.110000 | 5.01e-01 |
MyD88-independent TLR4 cascade | 106 | 5.01e-02 | 0.110000 | 1.54e-01 |
TRIF(TICAM1)-mediated TLR4 signaling | 106 | 5.01e-02 | 0.110000 | 1.54e-01 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 50 | 1.78e-01 | 0.110000 | 3.71e-01 |
Diseases of glycosylation | 127 | 3.24e-02 | 0.110000 | 1.13e-01 |
CaM pathway | 31 | 2.89e-01 | -0.110000 | 4.96e-01 |
Calmodulin induced events | 31 | 2.89e-01 | -0.110000 | 4.96e-01 |
Interferon gamma signaling | 73 | 1.04e-01 | -0.110000 | 2.50e-01 |
Hemostasis | 475 | 4.75e-05 | 0.109000 | 4.09e-04 |
ATF4 activates genes in response to endoplasmic reticulum stress | 27 | 3.26e-01 | 0.109000 | 5.36e-01 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | 25 | 3.45e-01 | 0.109000 | 5.52e-01 |
Cytosolic sensors of pathogen-associated DNA | 61 | 1.41e-01 | 0.109000 | 3.14e-01 |
RAF-independent MAPK1/3 activation | 20 | 3.99e-01 | 0.109000 | 6.01e-01 |
SHC1 events in ERBB2 signaling | 20 | 4.00e-01 | -0.109000 | 6.01e-01 |
Base Excision Repair | 50 | 1.84e-01 | 0.109000 | 3.82e-01 |
Platelet calcium homeostasis | 21 | 3.90e-01 | 0.108000 | 5.92e-01 |
Signaling by ERBB2 KD Mutants | 23 | 3.70e-01 | -0.108000 | 5.78e-01 |
SARS-CoV-2 activates/modulates innate and adaptive immune responses | 101 | 6.14e-02 | -0.108000 | 1.76e-01 |
L1CAM interactions | 97 | 6.73e-02 | 0.108000 | 1.89e-01 |
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 37 | 2.58e-01 | 0.107000 | 4.67e-01 |
Synthesis of very long-chain fatty acyl-CoAs | 17 | 4.46e-01 | 0.107000 | 6.45e-01 |
Interleukin receptor SHC signaling | 20 | 4.09e-01 | -0.107000 | 6.10e-01 |
Signaling by Activin | 13 | 5.06e-01 | 0.106000 | 6.95e-01 |
Elevation of cytosolic Ca2+ levels | 12 | 5.24e-01 | 0.106000 | 7.09e-01 |
CREB1 phosphorylation through the activation of Adenylate Cyclase | 11 | 5.42e-01 | -0.106000 | 7.26e-01 |
Cytoprotection by HMOX1 | 58 | 1.62e-01 | 0.106000 | 3.43e-01 |
Defective pyroptosis | 19 | 4.23e-01 | -0.106000 | 6.22e-01 |
Regulation of MECP2 expression and activity | 27 | 3.41e-01 | -0.106000 | 5.49e-01 |
Neurotransmitter release cycle | 36 | 2.72e-01 | 0.106000 | 4.78e-01 |
RNA Polymerase II Transcription Termination | 66 | 1.38e-01 | -0.106000 | 3.09e-01 |
Potassium Channels | 52 | 1.90e-01 | 0.105000 | 3.89e-01 |
Nuclear signaling by ERBB4 | 27 | 3.45e-01 | -0.105000 | 5.52e-01 |
Activation of SMO | 16 | 4.67e-01 | 0.105000 | 6.62e-01 |
Cohesin Loading onto Chromatin | 10 | 5.66e-01 | -0.105000 | 7.43e-01 |
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 16 | 4.68e-01 | -0.105000 | 6.62e-01 |
Recycling pathway of L1 | 40 | 2.53e-01 | 0.105000 | 4.60e-01 |
Degradation of cysteine and homocysteine | 12 | 5.31e-01 | 0.104000 | 7.16e-01 |
Nucleotide biosynthesis | 12 | 5.31e-01 | 0.104000 | 7.16e-01 |
Chromosome Maintenance | 92 | 8.51e-02 | 0.104000 | 2.20e-01 |
Signaling by FLT3 fusion proteins | 19 | 4.33e-01 | 0.104000 | 6.30e-01 |
RIPK1-mediated regulated necrosis | 30 | 3.26e-01 | 0.104000 | 5.36e-01 |
Regulation of necroptotic cell death | 30 | 3.26e-01 | 0.104000 | 5.36e-01 |
Biological oxidations | 138 | 3.59e-02 | 0.104000 | 1.22e-01 |
Defective B3GALTL causes PpS | 34 | 2.99e-01 | -0.103000 | 5.06e-01 |
Recognition of DNA damage by PCNA-containing replication complex | 29 | 3.38e-01 | 0.103000 | 5.45e-01 |
Transcriptional Regulation by NPAS4 | 30 | 3.30e-01 | 0.103000 | 5.36e-01 |
Post-translational modification: synthesis of GPI-anchored proteins | 57 | 1.81e-01 | 0.103000 | 3.75e-01 |
Platelet activation, signaling and aggregation | 217 | 9.44e-03 | 0.102000 | 4.37e-02 |
Notch-HLH transcription pathway | 28 | 3.49e-01 | -0.102000 | 5.56e-01 |
Phase II - Conjugation of compounds | 68 | 1.45e-01 | 0.102000 | 3.21e-01 |
MyD88 cascade initiated on plasma membrane | 93 | 8.89e-02 | 0.102000 | 2.26e-01 |
Toll Like Receptor 10 (TLR10) Cascade | 93 | 8.89e-02 | 0.102000 | 2.26e-01 |
Toll Like Receptor 5 (TLR5) Cascade | 93 | 8.89e-02 | 0.102000 | 2.26e-01 |
TNFR1-induced proapoptotic signaling | 25 | 3.77e-01 | -0.102000 | 5.80e-01 |
RMTs methylate histone arginines | 33 | 3.10e-01 | 0.102000 | 5.19e-01 |
NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 5.60e-01 | 0.102000 | 7.42e-01 |
Ephrin signaling | 17 | 4.69e-01 | -0.101000 | 6.62e-01 |
Signaling by ERBB2 ECD mutants | 16 | 4.83e-01 | -0.101000 | 6.76e-01 |
Interleukin-17 signaling | 67 | 1.53e-01 | 0.101000 | 3.30e-01 |
Nuclear Envelope Breakdown | 53 | 2.03e-01 | -0.101000 | 4.06e-01 |
Meiosis | 50 | 2.17e-01 | 0.101000 | 4.18e-01 |
Signaling by NTRKs | 123 | 5.55e-02 | 0.100000 | 1.63e-01 |
RUNX2 regulates bone development | 27 | 3.69e-01 | 0.099900 | 5.78e-01 |
IRS-mediated signalling | 34 | 3.14e-01 | 0.099800 | 5.23e-01 |
RND1 GTPase cycle | 37 | 2.94e-01 | 0.099800 | 5.00e-01 |
Epigenetic regulation of gene expression | 132 | 4.84e-02 | -0.099600 | 1.51e-01 |
Signaling by high-kinase activity BRAF mutants | 30 | 3.46e-01 | -0.099400 | 5.53e-01 |
SARS-CoV Infections | 375 | 1.03e-03 | 0.099000 | 6.36e-03 |
RUNX2 regulates osteoblast differentiation | 21 | 4.33e-01 | 0.098900 | 6.30e-01 |
Diseases of metabolism | 206 | 1.48e-02 | 0.098700 | 6.35e-02 |
SHC1 events in ERBB4 signaling | 12 | 5.55e-01 | -0.098500 | 7.38e-01 |
Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 3.21e-01 | 0.098400 | 5.31e-01 |
Lysosome Vesicle Biogenesis | 33 | 3.28e-01 | -0.098400 | 5.36e-01 |
Pyruvate metabolism and Citric Acid (TCA) cycle | 51 | 2.25e-01 | 0.098200 | 4.30e-01 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 11 | 5.74e-01 | -0.098000 | 7.46e-01 |
alpha-linolenic acid (ALA) metabolism | 11 | 5.74e-01 | -0.098000 | 7.46e-01 |
M Phase | 342 | 1.89e-03 | 0.098000 | 1.07e-02 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 107 | 8.03e-02 | 0.097900 | 2.14e-01 |
Toll Like Receptor 2 (TLR2) Cascade | 107 | 8.03e-02 | 0.097900 | 2.14e-01 |
Toll Like Receptor TLR1:TLR2 Cascade | 107 | 8.03e-02 | 0.097900 | 2.14e-01 |
Toll Like Receptor TLR6:TLR2 Cascade | 107 | 8.03e-02 | 0.097900 | 2.14e-01 |
Signaling by Non-Receptor Tyrosine Kinases | 51 | 2.27e-01 | 0.097900 | 4.31e-01 |
Signaling by PTK6 | 51 | 2.27e-01 | 0.097900 | 4.31e-01 |
Nucleotide-like (purinergic) receptors | 15 | 5.12e-01 | -0.097900 | 7.00e-01 |
Formation of TC-NER Pre-Incision Complex | 53 | 2.18e-01 | 0.097800 | 4.21e-01 |
EML4 and NUDC in mitotic spindle formation | 101 | 9.13e-02 | 0.097300 | 2.31e-01 |
PECAM1 interactions | 11 | 5.78e-01 | -0.097000 | 7.47e-01 |
Downstream signal transduction | 28 | 3.80e-01 | 0.095800 | 5.81e-01 |
RHO GTPases Activate Formins | 123 | 6.82e-02 | 0.095300 | 1.92e-01 |
RA biosynthesis pathway | 16 | 5.09e-01 | -0.095300 | 6.98e-01 |
Defects in vitamin and cofactor metabolism | 20 | 4.62e-01 | 0.095100 | 6.60e-01 |
Insulin receptor signalling cascade | 39 | 3.04e-01 | 0.095100 | 5.11e-01 |
Signaling by PDGFR in disease | 20 | 4.62e-01 | 0.095100 | 6.60e-01 |
Kinesins | 46 | 2.65e-01 | 0.095100 | 4.71e-01 |
Neurotransmitter receptors and postsynaptic signal transmission | 138 | 5.44e-02 | 0.095000 | 1.62e-01 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 19 | 4.74e-01 | 0.094900 | 6.68e-01 |
Resolution of Sister Chromatid Cohesion | 110 | 8.77e-02 | 0.094300 | 2.26e-01 |
cGMP effects | 13 | 5.58e-01 | 0.093900 | 7.40e-01 |
Signaling by RAF1 mutants | 34 | 3.45e-01 | -0.093600 | 5.52e-01 |
Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 1.96e-01 | 0.093500 | 3.96e-01 |
Transmission across Chemical Synapses | 182 | 3.01e-02 | 0.093300 | 1.07e-01 |
DCC mediated attractive signaling | 13 | 5.62e-01 | 0.093000 | 7.42e-01 |
Stimuli-sensing channels | 71 | 1.77e-01 | -0.092800 | 3.70e-01 |
G alpha (12/13) signalling events | 70 | 1.82e-01 | -0.092200 | 3.78e-01 |
Platelet Aggregation (Plug Formation) | 29 | 3.91e-01 | 0.092100 | 5.92e-01 |
RHOH GTPase cycle | 31 | 3.75e-01 | 0.092000 | 5.79e-01 |
Neutrophil degranulation | 408 | 1.48e-03 | 0.092000 | 8.63e-03 |
Antigen processing: Ubiquitination & Proteasome degradation | 283 | 7.91e-03 | 0.091900 | 3.82e-02 |
Rap1 signalling | 13 | 5.66e-01 | -0.091800 | 7.43e-01 |
Circadian Clock | 66 | 1.98e-01 | 0.091700 | 3.98e-01 |
Myogenesis | 20 | 4.78e-01 | 0.091600 | 6.72e-01 |
Cytokine Signaling in Immune system | 577 | 1.90e-04 | 0.091300 | 1.43e-03 |
WNT5A-dependent internalization of FZD4 | 14 | 5.57e-01 | 0.090600 | 7.40e-01 |
Cell-extracellular matrix interactions | 18 | 5.07e-01 | 0.090400 | 6.95e-01 |
Basigin interactions | 21 | 4.75e-01 | 0.090100 | 6.69e-01 |
Extra-nuclear estrogen signaling | 65 | 2.09e-01 | 0.090100 | 4.11e-01 |
KSRP (KHSRP) binds and destabilizes mRNA | 17 | 5.21e-01 | -0.090000 | 7.09e-01 |
p38MAPK events | 13 | 5.75e-01 | -0.089800 | 7.47e-01 |
Ion transport by P-type ATPases | 40 | 3.28e-01 | 0.089300 | 5.36e-01 |
Phase 0 - rapid depolarisation | 22 | 4.69e-01 | 0.089300 | 6.62e-01 |
Platelet homeostasis | 68 | 2.03e-01 | 0.089300 | 4.06e-01 |
RIP-mediated NFkB activation via ZBP1 | 16 | 5.38e-01 | 0.089000 | 7.23e-01 |
GPCR ligand binding | 194 | 3.35e-02 | 0.088700 | 1.14e-01 |
Cellular response to heat stress | 95 | 1.36e-01 | 0.088600 | 3.05e-01 |
CASP8 activity is inhibited | 10 | 6.28e-01 | -0.088600 | 7.89e-01 |
Dimerization of procaspase-8 | 10 | 6.28e-01 | -0.088600 | 7.89e-01 |
Regulation by c-FLIP | 10 | 6.28e-01 | -0.088600 | 7.89e-01 |
NRAGE signals death through JNK | 56 | 2.52e-01 | -0.088500 | 4.59e-01 |
Cell Cycle, Mitotic | 479 | 9.50e-04 | 0.088500 | 5.95e-03 |
Nucleotide Excision Repair | 110 | 1.09e-01 | 0.088400 | 2.58e-01 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 5.28e-01 | -0.088300 | 7.14e-01 |
NCAM1 interactions | 30 | 4.04e-01 | 0.088100 | 6.04e-01 |
Diseases of carbohydrate metabolism | 28 | 4.23e-01 | 0.087500 | 6.22e-01 |
IRAK4 deficiency (TLR2/4) | 15 | 5.60e-01 | -0.086900 | 7.42e-01 |
G1/S-Specific Transcription | 25 | 4.53e-01 | -0.086700 | 6.52e-01 |
Regulation of TLR by endogenous ligand | 15 | 5.61e-01 | -0.086700 | 7.42e-01 |
SARS-CoV-2 Infection | 265 | 1.54e-02 | 0.086600 | 6.56e-02 |
Telomere C-strand synthesis initiation | 13 | 5.91e-01 | 0.086200 | 7.55e-01 |
Formation of Incision Complex in GG-NER | 43 | 3.30e-01 | 0.085900 | 5.36e-01 |
Post NMDA receptor activation events | 63 | 2.39e-01 | 0.085800 | 4.43e-01 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 14 | 5.79e-01 | 0.085700 | 7.48e-01 |
mRNA decay by 3’ to 5’ exoribonuclease | 13 | 5.93e-01 | 0.085500 | 7.57e-01 |
Downregulation of ERBB2 signaling | 27 | 4.42e-01 | 0.085500 | 6.42e-01 |
PI3K/AKT Signaling in Cancer | 81 | 1.85e-01 | 0.085200 | 3.83e-01 |
Signal amplification | 27 | 4.45e-01 | 0.085000 | 6.44e-01 |
Signal Transduction | 2005 | 6.41e-10 | 0.085000 | 1.96e-08 |
Regulated proteolysis of p75NTR | 11 | 6.26e-01 | 0.085000 | 7.89e-01 |
RHO GTPase Effectors | 242 | 2.36e-02 | 0.084700 | 8.99e-02 |
RNA Polymerase III Transcription Initiation | 36 | 3.80e-01 | 0.084600 | 5.81e-01 |
Class A/1 (Rhodopsin-like receptors) | 141 | 8.50e-02 | 0.084100 | 2.20e-01 |
MET activates RAP1 and RAC1 | 11 | 6.29e-01 | -0.084000 | 7.90e-01 |
Sensory perception of taste | 16 | 5.62e-01 | -0.083900 | 7.42e-01 |
RHO GTPases Activate WASPs and WAVEs | 35 | 3.91e-01 | 0.083800 | 5.92e-01 |
Sensory Perception | 146 | 8.10e-02 | 0.083700 | 2.14e-01 |
Toll Like Receptor 4 (TLR4) Cascade | 135 | 9.34e-02 | 0.083700 | 2.33e-01 |
SIRT1 negatively regulates rRNA expression | 14 | 5.89e-01 | -0.083500 | 7.54e-01 |
Negative regulators of DDX58/IFIH1 signaling | 34 | 4.00e-01 | 0.083400 | 6.01e-01 |
Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 5.77e-01 | 0.083300 | 7.47e-01 |
Transcriptional Regulation by TP53 | 339 | 8.59e-03 | 0.083300 | 4.06e-02 |
Inflammasomes | 20 | 5.21e-01 | 0.082900 | 7.09e-01 |
SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 16 | 5.66e-01 | -0.082900 | 7.43e-01 |
Amino acids regulate mTORC1 | 49 | 3.16e-01 | 0.082800 | 5.25e-01 |
Tight junction interactions | 16 | 5.67e-01 | -0.082700 | 7.43e-01 |
Signaling by FGFR4 in disease | 10 | 6.52e-01 | -0.082400 | 8.05e-01 |
Early Phase of HIV Life Cycle | 14 | 5.97e-01 | -0.081700 | 7.60e-01 |
Pre-NOTCH Expression and Processing | 55 | 2.95e-01 | 0.081600 | 5.01e-01 |
Signaling by Receptor Tyrosine Kinases | 462 | 2.79e-03 | 0.081500 | 1.53e-02 |
Regulation of TP53 Activity | 148 | 8.93e-02 | 0.081000 | 2.27e-01 |
Interleukin-2 family signaling | 33 | 4.21e-01 | -0.080900 | 6.21e-01 |
Signaling by Hippo | 19 | 5.42e-01 | 0.080900 | 7.26e-01 |
Transcriptional regulation of white adipocyte differentiation | 81 | 2.09e-01 | 0.080800 | 4.11e-01 |
Processive synthesis on the lagging strand | 15 | 5.88e-01 | -0.080700 | 7.54e-01 |
GABA receptor activation | 40 | 3.77e-01 | 0.080700 | 5.80e-01 |
Insulin processing | 21 | 5.24e-01 | 0.080400 | 7.09e-01 |
MTOR signalling | 40 | 3.80e-01 | 0.080200 | 5.81e-01 |
Regulation of Complement cascade | 34 | 4.21e-01 | 0.079800 | 6.21e-01 |
FCGR3A-mediated IL10 synthesis | 40 | 3.84e-01 | -0.079500 | 5.86e-01 |
TBC/RABGAPs | 44 | 3.63e-01 | -0.079300 | 5.72e-01 |
Cell-Cell communication | 113 | 1.47e-01 | 0.079000 | 3.21e-01 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 5.73e-01 | -0.078900 | 7.46e-01 |
Lagging Strand Synthesis | 20 | 5.42e-01 | -0.078900 | 7.26e-01 |
Amino acid transport across the plasma membrane | 20 | 5.43e-01 | 0.078600 | 7.26e-01 |
Signaling by NOTCH3 | 45 | 3.62e-01 | 0.078600 | 5.72e-01 |
Factors involved in megakaryocyte development and platelet production | 116 | 1.45e-01 | 0.078500 | 3.20e-01 |
Protein-protein interactions at synapses | 62 | 2.87e-01 | 0.078200 | 4.96e-01 |
Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 2.16e-01 | 0.078100 | 4.18e-01 |
Cell junction organization | 86 | 2.13e-01 | 0.077700 | 4.14e-01 |
Glucagon signaling in metabolic regulation | 26 | 4.94e-01 | 0.077500 | 6.86e-01 |
Maturation of nucleoprotein 9694631 | 15 | 6.03e-01 | -0.077500 | 7.66e-01 |
Cell Cycle | 589 | 1.38e-03 | 0.077500 | 8.11e-03 |
Transport of small molecules | 521 | 2.88e-03 | 0.076600 | 1.57e-02 |
Polo-like kinase mediated events | 14 | 6.21e-01 | -0.076400 | 7.85e-01 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 2.45e-01 | 0.076200 | 4.51e-01 |
Condensation of Prometaphase Chromosomes | 11 | 6.64e-01 | -0.075600 | 8.16e-01 |
Ca2+ pathway | 53 | 3.45e-01 | 0.075000 | 5.52e-01 |
SARS-CoV-2-host interactions | 176 | 8.78e-02 | 0.074700 | 2.26e-01 |
VxPx cargo-targeting to cilium | 17 | 5.94e-01 | -0.074700 | 7.58e-01 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 12 | 6.55e-01 | 0.074500 | 8.07e-01 |
Activation of RAC1 | 11 | 6.70e-01 | 0.074200 | 8.16e-01 |
Bile acid and bile salt metabolism | 28 | 4.98e-01 | -0.074100 | 6.89e-01 |
RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 5.00e-01 | 0.073700 | 6.90e-01 |
Activation of the pre-replicative complex | 29 | 4.93e-01 | 0.073600 | 6.85e-01 |
Innate Immune System | 844 | 3.23e-04 | 0.073400 | 2.31e-03 |
G-protein mediated events | 49 | 3.77e-01 | -0.072900 | 5.80e-01 |
Role of LAT2/NTAL/LAB on calcium mobilization | 18 | 5.92e-01 | -0.072900 | 7.57e-01 |
Sphingolipid metabolism | 73 | 2.82e-01 | 0.072900 | 4.88e-01 |
Interleukin-37 signaling | 20 | 5.73e-01 | -0.072800 | 7.46e-01 |
HS-GAG degradation | 22 | 5.55e-01 | -0.072800 | 7.38e-01 |
Mitochondrial calcium ion transport | 21 | 5.65e-01 | 0.072600 | 7.43e-01 |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 19 | 5.84e-01 | 0.072500 | 7.51e-01 |
Signaling by Ligand-Responsive EGFR Variants in Cancer | 19 | 5.84e-01 | 0.072500 | 7.51e-01 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 99 | 2.16e-01 | 0.072000 | 4.18e-01 |
Sensory processing of sound by inner hair cells of the cochlea | 47 | 3.94e-01 | 0.071900 | 5.95e-01 |
Gap junction degradation | 12 | 6.66e-01 | -0.071900 | 8.16e-01 |
EPHB-mediated forward signaling | 38 | 4.47e-01 | -0.071400 | 6.45e-01 |
Phospholipid metabolism | 177 | 1.04e-01 | -0.071000 | 2.49e-01 |
Trafficking of GluR2-containing AMPA receptors | 14 | 6.48e-01 | -0.070400 | 8.02e-01 |
Viral Messenger RNA Synthesis | 44 | 4.20e-01 | -0.070300 | 6.21e-01 |
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 17 | 6.16e-01 | -0.070200 | 7.81e-01 |
Regulation of actin dynamics for phagocytic cup formation | 62 | 3.40e-01 | 0.070000 | 5.48e-01 |
Neuronal System | 256 | 5.49e-02 | 0.069800 | 1.62e-01 |
MyD88 dependent cascade initiated on endosome | 100 | 2.29e-01 | 0.069600 | 4.34e-01 |
Regulation of signaling by CBL | 22 | 5.72e-01 | 0.069600 | 7.46e-01 |
RHOU GTPase cycle | 39 | 4.54e-01 | -0.069200 | 6.52e-01 |
Cyclin A/B1/B2 associated events during G2/M transition | 22 | 5.75e-01 | 0.069000 | 7.47e-01 |
Mitochondrial biogenesis | 85 | 2.74e-01 | 0.068700 | 4.79e-01 |
Cell-cell junction organization | 61 | 3.58e-01 | 0.068000 | 5.67e-01 |
HCMV Late Events | 59 | 3.68e-01 | 0.067700 | 5.77e-01 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane | 62 | 3.57e-01 | 0.067600 | 5.66e-01 |
CDC42 GTPase cycle | 145 | 1.61e-01 | -0.067400 | 3.43e-01 |
Antiviral mechanism by IFN-stimulated genes | 79 | 3.01e-01 | -0.067300 | 5.08e-01 |
Nonhomologous End-Joining (NHEJ) | 34 | 5.00e-01 | -0.066900 | 6.90e-01 |
Nitric oxide stimulates guanylate cyclase | 16 | 6.44e-01 | 0.066700 | 8.00e-01 |
Sensory processing of sound by outer hair cells of the cochlea | 35 | 4.96e-01 | 0.066600 | 6.88e-01 |
DAG and IP3 signaling | 37 | 4.87e-01 | -0.066100 | 6.79e-01 |
Regulation of NF-kappa B signaling | 18 | 6.28e-01 | 0.066000 | 7.89e-01 |
FCERI mediated MAPK activation | 33 | 5.12e-01 | -0.066000 | 7.00e-01 |
Removal of the Flap Intermediate | 14 | 6.75e-01 | -0.064700 | 8.20e-01 |
Golgi Associated Vesicle Biogenesis | 55 | 4.10e-01 | 0.064200 | 6.10e-01 |
Metabolism of water-soluble vitamins and cofactors | 108 | 2.50e-01 | 0.064200 | 4.56e-01 |
Eicosanoid ligand-binding receptors | 13 | 6.93e-01 | -0.063300 | 8.31e-01 |
Other semaphorin interactions | 19 | 6.33e-01 | -0.063300 | 7.93e-01 |
RNA Polymerase III Abortive And Retractive Initiation | 41 | 4.85e-01 | 0.063100 | 6.77e-01 |
RNA Polymerase III Transcription | 41 | 4.85e-01 | 0.063100 | 6.77e-01 |
Class I MHC mediated antigen processing & presentation | 344 | 4.56e-02 | 0.062900 | 1.45e-01 |
Transcriptional Regulation by VENTX | 38 | 5.04e-01 | 0.062600 | 6.94e-01 |
Sema3A PAK dependent Axon repulsion | 16 | 6.67e-01 | -0.062200 | 8.16e-01 |
Regulation of CDH11 gene transcription | 10 | 7.34e-01 | 0.062100 | 8.55e-01 |
Biotin transport and metabolism | 11 | 7.23e-01 | -0.061700 | 8.54e-01 |
MAP2K and MAPK activation | 34 | 5.34e-01 | -0.061600 | 7.19e-01 |
RAC3 GTPase cycle | 85 | 3.28e-01 | 0.061400 | 5.36e-01 |
MyD88 deficiency (TLR2/4) | 14 | 6.92e-01 | -0.061200 | 8.31e-01 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 7.37e-01 | -0.061200 | 8.57e-01 |
Regulation of TP53 Activity through Phosphorylation | 85 | 3.35e-01 | 0.060500 | 5.42e-01 |
Extension of Telomeres | 49 | 4.64e-01 | 0.060500 | 6.61e-01 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 5.86e-01 | 0.060500 | 7.53e-01 |
Glucose metabolism | 81 | 3.47e-01 | 0.060500 | 5.53e-01 |
Condensation of Prophase Chromosomes | 19 | 6.48e-01 | -0.060500 | 8.02e-01 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | 101 | 2.96e-01 | 0.060200 | 5.01e-01 |
G beta:gamma signalling through PI3Kgamma | 20 | 6.43e-01 | -0.059800 | 8.00e-01 |
Paradoxical activation of RAF signaling by kinase inactive BRAF | 38 | 5.24e-01 | -0.059800 | 7.09e-01 |
Signaling by RAS mutants | 38 | 5.24e-01 | -0.059800 | 7.09e-01 |
Signaling by moderate kinase activity BRAF mutants | 38 | 5.24e-01 | -0.059800 | 7.09e-01 |
Signaling downstream of RAS mutants | 38 | 5.24e-01 | -0.059800 | 7.09e-01 |
Regulation of KIT signaling | 15 | 6.90e-01 | -0.059500 | 8.29e-01 |
E2F mediated regulation of DNA replication | 21 | 6.39e-01 | -0.059200 | 7.96e-01 |
Hyaluronan uptake and degradation | 11 | 7.35e-01 | -0.059000 | 8.55e-01 |
PRC2 methylates histones and DNA | 19 | 6.57e-01 | 0.058900 | 8.08e-01 |
Regulation of TP53 Activity through Methylation | 19 | 6.58e-01 | 0.058700 | 8.09e-01 |
G alpha (s) signalling events | 84 | 3.55e-01 | 0.058500 | 5.63e-01 |
NOD1/2 Signaling Pathway | 36 | 5.44e-01 | -0.058500 | 7.27e-01 |
SUMOylation of DNA damage response and repair proteins | 77 | 3.78e-01 | -0.058200 | 5.80e-01 |
Regulation of HSF1-mediated heat shock response | 78 | 3.75e-01 | 0.058100 | 5.79e-01 |
DNA Damage Bypass | 45 | 5.03e-01 | 0.057700 | 6.93e-01 |
Sensory processing of sound | 50 | 4.84e-01 | 0.057300 | 6.76e-01 |
GRB2:SOS provides linkage to MAPK signaling for Integrins | 11 | 7.42e-01 | -0.057300 | 8.61e-01 |
FLT3 Signaling | 34 | 5.64e-01 | 0.057100 | 7.43e-01 |
Dual incision in TC-NER | 65 | 4.28e-01 | 0.056900 | 6.27e-01 |
RHOQ GTPase cycle | 57 | 4.58e-01 | -0.056800 | 6.57e-01 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 18 | 6.77e-01 | 0.056700 | 8.20e-01 |
Interleukin-6 signaling | 10 | 7.57e-01 | 0.056400 | 8.70e-01 |
RUNX3 regulates NOTCH signaling | 14 | 7.15e-01 | -0.056400 | 8.49e-01 |
Sensory perception of sweet, bitter, and umami (glutamate) taste | 13 | 7.26e-01 | -0.056200 | 8.55e-01 |
Cargo trafficking to the periciliary membrane | 45 | 5.15e-01 | 0.056100 | 7.03e-01 |
Heparan sulfate/heparin (HS-GAG) metabolism | 43 | 5.25e-01 | 0.056100 | 7.10e-01 |
Vesicle-mediated transport | 603 | 1.94e-02 | 0.056000 | 7.80e-02 |
Regulation of Expression and Function of Type II Classical Cadherins | 29 | 6.03e-01 | 0.055800 | 7.66e-01 |
Regulation of Homotypic Cell-Cell Adhesion | 29 | 6.03e-01 | 0.055800 | 7.66e-01 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 57 | 4.67e-01 | 0.055800 | 6.61e-01 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants | 57 | 4.67e-01 | 0.055800 | 6.61e-01 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 57 | 4.67e-01 | 0.055800 | 6.61e-01 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer | 57 | 4.67e-01 | 0.055800 | 6.61e-01 |
Signaling by NOTCH1 in Cancer | 57 | 4.67e-01 | 0.055800 | 6.61e-01 |
Membrane Trafficking | 571 | 2.40e-02 | 0.055500 | 9.06e-02 |
Retrograde transport at the Trans-Golgi-Network | 49 | 5.03e-01 | -0.055300 | 6.93e-01 |
Transcription of E2F targets under negative control by DREAM complex | 18 | 6.85e-01 | 0.055300 | 8.25e-01 |
Synthesis of PC | 23 | 6.48e-01 | 0.055100 | 8.02e-01 |
Immune System | 1588 | 3.13e-04 | 0.054900 | 2.24e-03 |
Cobalamin (Cbl, vitamin B12) transport and metabolism | 15 | 7.13e-01 | 0.054800 | 8.48e-01 |
Toll Like Receptor 9 (TLR9) Cascade | 104 | 3.36e-01 | 0.054700 | 5.43e-01 |
ADORA2B mediated anti-inflammatory cytokines production | 35 | 5.76e-01 | 0.054600 | 7.47e-01 |
ISG15 antiviral mechanism | 71 | 4.30e-01 | -0.054200 | 6.28e-01 |
Reproduction | 67 | 4.43e-01 | 0.054200 | 6.42e-01 |
Transport of inorganic cations/anions and amino acids/oligopeptides | 66 | 4.48e-01 | -0.054100 | 6.46e-01 |
Interferon Signaling | 165 | 2.34e-01 | -0.053800 | 4.39e-01 |
Regulated Necrosis | 51 | 5.07e-01 | 0.053800 | 6.95e-01 |
Metabolism of nitric oxide: NOS3 activation and regulation | 15 | 7.21e-01 | 0.053200 | 8.54e-01 |
HDR through Single Strand Annealing (SSA) | 35 | 5.89e-01 | -0.052800 | 7.54e-01 |
Apoptotic execution phase | 42 | 5.54e-01 | 0.052700 | 7.38e-01 |
HCMV Early Events | 75 | 4.31e-01 | 0.052600 | 6.30e-01 |
MicroRNA (miRNA) biogenesis | 24 | 6.57e-01 | 0.052400 | 8.08e-01 |
MET receptor recycling | 10 | 7.74e-01 | -0.052400 | 8.74e-01 |
Diseases associated with the TLR signaling cascade | 27 | 6.39e-01 | -0.052200 | 7.96e-01 |
Diseases of Immune System | 27 | 6.39e-01 | -0.052200 | 7.96e-01 |
G alpha (i) signalling events | 171 | 2.43e-01 | 0.051800 | 4.49e-01 |
Opioid Signalling | 77 | 4.33e-01 | 0.051800 | 6.30e-01 |
Heme signaling | 44 | 5.53e-01 | -0.051700 | 7.38e-01 |
PKA-mediated phosphorylation of CREB | 19 | 6.97e-01 | -0.051500 | 8.34e-01 |
Complement cascade | 38 | 5.83e-01 | 0.051500 | 7.51e-01 |
RHOBTB GTPase Cycle | 35 | 6.03e-01 | 0.050800 | 7.66e-01 |
Fcgamma receptor (FCGR) dependent phagocytosis | 85 | 4.21e-01 | 0.050600 | 6.21e-01 |
PKA activation in glucagon signalling | 16 | 7.26e-01 | 0.050500 | 8.55e-01 |
G beta:gamma signalling through PLC beta | 15 | 7.35e-01 | -0.050500 | 8.55e-01 |
Glyoxylate metabolism and glycine degradation | 22 | 6.82e-01 | 0.050500 | 8.24e-01 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 80 | 4.36e-01 | 0.050400 | 6.33e-01 |
Signaling by NOTCH1 | 70 | 4.66e-01 | 0.050400 | 6.61e-01 |
RNA polymerase II transcribes snRNA genes | 71 | 4.64e-01 | 0.050300 | 6.61e-01 |
Transcriptional Regulation by MECP2 | 45 | 5.63e-01 | 0.049900 | 7.42e-01 |
PKA activation | 17 | 7.23e-01 | 0.049700 | 8.54e-01 |
SLC-mediated transmembrane transport | 151 | 2.92e-01 | 0.049700 | 4.99e-01 |
Synthesis of bile acids and bile salts | 25 | 6.67e-01 | -0.049700 | 8.16e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 24 | 6.76e-01 | 0.049300 | 8.20e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 24 | 6.76e-01 | 0.049300 | 8.20e-01 |
Defective homologous recombination repair (HRR) due to BRCA1 loss of function | 24 | 6.76e-01 | 0.049300 | 8.20e-01 |
Defective homologous recombination repair (HRR) due to PALB2 loss of function | 24 | 6.76e-01 | 0.049300 | 8.20e-01 |
Signaling by FGFR1 in disease | 32 | 6.30e-01 | 0.049200 | 7.90e-01 |
Diseases of programmed cell death | 47 | 5.61e-01 | 0.049000 | 7.42e-01 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity | 23 | 6.84e-01 | -0.049000 | 8.24e-01 |
Trafficking of AMPA receptors | 23 | 6.84e-01 | -0.049000 | 8.24e-01 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 21 | 6.98e-01 | -0.049000 | 8.34e-01 |
RHOV GTPase cycle | 34 | 6.22e-01 | -0.048900 | 7.85e-01 |
Voltage gated Potassium channels | 17 | 7.28e-01 | -0.048800 | 8.55e-01 |
HDR through Homologous Recombination (HRR) | 65 | 4.98e-01 | -0.048600 | 6.89e-01 |
Effects of PIP2 hydrolysis | 22 | 6.94e-01 | -0.048400 | 8.32e-01 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 7.64e-01 | 0.048200 | 8.70e-01 |
Metabolism of steroids | 118 | 3.73e-01 | 0.047600 | 5.78e-01 |
SUMOylation of chromatin organization proteins | 57 | 5.37e-01 | -0.047300 | 7.23e-01 |
CRMPs in Sema3A signaling | 14 | 7.60e-01 | -0.047100 | 8.70e-01 |
G beta:gamma signalling through BTK | 13 | 7.69e-01 | 0.047000 | 8.72e-01 |
Activated NOTCH1 Transmits Signal to the Nucleus | 28 | 6.67e-01 | 0.047000 | 8.16e-01 |
Mitotic Spindle Checkpoint | 103 | 4.11e-01 | 0.047000 | 6.10e-01 |
Transcriptional Regulation by E2F6 | 34 | 6.36e-01 | 0.046800 | 7.96e-01 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 7.70e-01 | -0.046800 | 8.73e-01 |
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 86 | 4.54e-01 | 0.046800 | 6.52e-01 |
Amplification of signal from the kinetochores | 86 | 4.54e-01 | 0.046800 | 6.52e-01 |
Interleukin-20 family signaling | 14 | 7.62e-01 | 0.046700 | 8.70e-01 |
Listeria monocytogenes entry into host cells | 18 | 7.32e-01 | 0.046600 | 8.55e-01 |
Glutathione conjugation | 28 | 6.70e-01 | 0.046500 | 8.16e-01 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 7.20e-01 | -0.046300 | 8.54e-01 |
Adaptive Immune System | 642 | 5.03e-02 | 0.045500 | 1.54e-01 |
Signaling by Rho GTPases | 593 | 6.02e-02 | 0.045400 | 1.73e-01 |
Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 608 | 5.82e-02 | 0.045200 | 1.70e-01 |
RND3 GTPase cycle | 36 | 6.40e-01 | 0.045000 | 7.98e-01 |
Pre-NOTCH Transcription and Translation | 39 | 6.28e-01 | 0.044800 | 7.89e-01 |
Signaling by Retinoic Acid | 36 | 6.44e-01 | -0.044500 | 8.00e-01 |
SUMOylation of transcription cofactors | 44 | 6.10e-01 | 0.044400 | 7.74e-01 |
RAC2 GTPase cycle | 84 | 4.83e-01 | 0.044300 | 6.76e-01 |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | 12 | 7.91e-01 | -0.044200 | 8.85e-01 |
WNT ligand biogenesis and trafficking | 16 | 7.59e-01 | 0.044200 | 8.70e-01 |
Processing of Capped Intronless Pre-mRNA | 29 | 6.80e-01 | -0.044200 | 8.23e-01 |
HDACs deacetylate histones | 36 | 6.49e-01 | 0.043900 | 8.02e-01 |
Signaling by NTRK3 (TRKC) | 16 | 7.61e-01 | 0.043900 | 8.70e-01 |
Constitutive Signaling by Aberrant PI3K in Cancer | 54 | 5.78e-01 | 0.043800 | 7.47e-01 |
Killing mechanisms | 10 | 8.11e-01 | 0.043700 | 8.98e-01 |
WNT5:FZD7-mediated leishmania damping | 10 | 8.11e-01 | 0.043700 | 8.98e-01 |
Regulation of FOXO transcriptional activity by acetylation | 10 | 8.11e-01 | 0.043600 | 8.98e-01 |
HDMs demethylate histones | 21 | 7.30e-01 | -0.043400 | 8.55e-01 |
Pregnenolone biosynthesis | 10 | 8.13e-01 | -0.043300 | 8.98e-01 |
Acyl chain remodelling of PG | 11 | 8.05e-01 | -0.043100 | 8.96e-01 |
FOXO-mediated transcription of cell death genes | 15 | 7.73e-01 | 0.043000 | 8.74e-01 |
Formation of annular gap junctions | 11 | 8.06e-01 | -0.042800 | 8.96e-01 |
mRNA Splicing | 210 | 2.89e-01 | 0.042500 | 4.96e-01 |
Semaphorin interactions | 61 | 5.68e-01 | 0.042300 | 7.43e-01 |
Signaling by Nuclear Receptors | 214 | 2.91e-01 | 0.041900 | 4.98e-01 |
Processing of DNA double-strand break ends | 60 | 5.77e-01 | 0.041600 | 7.47e-01 |
mRNA Splicing - Major Pathway | 202 | 3.11e-01 | 0.041400 | 5.19e-01 |
mRNA decay by 5’ to 3’ exoribonuclease | 15 | 7.81e-01 | 0.041400 | 8.78e-01 |
RNA Polymerase I Promoter Escape | 37 | 6.66e-01 | 0.041100 | 8.16e-01 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta | 65 | 5.67e-01 | 0.041000 | 7.43e-01 |
Thrombin signalling through proteinase activated receptors (PARs) | 25 | 7.23e-01 | 0.040900 | 8.54e-01 |
SUMO E3 ligases SUMOylate target proteins | 161 | 3.72e-01 | -0.040900 | 5.78e-01 |
Endogenous sterols | 20 | 7.56e-01 | 0.040100 | 8.70e-01 |
DNA strand elongation | 31 | 7.00e-01 | 0.040000 | 8.35e-01 |
RHOJ GTPase cycle | 52 | 6.19e-01 | 0.039800 | 7.84e-01 |
Recruitment of NuMA to mitotic centrosomes | 86 | 5.24e-01 | 0.039800 | 7.09e-01 |
Regulation of beta-cell development | 18 | 7.73e-01 | -0.039300 | 8.74e-01 |
Organelle biogenesis and maintenance | 270 | 2.68e-01 | 0.039300 | 4.73e-01 |
Positive epigenetic regulation of rRNA expression | 52 | 6.26e-01 | 0.039100 | 7.89e-01 |
Glycolysis | 64 | 5.89e-01 | 0.039100 | 7.54e-01 |
Transcriptional activation of mitochondrial biogenesis | 49 | 6.37e-01 | -0.039000 | 7.96e-01 |
Signal transduction by L1 | 20 | 7.63e-01 | 0.038900 | 8.70e-01 |
RET signaling | 33 | 6.99e-01 | 0.038800 | 8.35e-01 |
Scavenging by Class A Receptors | 16 | 7.90e-01 | -0.038500 | 8.85e-01 |
Thromboxane signalling through TP receptor | 19 | 7.73e-01 | 0.038200 | 8.74e-01 |
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 23 | 7.55e-01 | 0.037600 | 8.70e-01 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 85 | 5.54e-01 | -0.037200 | 7.38e-01 |
DNA Repair | 279 | 2.94e-01 | 0.036600 | 5.00e-01 |
Phosphorylation of the APC/C | 20 | 7.77e-01 | -0.036500 | 8.76e-01 |
Intra-Golgi traffic | 42 | 6.83e-01 | -0.036500 | 8.24e-01 |
Telomere C-strand (Lagging Strand) Synthesis | 34 | 7.13e-01 | 0.036400 | 8.48e-01 |
PCNA-Dependent Long Patch Base Excision Repair | 21 | 7.73e-01 | 0.036300 | 8.74e-01 |
Integrin signaling | 22 | 7.69e-01 | -0.036100 | 8.72e-01 |
Aflatoxin activation and detoxification | 11 | 8.38e-01 | 0.035700 | 9.09e-01 |
Negative regulation of the PI3K/AKT network | 87 | 5.66e-01 | 0.035600 | 7.43e-01 |
RHOD GTPase cycle | 49 | 6.68e-01 | 0.035500 | 8.16e-01 |
EPH-Ephrin signaling | 82 | 5.84e-01 | 0.035000 | 7.51e-01 |
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 22 | 7.77e-01 | 0.034900 | 8.76e-01 |
SUMOylation of RNA binding proteins | 47 | 6.82e-01 | -0.034600 | 8.24e-01 |
RAB GEFs exchange GTP for GDP on RABs | 86 | 5.84e-01 | 0.034200 | 7.51e-01 |
Constitutive Signaling by Overexpressed ERBB2 | 11 | 8.44e-01 | -0.034200 | 9.13e-01 |
Signaling by CSF1 (M-CSF) in myeloid cells | 30 | 7.48e-01 | -0.033900 | 8.63e-01 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 11 | 8.47e-01 | -0.033600 | 9.13e-01 |
TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 8.16e-01 | 0.033600 | 8.99e-01 |
Striated Muscle Contraction | 20 | 7.97e-01 | 0.033200 | 8.89e-01 |
Signaling by BRAF and RAF1 fusions | 56 | 6.70e-01 | -0.033000 | 8.16e-01 |
Signaling by EGFR | 46 | 6.99e-01 | -0.033000 | 8.35e-01 |
Diseases associated with N-glycosylation of proteins | 20 | 7.99e-01 | 0.032900 | 8.91e-01 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 36 | 7.33e-01 | -0.032900 | 8.55e-01 |
Citric acid cycle (TCA cycle) | 22 | 7.90e-01 | 0.032700 | 8.85e-01 |
Signaling by ERBB2 | 47 | 7.01e-01 | 0.032400 | 8.36e-01 |
Cytochrome P450 - arranged by substrate type | 33 | 7.48e-01 | 0.032300 | 8.63e-01 |
Deadenylation-dependent mRNA decay | 50 | 6.94e-01 | 0.032200 | 8.32e-01 |
Interleukin-3, Interleukin-5 and GM-CSF signaling | 41 | 7.21e-01 | -0.032200 | 8.54e-01 |
SLC transporter disorders | 69 | 6.46e-01 | -0.032000 | 8.02e-01 |
Fatty acid metabolism | 140 | 5.16e-01 | 0.031800 | 7.04e-01 |
Binding and Uptake of Ligands by Scavenger Receptors | 35 | 7.45e-01 | 0.031800 | 8.62e-01 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 8.31e-01 | 0.031800 | 9.09e-01 |
Signaling by cytosolic FGFR1 fusion mutants | 18 | 8.16e-01 | -0.031700 | 8.99e-01 |
Nicotinate metabolism | 27 | 7.76e-01 | 0.031700 | 8.75e-01 |
Adenylate cyclase inhibitory pathway | 13 | 8.43e-01 | 0.031700 | 9.13e-01 |
Frs2-mediated activation | 12 | 8.50e-01 | -0.031500 | 9.14e-01 |
Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 8.09e-01 | -0.031300 | 8.98e-01 |
Cell death signalling via NRAGE, NRIF and NADE | 73 | 6.46e-01 | -0.031100 | 8.02e-01 |
Aspirin ADME | 15 | 8.35e-01 | -0.031100 | 9.09e-01 |
Synthesis of PA | 31 | 7.65e-01 | -0.031000 | 8.71e-01 |
Apoptotic cleavage of cellular proteins | 34 | 7.56e-01 | 0.030800 | 8.70e-01 |
The role of Nef in HIV-1 replication and disease pathogenesis | 24 | 7.95e-01 | -0.030600 | 8.88e-01 |
SARS-CoV-1 activates/modulates innate immune responses | 39 | 7.42e-01 | 0.030400 | 8.61e-01 |
Germ layer formation at gastrulation | 10 | 8.68e-01 | -0.030300 | 9.20e-01 |
Signaling by GPCR | 396 | 3.04e-01 | 0.030200 | 5.11e-01 |
SUMOylation | 167 | 5.01e-01 | -0.030200 | 6.92e-01 |
NoRC negatively regulates rRNA expression | 52 | 7.14e-01 | 0.029400 | 8.48e-01 |
Oncogenic MAPK signaling | 72 | 6.70e-01 | -0.029000 | 8.16e-01 |
Signalling to RAS | 20 | 8.23e-01 | 0.028900 | 9.05e-01 |
InlB-mediated entry of Listeria monocytogenes into host cell | 14 | 8.52e-01 | 0.028800 | 9.15e-01 |
ERK/MAPK targets | 22 | 8.16e-01 | 0.028700 | 8.99e-01 |
Intrinsic Pathway for Apoptosis | 52 | 7.21e-01 | 0.028700 | 8.54e-01 |
Role of phospholipids in phagocytosis | 26 | 8.01e-01 | -0.028600 | 8.92e-01 |
SUMOylation of transcription factors | 17 | 8.42e-01 | -0.027900 | 9.12e-01 |
Retrograde neurotrophin signalling | 14 | 8.60e-01 | 0.027300 | 9.17e-01 |
Acyl chain remodelling of PS | 14 | 8.60e-01 | -0.027200 | 9.17e-01 |
NOTCH3 Intracellular Domain Regulates Transcription | 21 | 8.30e-01 | 0.027100 | 9.09e-01 |
p75 NTR receptor-mediated signalling | 92 | 6.53e-01 | 0.027100 | 8.06e-01 |
TP53 Regulates Transcription of Cell Death Genes | 40 | 7.68e-01 | -0.027000 | 8.72e-01 |
Mitochondrial tRNA aminoacylation | 21 | 8.31e-01 | -0.026900 | 9.09e-01 |
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 94 | 6.52e-01 | -0.026900 | 8.05e-01 |
SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 12 | 8.73e-01 | 0.026800 | 9.22e-01 |
Regulation of PLK1 Activity at G2/M Transition | 85 | 6.71e-01 | 0.026700 | 8.16e-01 |
Toll-like Receptor Cascades | 155 | 5.69e-01 | 0.026500 | 7.44e-01 |
Diseases of DNA repair | 48 | 7.51e-01 | 0.026400 | 8.66e-01 |
FOXO-mediated transcription | 56 | 7.34e-01 | 0.026200 | 8.55e-01 |
Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 8.35e-01 | -0.026200 | 9.09e-01 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 8.35e-01 | -0.026200 | 9.09e-01 |
RNA Polymerase I Promoter Clearance | 56 | 7.36e-01 | 0.026100 | 8.55e-01 |
RNA Polymerase I Transcription | 56 | 7.36e-01 | 0.026100 | 8.55e-01 |
Regulation of PTEN mRNA translation | 11 | 8.81e-01 | 0.026000 | 9.29e-01 |
NOTCH4 Intracellular Domain Regulates Transcription | 19 | 8.44e-01 | -0.026000 | 9.13e-01 |
Metabolism of non-coding RNA | 53 | 7.46e-01 | -0.025800 | 8.62e-01 |
snRNP Assembly | 53 | 7.46e-01 | -0.025800 | 8.62e-01 |
EPH-ephrin mediated repulsion of cells | 44 | 7.68e-01 | -0.025700 | 8.72e-01 |
Peroxisomal protein import | 57 | 7.38e-01 | -0.025600 | 8.57e-01 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 8.68e-01 | 0.025600 | 9.20e-01 |
Signaling by EGFR in Cancer | 22 | 8.37e-01 | -0.025400 | 9.09e-01 |
FCGR3A-mediated phagocytosis | 60 | 7.35e-01 | 0.025300 | 8.55e-01 |
Leishmania phagocytosis | 60 | 7.35e-01 | 0.025300 | 8.55e-01 |
Parasite infection | 60 | 7.35e-01 | 0.025300 | 8.55e-01 |
Cilium Assembly | 185 | 5.55e-01 | 0.025200 | 7.38e-01 |
Establishment of Sister Chromatid Cohesion | 11 | 8.85e-01 | -0.025100 | 9.33e-01 |
RND2 GTPase cycle | 36 | 7.95e-01 | -0.025000 | 8.88e-01 |
Impaired BRCA2 binding to PALB2 | 23 | 8.36e-01 | 0.025000 | 9.09e-01 |
Signaling by ERBB4 | 50 | 7.62e-01 | -0.024700 | 8.70e-01 |
Gene expression (Transcription) | 1343 | 1.33e-01 | -0.024700 | 3.01e-01 |
Sulfur amino acid metabolism | 23 | 8.38e-01 | 0.024700 | 9.09e-01 |
Cargo recognition for clathrin-mediated endocytosis | 91 | 6.86e-01 | -0.024600 | 8.25e-01 |
RHO GTPases Activate NADPH Oxidases | 21 | 8.47e-01 | 0.024300 | 9.13e-01 |
HuR (ELAVL1) binds and stabilizes mRNA | 10 | 8.95e-01 | 0.024100 | 9.38e-01 |
SUMOylation of intracellular receptors | 27 | 8.29e-01 | -0.024000 | 9.09e-01 |
Signaling by NTRK2 (TRKB) | 21 | 8.50e-01 | -0.023900 | 9.14e-01 |
Mitotic Prometaphase | 186 | 5.82e-01 | 0.023400 | 7.51e-01 |
AURKA Activation by TPX2 | 70 | 7.36e-01 | -0.023400 | 8.55e-01 |
Expression and translocation of olfactory receptors | 23 | 8.48e-01 | 0.023000 | 9.13e-01 |
FCERI mediated Ca+2 mobilization | 32 | 8.22e-01 | -0.022900 | 9.05e-01 |
Gene Silencing by RNA | 78 | 7.33e-01 | -0.022300 | 8.55e-01 |
ADP signalling through P2Y purinoceptor 1 | 20 | 8.63e-01 | 0.022300 | 9.17e-01 |
Inositol phosphate metabolism | 41 | 8.14e-01 | -0.021300 | 8.99e-01 |
Netrin-1 signaling | 41 | 8.16e-01 | 0.021000 | 8.99e-01 |
Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 8.48e-01 | 0.020900 | 9.13e-01 |
Drug ADME | 59 | 7.87e-01 | 0.020300 | 8.84e-01 |
Signaling by NODAL | 13 | 9.00e-01 | 0.020200 | 9.40e-01 |
Termination of translesion DNA synthesis | 31 | 8.46e-01 | 0.020100 | 9.13e-01 |
Signal regulatory protein family interactions | 11 | 9.09e-01 | 0.019900 | 9.45e-01 |
Costimulation by the CD28 family | 48 | 8.12e-01 | 0.019800 | 8.98e-01 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 25 | 8.64e-01 | 0.019800 | 9.17e-01 |
VEGFR2 mediated vascular permeability | 27 | 8.60e-01 | 0.019700 | 9.17e-01 |
Dual Incision in GG-NER | 41 | 8.28e-01 | -0.019600 | 9.09e-01 |
Centrosome maturation | 79 | 7.64e-01 | -0.019600 | 8.70e-01 |
Recruitment of mitotic centrosome proteins and complexes | 79 | 7.64e-01 | -0.019600 | 8.70e-01 |
tRNA processing in the nucleus | 59 | 7.95e-01 | -0.019600 | 8.88e-01 |
TP53 Regulates Transcription of Cell Cycle Genes | 44 | 8.24e-01 | 0.019400 | 9.06e-01 |
Clathrin-mediated endocytosis | 130 | 7.11e-01 | -0.018800 | 8.47e-01 |
G0 and Early G1 | 25 | 8.72e-01 | -0.018700 | 9.22e-01 |
Prolactin receptor signaling | 11 | 9.15e-01 | -0.018500 | 9.50e-01 |
TNF signaling | 57 | 8.10e-01 | -0.018400 | 8.98e-01 |
Arachidonic acid metabolism | 37 | 8.48e-01 | 0.018200 | 9.13e-01 |
Glutamate Neurotransmitter Release Cycle | 21 | 8.86e-01 | 0.018100 | 9.33e-01 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 17 | 8.98e-01 | 0.017900 | 9.40e-01 |
G alpha (q) signalling events | 128 | 7.27e-01 | -0.017900 | 8.55e-01 |
Regulation of TNFR1 signaling | 48 | 8.32e-01 | 0.017700 | 9.09e-01 |
Pyroptosis | 21 | 8.89e-01 | -0.017500 | 9.35e-01 |
CD28 dependent PI3K/Akt signaling | 20 | 8.93e-01 | 0.017400 | 9.37e-01 |
Processing of Capped Intron-Containing Pre-mRNA | 278 | 6.20e-01 | -0.017300 | 7.85e-01 |
Glycerophospholipid biosynthesis | 100 | 7.65e-01 | -0.017300 | 8.71e-01 |
RHOB GTPase cycle | 64 | 8.11e-01 | -0.017300 | 8.98e-01 |
RNA Polymerase I Transcription Termination | 30 | 8.72e-01 | 0.017000 | 9.22e-01 |
p130Cas linkage to MAPK signaling for integrins | 11 | 9.23e-01 | 0.016900 | 9.56e-01 |
Presynaptic phase of homologous DNA pairing and strand exchange | 38 | 8.59e-01 | 0.016700 | 9.17e-01 |
Homology Directed Repair | 100 | 7.78e-01 | -0.016300 | 8.76e-01 |
ZBP1(DAI) mediated induction of type I IFNs | 19 | 9.03e-01 | 0.016200 | 9.42e-01 |
Homologous DNA Pairing and Strand Exchange | 41 | 8.60e-01 | -0.015900 | 9.17e-01 |
CD28 co-stimulation | 30 | 8.82e-01 | 0.015700 | 9.29e-01 |
RNA Polymerase II Transcription | 1185 | 3.72e-01 | -0.015500 | 5.78e-01 |
Generic Transcription Pathway | 1067 | 3.97e-01 | -0.015500 | 5.98e-01 |
TNFR1-induced NF-kappa-B signaling pathway | 33 | 8.78e-01 | -0.015400 | 9.27e-01 |
Plasma lipoprotein remodeling | 19 | 9.08e-01 | -0.015400 | 9.45e-01 |
Anti-inflammatory response favouring Leishmania parasite infection | 70 | 8.34e-01 | -0.014500 | 9.09e-01 |
Leishmania parasite growth and survival | 70 | 8.34e-01 | -0.014500 | 9.09e-01 |
NCAM signaling for neurite out-growth | 49 | 8.61e-01 | -0.014400 | 9.17e-01 |
RAC1 GTPase cycle | 172 | 7.45e-01 | -0.014400 | 8.62e-01 |
tRNA modification in the nucleus and cytosol | 43 | 8.70e-01 | 0.014400 | 9.21e-01 |
Leishmania infection | 149 | 7.63e-01 | 0.014300 | 8.70e-01 |
Parasitic Infection Pathways | 149 | 7.63e-01 | 0.014300 | 8.70e-01 |
trans-Golgi Network Vesicle Budding | 70 | 8.38e-01 | -0.014200 | 9.09e-01 |
Regulation of CDH11 Expression and Function | 27 | 9.01e-01 | 0.013800 | 9.41e-01 |
G2/M DNA damage checkpoint | 57 | 8.58e-01 | 0.013700 | 9.17e-01 |
Depolymerization of the Nuclear Lamina | 15 | 9.28e-01 | -0.013500 | 9.59e-01 |
Resolution of Abasic Sites (AP sites) | 38 | 8.87e-01 | 0.013400 | 9.33e-01 |
RHO GTPases activate KTN1 | 10 | 9.42e-01 | -0.013200 | 9.66e-01 |
Transcriptional regulation by small RNAs | 53 | 8.69e-01 | -0.013100 | 9.20e-01 |
RHOBTB1 GTPase cycle | 23 | 9.14e-01 | -0.013000 | 9.49e-01 |
Activation of HOX genes during differentiation | 65 | 8.56e-01 | 0.013000 | 9.17e-01 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis | 65 | 8.56e-01 | 0.013000 | 9.17e-01 |
G beta:gamma signalling through CDC42 | 15 | 9.31e-01 | 0.012900 | 9.61e-01 |
Postmitotic nuclear pore complex (NPC) reformation | 27 | 9.08e-01 | 0.012800 | 9.45e-01 |
Advanced glycosylation endproduct receptor signaling | 11 | 9.42e-01 | -0.012700 | 9.66e-01 |
Impaired BRCA2 binding to RAD51 | 33 | 9.00e-01 | -0.012700 | 9.40e-01 |
Loss of Nlp from mitotic centrosomes | 67 | 8.64e-01 | -0.012100 | 9.17e-01 |
Loss of proteins required for interphase microtubule organization from the centrosome | 67 | 8.64e-01 | -0.012100 | 9.17e-01 |
Nuclear Receptor transcription pathway | 40 | 8.95e-01 | 0.012100 | 9.38e-01 |
Neurexins and neuroligins | 40 | 8.95e-01 | 0.012000 | 9.38e-01 |
Negative regulation of MET activity | 20 | 9.27e-01 | -0.011800 | 9.59e-01 |
Carnitine metabolism | 13 | 9.42e-01 | 0.011700 | 9.66e-01 |
HATs acetylate histones | 82 | 8.57e-01 | 0.011500 | 9.17e-01 |
Chromatin modifying enzymes | 202 | 7.88e-01 | -0.011000 | 8.84e-01 |
Chromatin organization | 202 | 7.88e-01 | -0.011000 | 8.84e-01 |
Polymerase switching on the C-strand of the telomere | 26 | 9.23e-01 | 0.010900 | 9.56e-01 |
GPCR downstream signalling | 356 | 7.29e-01 | 0.010700 | 8.55e-01 |
Regulation of lipid metabolism by PPARalpha | 106 | 8.55e-01 | -0.010300 | 9.17e-01 |
RHOA GTPase cycle | 141 | 8.36e-01 | -0.010100 | 9.09e-01 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 9.29e-01 | -0.010100 | 9.59e-01 |
Synthesis of IP3 and IP4 in the cytosol | 22 | 9.36e-01 | 0.009930 | 9.63e-01 |
Rab regulation of trafficking | 118 | 8.52e-01 | -0.009920 | 9.15e-01 |
Surfactant metabolism | 19 | 9.47e-01 | 0.008800 | 9.70e-01 |
Activation of ATR in response to replication stress | 31 | 9.33e-01 | 0.008690 | 9.62e-01 |
GPVI-mediated activation cascade | 31 | 9.38e-01 | 0.008100 | 9.63e-01 |
Glycosphingolipid metabolism | 36 | 9.34e-01 | 0.007970 | 9.62e-01 |
RNA Polymerase I Transcription Initiation | 47 | 9.27e-01 | 0.007710 | 9.59e-01 |
Disorders of Developmental Biology | 11 | 9.65e-01 | 0.007680 | 9.80e-01 |
Disorders of Nervous System Development | 11 | 9.65e-01 | 0.007680 | 9.80e-01 |
Loss of function of MECP2 in Rett syndrome | 11 | 9.65e-01 | 0.007680 | 9.80e-01 |
Pervasive developmental disorders | 11 | 9.65e-01 | 0.007680 | 9.80e-01 |
Signaling by VEGF | 104 | 8.94e-01 | -0.007570 | 9.38e-01 |
Triglyceride metabolism | 24 | 9.49e-01 | 0.007490 | 9.72e-01 |
Anchoring of the basal body to the plasma membrane | 95 | 9.05e-01 | -0.007080 | 9.44e-01 |
O-linked glycosylation | 85 | 9.12e-01 | -0.006950 | 9.47e-01 |
HDR through MMEJ (alt-NHEJ) | 12 | 9.67e-01 | 0.006930 | 9.80e-01 |
Synthesis of PIPs at the plasma membrane | 50 | 9.37e-01 | 0.006500 | 9.63e-01 |
Interaction between L1 and Ankyrins | 22 | 9.58e-01 | -0.006470 | 9.79e-01 |
Nicotinamide salvaging | 16 | 9.65e-01 | -0.006370 | 9.80e-01 |
Deadenylation of mRNA | 22 | 9.63e-01 | -0.005760 | 9.80e-01 |
Death Receptor Signaling | 148 | 9.06e-01 | 0.005650 | 9.44e-01 |
Metabolism of lipids | 596 | 8.33e-01 | 0.005090 | 9.09e-01 |
Cell recruitment (pro-inflammatory response) | 24 | 9.66e-01 | 0.004970 | 9.80e-01 |
Purinergic signaling in leishmaniasis infection | 24 | 9.66e-01 | 0.004970 | 9.80e-01 |
Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 39 | 9.59e-01 | 0.004750 | 9.79e-01 |
Diseases of DNA Double-Strand Break Repair | 39 | 9.59e-01 | 0.004750 | 9.79e-01 |
Presynaptic function of Kainate receptors | 16 | 9.75e-01 | 0.004450 | 9.86e-01 |
EGFR downregulation | 27 | 9.68e-01 | -0.004430 | 9.80e-01 |
Signaling by SCF-KIT | 39 | 9.64e-01 | 0.004220 | 9.80e-01 |
DNA Double-Strand Break Repair | 129 | 9.36e-01 | -0.004080 | 9.63e-01 |
eNOS activation | 11 | 9.83e-01 | 0.003660 | 9.93e-01 |
VEGFA-VEGFR2 Pathway | 95 | 9.60e-01 | -0.003010 | 9.79e-01 |
RHO GTPase cycle | 415 | 9.23e-01 | 0.002790 | 9.56e-01 |
Ion channel transport | 129 | 9.57e-01 | 0.002720 | 9.79e-01 |
G-protein activation | 18 | 9.88e-01 | 0.002110 | 9.93e-01 |
Prolonged ERK activation events | 14 | 9.90e-01 | 0.002010 | 9.93e-01 |
tRNA processing | 109 | 9.74e-01 | -0.001830 | 9.85e-01 |
Plasma lipoprotein clearance | 33 | 9.86e-01 | -0.001750 | 9.93e-01 |
Negative epigenetic regulation of rRNA expression | 55 | 9.84e-01 | -0.001610 | 9.93e-01 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 30 | 9.88e-01 | 0.001540 | 9.93e-01 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 55 | 9.84e-01 | 0.001520 | 9.93e-01 |
Interferon alpha/beta signaling | 57 | 9.84e-01 | 0.001500 | 9.93e-01 |
RHOF GTPase cycle | 38 | 9.89e-01 | -0.001280 | 9.93e-01 |
Plasma lipoprotein assembly, remodeling, and clearance | 56 | 9.88e-01 | 0.001130 | 9.93e-01 |
B-WICH complex positively regulates rRNA expression | 37 | 9.91e-01 | -0.001090 | 9.94e-01 |
RHOC GTPase cycle | 69 | 9.89e-01 | -0.000924 | 9.93e-01 |
Regulation of innate immune responses to cytosolic DNA | 13 | 9.96e-01 | 0.000773 | 9.96e-01 |
Mitotic Prophase | 88 | 9.92e-01 | -0.000602 | 9.94e-01 |
PPARA activates gene expression | 104 | 9.93e-01 | 0.000499 | 9.94e-01 |
Signalling to ERKs | 33 | 9.96e-01 | -0.000456 | 9.96e-01 |
Eukaryotic Translation Elongation
370 | |
---|---|
set | Eukaryotic Translation Elongation |
setSize | 91 |
pANOVA | 1.75e-32 |
s.dist | 0.719 |
p.adjustANOVA | 5.13e-30 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
EEF1B2 | 7515 |
RPL36 | 7508 |
RPL5 | 7478 |
EEF2 | 7470 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
EEF1B2 | 7515 |
RPL36 | 7508 |
RPL5 | 7478 |
EEF2 | 7470 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EEF1G | 7385 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
RPL13 | 7009 |
EEF1D | 6985 |
RPL15 | 6959 |
EEF1A1P5 | 6931 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
EEF1A1 | 6422 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
RPL14 | 5533 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
RPL21 | 4774 |
RPL38 | 4758 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
RPL36A | 3707 |
RPS27L | 3593 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
RPS26 | -3603 |
Peptide chain elongation
850 | |
---|---|
set | Peptide chain elongation |
setSize | 87 |
pANOVA | 1.19e-30 |
s.dist | 0.713 |
p.adjustANOVA | 1.75e-28 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
EEF2 | 7470 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
EEF2 | 7470 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
RPL13 | 7009 |
RPL15 | 6959 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
EEF1A1 | 6422 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
RPL14 | 5533 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
RPL21 | 4774 |
RPL38 | 4758 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
RPL36A | 3707 |
RPS27L | 3593 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
RPS26 | -3603 |
Viral mRNA Translation
1417 | |
---|---|
set | Viral mRNA Translation |
setSize | 87 |
pANOVA | 4.76e-30 |
s.dist | 0.705 |
p.adjustANOVA | 6.34e-28 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
RPL13 | 7009 |
RPL15 | 6959 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
RPL14 | 5533 |
GRSF1 | 5531 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
RPL21 | 4774 |
RPL38 | 4758 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
RPL36A | 3707 |
RPS27L | 3593 |
DNAJC3 | 3095 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
RPS26 | -3603 |
Formation of a pool of free 40S subunits
414 | |
---|---|
set | Formation of a pool of free 40S subunits |
setSize | 99 |
pANOVA | 4.49e-32 |
s.dist | 0.685 |
p.adjustANOVA | 8.21e-30 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
EIF3A | 7011 |
RPL13 | 7009 |
RPL15 | 6959 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
EIF3C | 6567 |
RPS29 | 6566 |
RPL32 | 6545 |
EIF3L | 6537 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
EIF3F | 5549 |
RPL14 | 5533 |
EIF3E | 5427 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
EIF3D | 4876 |
RPL21 | 4774 |
RPL38 | 4758 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
RPL36A | 3707 |
RPS27L | 3593 |
EIF3M | 2905 |
EIF3J | 2286 |
EIF3K | 2031 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
EIF3B | 1081 |
EIF1AX | -2134 |
RPS26 | -3603 |
SARS-CoV-1 modulates host translation machinery
1092 | |
---|---|
set | SARS-CoV-1 modulates host translation machinery |
setSize | 36 |
pANOVA | 1.35e-12 |
s.dist | 0.682 |
p.adjustANOVA | 4.6e-11 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS19 | 7955 |
RPS3 | 7856 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPS15 | 7091 |
RPS18 | 6831 |
RPS28 | 6826 |
RPS13 | 6748 |
RPS12 | 6739 |
RPS29 | 6566 |
EEF1A1 | 6422 |
RPS17 | 6407 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
GeneID | Gene Rank |
---|---|
RPS19 | 7955 |
RPS3 | 7856 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPS15 | 7091 |
RPS18 | 6831 |
RPS28 | 6826 |
RPS13 | 6748 |
RPS12 | 6739 |
RPS29 | 6566 |
EEF1A1 | 6422 |
RPS17 | 6407 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
HNRNPA1 | 5390 |
RPS21 | 5369 |
RPS16 | 5037 |
RPS20 | 4668 |
RPS14 | 4569 |
RPS27L | 3593 |
RPS4Y1 | 1834 |
RPS26 | -3603 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
782 | |
---|---|
set | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) |
setSize | 93 |
pANOVA | 1.43e-29 |
s.dist | 0.677 |
p.adjustANOVA | 1.74e-27 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
RPL13 | 7009 |
RPL15 | 6959 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
GSPT1 | 5769 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
ETF1 | 5555 |
RPL14 | 5533 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
RPL21 | 4774 |
RPL38 | 4758 |
EIF4G1 | 4736 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
NCBP2 | 4271 |
RPL36A | 3707 |
RPS27L | 3593 |
PABPC1 | 2170 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
UPF1 | 792 |
GSPT2 | 170 |
NCBP1 | -364 |
RPS26 | -3603 |
Eukaryotic Translation Termination
372 | |
---|---|
set | Eukaryotic Translation Termination |
setSize | 91 |
pANOVA | 1.13e-28 |
s.dist | 0.673 |
p.adjustANOVA | 1.18e-26 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
RPL13 | 7009 |
RPL15 | 6959 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
GSPT1 | 5769 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
ETF1 | 5555 |
RPL14 | 5533 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
RPL21 | 4774 |
RPL38 | 4758 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
TRMT112 | 4285 |
RPL36A | 3707 |
RPS27L | 3593 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
APEH | 278 |
GSPT2 | 170 |
RPS26 | -3603 |
N6AMT1 | -7350 |
Formation of tubulin folding intermediates by CCT/TriC
424 | |
---|---|
set | Formation of tubulin folding intermediates by CCT/TriC |
setSize | 20 |
pANOVA | 2.11e-07 |
s.dist | 0.67 |
p.adjustANOVA | 3.4e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TUBB2A | 8415 |
TUBA4A | 8266 |
TCP1 | 8092 |
CCT6A | 7866 |
CCT7 | 7846 |
CCT4 | 7711 |
TUBA1C | 7408 |
CCT6B | 6803 |
CCT3 | 6460 |
CCT2 | 6386 |
TUBA1B | 6282 |
TUBB4B | 5985 |
TUBAL3 | 5741 |
TUBB2B | 4999 |
TUBA1A | 3673 |
TUBB6 | 3486 |
CCT8 | 3425 |
TUBA8 | 2868 |
TUBB3 | 2464 |
CCT5 | 2207 |
GeneID | Gene Rank |
---|---|
TUBB2A | 8415 |
TUBA4A | 8266 |
TCP1 | 8092 |
CCT6A | 7866 |
CCT7 | 7846 |
CCT4 | 7711 |
TUBA1C | 7408 |
CCT6B | 6803 |
CCT3 | 6460 |
CCT2 | 6386 |
TUBA1B | 6282 |
TUBB4B | 5985 |
TUBAL3 | 5741 |
TUBB2B | 4999 |
TUBA1A | 3673 |
TUBB6 | 3486 |
CCT8 | 3425 |
TUBA8 | 2868 |
TUBB3 | 2464 |
CCT5 | 2207 |
Selenocysteine synthesis
1138 | |
---|---|
set | Selenocysteine synthesis |
setSize | 91 |
pANOVA | 3.37e-28 |
s.dist | 0.667 |
p.adjustANOVA | 2.9e-26 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
RPL13 | 7009 |
SARS1 | 6962 |
RPL15 | 6959 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
RPL14 | 5533 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
RPL21 | 4774 |
RPL38 | 4758 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
PSTK | 4376 |
RPL36A | 3707 |
RPS27L | 3593 |
EEFSEC | 2815 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
SEPHS2 | 1467 |
RPS26 | -3603 |
SEPSECS | -5068 |
SECISBP2 | -6240 |
L13a-mediated translational silencing of Ceruloplasmin expression
623 | |
---|---|
set | L13a-mediated translational silencing of Ceruloplasmin expression |
setSize | 109 |
pANOVA | 2.15e-33 |
s.dist | 0.667 |
p.adjustANOVA | 1.05e-30 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
EIF3A | 7011 |
RPL13 | 7009 |
RPL15 | 6959 |
EIF4H | 6951 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
EIF3C | 6567 |
RPS29 | 6566 |
RPL32 | 6545 |
EIF3L | 6537 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
EIF4B | 5889 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
EIF3F | 5549 |
RPL14 | 5533 |
EIF3E | 5427 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
EIF3D | 4876 |
RPL21 | 4774 |
RPL38 | 4758 |
EIF4G1 | 4736 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
EIF4A1 | 4003 |
RPL36A | 3707 |
RPS27L | 3593 |
EIF3M | 2905 |
EIF3J | 2286 |
EIF4A2 | 2172 |
PABPC1 | 2170 |
EIF3K | 2031 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
EIF3B | 1081 |
EIF4E | 687 |
EIF2S3 | 281 |
EIF1AX | -2134 |
RPS26 | -3603 |
GTP hydrolysis and joining of the 60S ribosomal subunit
461 | |
---|---|
set | GTP hydrolysis and joining of the 60S ribosomal subunit |
setSize | 110 |
pANOVA | 7.05e-33 |
s.dist | 0.658 |
p.adjustANOVA | 2.58e-30 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
EIF3A | 7011 |
RPL13 | 7009 |
RPL15 | 6959 |
EIF4H | 6951 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
EIF3C | 6567 |
RPS29 | 6566 |
RPL32 | 6545 |
EIF3L | 6537 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
EIF4B | 5889 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
EIF3F | 5549 |
RPL14 | 5533 |
EIF3E | 5427 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
EIF3D | 4876 |
RPL21 | 4774 |
RPL38 | 4758 |
EIF4G1 | 4736 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
EIF4A1 | 4003 |
RPL36A | 3707 |
RPS27L | 3593 |
EIF3M | 2905 |
EIF3J | 2286 |
EIF4A2 | 2172 |
EIF3K | 2031 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
EIF3B | 1081 |
EIF4E | 687 |
EIF5 | 366 |
EIF2S3 | 281 |
EIF5B | -22 |
EIF1AX | -2134 |
RPS26 | -3603 |
Folding of actin by CCT/TriC
404 | |
---|---|
set | Folding of actin by CCT/TriC |
setSize | 10 |
pANOVA | 0.000384 |
s.dist | 0.648 |
p.adjustANOVA | 0.00267 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TCP1 | 8092 |
CCT6A | 7866 |
CCT7 | 7846 |
CCT4 | 7711 |
CCT6B | 6803 |
CCT3 | 6460 |
CCT2 | 6386 |
CCT8 | 3425 |
CCT5 | 2207 |
ACTB | -345 |
GeneID | Gene Rank |
---|---|
TCP1 | 8092 |
CCT6A | 7866 |
CCT7 | 7846 |
CCT4 | 7711 |
CCT6B | 6803 |
CCT3 | 6460 |
CCT2 | 6386 |
CCT8 | 3425 |
CCT5 | 2207 |
ACTB | -345 |
SRP-dependent cotranslational protein targeting to membrane
1117 | |
---|---|
set | SRP-dependent cotranslational protein targeting to membrane |
setSize | 110 |
pANOVA | 1.21e-31 |
s.dist | 0.645 |
p.adjustANOVA | 1.96e-29 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SSR4 | 8445 |
RPL3 | 8213 |
RPLP0 | 8195 |
SSR2 | 8090 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
SRP68 | 7501 |
RPL5 | 7478 |
SRPRA | 7477 |
RPS5 | 7459 |
GeneID | Gene Rank |
---|---|
SSR4 | 8445 |
RPL3 | 8213 |
RPLP0 | 8195 |
SSR2 | 8090 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
SRP68 | 7501 |
RPL5 | 7478 |
SRPRA | 7477 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
SRP54 | 7238 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
RPL13 | 7009 |
RPL15 | 6959 |
RPL27A | 6925 |
RPN1 | 6897 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
SSR3 | 6579 |
RPS29 | 6566 |
RPL32 | 6545 |
DDOST | 6522 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
SEC11C | 6265 |
RPL34 | 6202 |
RPS10 | 6082 |
SEC61B | 6081 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
SSR1 | 5894 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
RPL14 | 5533 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
SEC11A | 4959 |
RPL21 | 4774 |
RPL38 | 4758 |
RPL35 | 4688 |
SRPRB | 4673 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
RPL36A | 3707 |
RPS27L | 3593 |
SPCS2 | 3211 |
RPN2 | 3032 |
TRAM1 | 2399 |
SRP72 | 2191 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
SPCS3 | 1674 |
RPL9 | 1672 |
SRP14 | 1061 |
SEC61A1 | 892 |
SEC61G | 572 |
SPCS1 | -729 |
SRP19 | -842 |
SRP9 | -1159 |
RPS26 | -3603 |
SEC61A2 | -5327 |
Prefoldin mediated transfer of substrate to CCT/TriC
891 | |
---|---|
set | Prefoldin mediated transfer of substrate to CCT/TriC |
setSize | 24 |
pANOVA | 6.78e-08 |
s.dist | 0.636 |
p.adjustANOVA | 1.38e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TUBB2A | 8415 |
TUBA4A | 8266 |
TCP1 | 8092 |
CCT6A | 7866 |
CCT7 | 7846 |
PFDN2 | 7815 |
CCT4 | 7711 |
TUBA1C | 7408 |
PFDN5 | 7033 |
CCT6B | 6803 |
CCT3 | 6460 |
CCT2 | 6386 |
TUBB4B | 5985 |
PFDN1 | 5844 |
VBP1 | 5257 |
TUBB2B | 4999 |
PFDN6 | 4015 |
TUBA1A | 3673 |
TUBB6 | 3486 |
CCT8 | 3425 |
GeneID | Gene Rank |
---|---|
TUBB2A | 8415 |
TUBA4A | 8266 |
TCP1 | 8092 |
CCT6A | 7866 |
CCT7 | 7846 |
PFDN2 | 7815 |
CCT4 | 7711 |
TUBA1C | 7408 |
PFDN5 | 7033 |
CCT6B | 6803 |
CCT3 | 6460 |
CCT2 | 6386 |
TUBB4B | 5985 |
PFDN1 | 5844 |
VBP1 | 5257 |
TUBB2B | 4999 |
PFDN6 | 4015 |
TUBA1A | 3673 |
TUBB6 | 3486 |
CCT8 | 3425 |
TUBB3 | 2464 |
CCT5 | 2207 |
PFDN4 | 1856 |
ACTB | -345 |
Formation of the ternary complex, and subsequently, the 43S complex
423 | |
---|---|
set | Formation of the ternary complex, and subsequently, the 43S complex |
setSize | 51 |
pANOVA | 4.1e-15 |
s.dist | 0.635 |
p.adjustANOVA | 1.54e-13 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
EIF2S1 | 7768 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPS15 | 7091 |
EIF3A | 7011 |
RPS18 | 6831 |
RPS28 | 6826 |
RPS13 | 6748 |
RPS12 | 6739 |
GeneID | Gene Rank |
---|---|
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
EIF2S1 | 7768 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPS15 | 7091 |
EIF3A | 7011 |
RPS18 | 6831 |
RPS28 | 6826 |
RPS13 | 6748 |
RPS12 | 6739 |
EIF3C | 6567 |
RPS29 | 6566 |
EIF3L | 6537 |
RPS17 | 6407 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
EIF3F | 5549 |
EIF3E | 5427 |
RPS21 | 5369 |
RPS16 | 5037 |
EIF3D | 4876 |
RPS20 | 4668 |
RPS14 | 4569 |
RPS27L | 3593 |
EIF3M | 2905 |
EIF3J | 2286 |
EIF3K | 2031 |
RPS4Y1 | 1834 |
EIF3B | 1081 |
EIF2S3 | 281 |
EIF1AX | -2134 |
RPS26 | -3603 |
Response of EIF2AK4 (GCN2) to amino acid deficiency
1078 | |
---|---|
set | Response of EIF2AK4 (GCN2) to amino acid deficiency |
setSize | 99 |
pANOVA | 1.17e-27 |
s.dist | 0.633 |
p.adjustANOVA | 9.49e-26 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ATF3 | 8509 |
RPL3 | 8213 |
RPLP0 | 8195 |
EIF2S2 | 8075 |
RPS19 | 7955 |
ATF4 | 7924 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
GeneID | Gene Rank |
---|---|
ATF3 | 8509 |
RPL3 | 8213 |
RPLP0 | 8195 |
EIF2S2 | 8075 |
RPS19 | 7955 |
ATF4 | 7924 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
RPL13 | 7009 |
RPL15 | 6959 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
CEBPB | 6582 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
RPL14 | 5533 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
RPL21 | 4774 |
RPL38 | 4758 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
RPL36A | 3707 |
RPS27L | 3593 |
CEBPG | 2356 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
IMPACT | 597 |
EIF2S3 | 281 |
TRIB3 | -1153 |
EIF2AK4 | -1649 |
ATF2 | -2809 |
ASNS | -2937 |
RPS26 | -3603 |
DDIT3 | -5113 |
GCN1 | -5596 |
Cap-dependent Translation Initiation
153 | |
---|---|
set | Cap-dependent Translation Initiation |
setSize | 117 |
pANOVA | 3.73e-32 |
s.dist | 0.631 |
p.adjustANOVA | 7.8e-30 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
EIF4EBP1 | 7864 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
EIF4EBP1 | 7864 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF2B2 | 7334 |
EIF3H | 7284 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
EIF3A | 7011 |
RPL13 | 7009 |
RPL15 | 6959 |
EIF4H | 6951 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
EIF3C | 6567 |
RPS29 | 6566 |
RPL32 | 6545 |
EIF3L | 6537 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
EIF4B | 5889 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
EIF3F | 5549 |
RPL14 | 5533 |
EIF3E | 5427 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
EIF3D | 4876 |
RPL21 | 4774 |
RPL38 | 4758 |
EIF4G1 | 4736 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
EIF2B3 | 4528 |
EIF4A1 | 4003 |
RPL36A | 3707 |
RPS27L | 3593 |
EIF3M | 2905 |
EIF3J | 2286 |
EIF4A2 | 2172 |
PABPC1 | 2170 |
EIF3K | 2031 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
EIF3B | 1081 |
EIF4E | 687 |
EIF5 | 366 |
EIF2S3 | 281 |
EIF5B | -22 |
EIF2B4 | -157 |
EIF1AX | -2134 |
RPS26 | -3603 |
EIF2B5 | -3891 |
EIF2B1 | -4304 |
Eukaryotic Translation Initiation
371 | |
---|---|
set | Eukaryotic Translation Initiation |
setSize | 117 |
pANOVA | 3.73e-32 |
s.dist | 0.631 |
p.adjustANOVA | 7.8e-30 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
EIF4EBP1 | 7864 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
EIF4EBP1 | 7864 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF2B2 | 7334 |
EIF3H | 7284 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
EIF3A | 7011 |
RPL13 | 7009 |
RPL15 | 6959 |
EIF4H | 6951 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
EIF3C | 6567 |
RPS29 | 6566 |
RPL32 | 6545 |
EIF3L | 6537 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
EIF4B | 5889 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
EIF3F | 5549 |
RPL14 | 5533 |
EIF3E | 5427 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
EIF3D | 4876 |
RPL21 | 4774 |
RPL38 | 4758 |
EIF4G1 | 4736 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
EIF2B3 | 4528 |
EIF4A1 | 4003 |
RPL36A | 3707 |
RPS27L | 3593 |
EIF3M | 2905 |
EIF3J | 2286 |
EIF4A2 | 2172 |
PABPC1 | 2170 |
EIF3K | 2031 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
EIF3B | 1081 |
EIF4E | 687 |
EIF5 | 366 |
EIF2S3 | 281 |
EIF5B | -22 |
EIF2B4 | -157 |
EIF1AX | -2134 |
RPS26 | -3603 |
EIF2B5 | -3891 |
EIF2B1 | -4304 |
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane
695 | |
---|---|
set | Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane |
setSize | 12 |
pANOVA | 0.000157 |
s.dist | 0.63 |
p.adjustANOVA | 0.00121 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TUBB2A | 8415 |
TUBA4A | 8266 |
TUBA1C | 7408 |
GJA1 | 6327 |
TUBA1B | 6282 |
TUBB4B | 5985 |
TUBAL3 | 5741 |
TUBB2B | 4999 |
TUBA1A | 3673 |
TUBB6 | 3486 |
TUBA8 | 2868 |
TUBB3 | 2464 |
GeneID | Gene Rank |
---|---|
TUBB2A | 8415 |
TUBA4A | 8266 |
TUBA1C | 7408 |
GJA1 | 6327 |
TUBA1B | 6282 |
TUBB4B | 5985 |
TUBAL3 | 5741 |
TUBB2B | 4999 |
TUBA1A | 3673 |
TUBB6 | 3486 |
TUBA8 | 2868 |
TUBB3 | 2464 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding
226 | |
---|---|
set | Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding |
setSize | 27 |
pANOVA | 1.56e-08 |
s.dist | 0.629 |
p.adjustANOVA | 3.81e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TUBB2A | 8415 |
TUBA4A | 8266 |
TCP1 | 8092 |
CCT6A | 7866 |
CCT7 | 7846 |
PFDN2 | 7815 |
CCT4 | 7711 |
TUBA1C | 7408 |
PFDN5 | 7033 |
CCT6B | 6803 |
CCT3 | 6460 |
CCT2 | 6386 |
TUBA1B | 6282 |
TUBB4B | 5985 |
PFDN1 | 5844 |
TUBAL3 | 5741 |
VBP1 | 5257 |
TUBB2B | 4999 |
PFDN6 | 4015 |
TUBA1A | 3673 |
GeneID | Gene Rank |
---|---|
TUBB2A | 8415 |
TUBA4A | 8266 |
TCP1 | 8092 |
CCT6A | 7866 |
CCT7 | 7846 |
PFDN2 | 7815 |
CCT4 | 7711 |
TUBA1C | 7408 |
PFDN5 | 7033 |
CCT6B | 6803 |
CCT3 | 6460 |
CCT2 | 6386 |
TUBA1B | 6282 |
TUBB4B | 5985 |
PFDN1 | 5844 |
TUBAL3 | 5741 |
VBP1 | 5257 |
TUBB2B | 4999 |
PFDN6 | 4015 |
TUBA1A | 3673 |
TUBB6 | 3486 |
CCT8 | 3425 |
TUBA8 | 2868 |
TUBB3 | 2464 |
CCT5 | 2207 |
PFDN4 | 1856 |
ACTB | -345 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
50 | |
---|---|
set | Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S |
setSize | 59 |
pANOVA | 2.82e-16 |
s.dist | 0.615 |
p.adjustANOVA | 1.18e-14 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
EIF4EBP1 | 7864 |
RPS3 | 7856 |
EIF2S1 | 7768 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPS15 | 7091 |
EIF3A | 7011 |
EIF4H | 6951 |
RPS18 | 6831 |
RPS28 | 6826 |
GeneID | Gene Rank |
---|---|
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
EIF4EBP1 | 7864 |
RPS3 | 7856 |
EIF2S1 | 7768 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPS15 | 7091 |
EIF3A | 7011 |
EIF4H | 6951 |
RPS18 | 6831 |
RPS28 | 6826 |
RPS13 | 6748 |
RPS12 | 6739 |
EIF3C | 6567 |
RPS29 | 6566 |
EIF3L | 6537 |
RPS17 | 6407 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
EIF4B | 5889 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
EIF3F | 5549 |
EIF3E | 5427 |
RPS21 | 5369 |
RPS16 | 5037 |
EIF3D | 4876 |
EIF4G1 | 4736 |
RPS20 | 4668 |
RPS14 | 4569 |
EIF4A1 | 4003 |
RPS27L | 3593 |
EIF3M | 2905 |
EIF3J | 2286 |
EIF4A2 | 2172 |
PABPC1 | 2170 |
EIF3K | 2031 |
RPS4Y1 | 1834 |
EIF3B | 1081 |
EIF4E | 687 |
EIF2S3 | 281 |
EIF1AX | -2134 |
RPS26 | -3603 |
Translation initiation complex formation
1369 | |
---|---|
set | Translation initiation complex formation |
setSize | 58 |
pANOVA | 8.92e-16 |
s.dist | 0.61 |
p.adjustANOVA | 3.53e-14 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
EIF2S1 | 7768 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPS15 | 7091 |
EIF3A | 7011 |
EIF4H | 6951 |
RPS18 | 6831 |
RPS28 | 6826 |
RPS13 | 6748 |
GeneID | Gene Rank |
---|---|
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
EIF2S1 | 7768 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPS15 | 7091 |
EIF3A | 7011 |
EIF4H | 6951 |
RPS18 | 6831 |
RPS28 | 6826 |
RPS13 | 6748 |
RPS12 | 6739 |
EIF3C | 6567 |
RPS29 | 6566 |
EIF3L | 6537 |
RPS17 | 6407 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
EIF4B | 5889 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
EIF3F | 5549 |
EIF3E | 5427 |
RPS21 | 5369 |
RPS16 | 5037 |
EIF3D | 4876 |
EIF4G1 | 4736 |
RPS20 | 4668 |
RPS14 | 4569 |
EIF4A1 | 4003 |
RPS27L | 3593 |
EIF3M | 2905 |
EIF3J | 2286 |
EIF4A2 | 2172 |
PABPC1 | 2170 |
EIF3K | 2031 |
RPS4Y1 | 1834 |
EIF3B | 1081 |
EIF4E | 687 |
EIF2S3 | 281 |
EIF1AX | -2134 |
RPS26 | -3603 |
Ribosomal scanning and start codon recognition
1085 | |
---|---|
set | Ribosomal scanning and start codon recognition |
setSize | 58 |
pANOVA | 1.34e-15 |
s.dist | 0.606 |
p.adjustANOVA | 5.17e-14 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
EIF2S1 | 7768 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPS15 | 7091 |
EIF3A | 7011 |
EIF4H | 6951 |
RPS18 | 6831 |
RPS28 | 6826 |
RPS13 | 6748 |
GeneID | Gene Rank |
---|---|
EIF2S2 | 8075 |
RPS19 | 7955 |
EIF3I | 7883 |
RPS3 | 7856 |
EIF2S1 | 7768 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
EIF3H | 7284 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
EIF3G | 7137 |
RPS15 | 7091 |
EIF3A | 7011 |
EIF4H | 6951 |
RPS18 | 6831 |
RPS28 | 6826 |
RPS13 | 6748 |
RPS12 | 6739 |
EIF3C | 6567 |
RPS29 | 6566 |
EIF3L | 6537 |
RPS17 | 6407 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
EIF4B | 5889 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
EIF3F | 5549 |
EIF3E | 5427 |
RPS21 | 5369 |
RPS16 | 5037 |
EIF3D | 4876 |
EIF4G1 | 4736 |
RPS20 | 4668 |
RPS14 | 4569 |
EIF4A1 | 4003 |
RPS27L | 3593 |
EIF3M | 2905 |
EIF3J | 2286 |
EIF4A2 | 2172 |
EIF3K | 2031 |
RPS4Y1 | 1834 |
EIF3B | 1081 |
EIF4E | 687 |
EIF5 | 366 |
EIF2S3 | 281 |
EIF1AX | -2134 |
RPS26 | -3603 |
Josephin domain DUBs
614 | |
---|---|
set | Josephin domain DUBs |
setSize | 10 |
pANOVA | 0.000934 |
s.dist | 0.604 |
p.adjustANOVA | 0.00588 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RAD23A | 8155 |
UBB | 8115 |
JOSD1 | 7717 |
UBA52 | 7629 |
UBC | 7555 |
VCP | 6975 |
RAD23B | 6333 |
RPS27A | 5715 |
JOSD2 | 2327 |
ATXN3 | -7688 |
GeneID | Gene Rank |
---|---|
RAD23A | 8155 |
UBB | 8115 |
JOSD1 | 7717 |
UBA52 | 7629 |
UBC | 7555 |
VCP | 6975 |
RAD23B | 6333 |
RPS27A | 5715 |
JOSD2 | 2327 |
ATXN3 | -7688 |
Selenoamino acid metabolism
1137 | |
---|---|
set | Selenoamino acid metabolism |
setSize | 113 |
pANOVA | 1.56e-28 |
s.dist | 0.603 |
p.adjustANOVA | 1.52e-26 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NNMT | 8444 |
EPRS1 | 8330 |
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
PAPSS2 | 7698 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
GeneID | Gene Rank |
---|---|
NNMT | 8444 |
EPRS1 | 8330 |
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
PAPSS2 | 7698 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
KARS1 | 7371 |
AHCY | 7259 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
RPL13 | 7009 |
SARS1 | 6962 |
RPL15 | 6959 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
IARS1 | 6655 |
RPL28 | 6643 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RPS10 | 6082 |
INMT | 6074 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
DARS1 | 5879 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
PAPSS1 | 5559 |
RPL14 | 5533 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
TXNRD1 | 5014 |
RPL21 | 4774 |
RPL38 | 4758 |
CBS | 4715 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
PSTK | 4376 |
AIMP2 | 3773 |
RPL36A | 3707 |
RPS27L | 3593 |
CTH | 2947 |
EEFSEC | 2815 |
EEF1E1 | 2660 |
RARS1 | 2511 |
GSR | 2189 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
SEPHS2 | 1467 |
AIMP1 | -1096 |
MARS1 | -2232 |
SCLY | -2874 |
QARS1 | -3397 |
RPS26 | -3603 |
LARS1 | -4201 |
SEPSECS | -5068 |
SECISBP2 | -6240 |
HNMT | -6411 |
Glycogen synthesis
492 | |
---|---|
set | Glycogen synthesis |
setSize | 12 |
pANOVA | 0.000483 |
s.dist | 0.582 |
p.adjustANOVA | 0.00327 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PGM1 | 8325 |
UBB | 8115 |
PPP1R3C | 7781 |
UBA52 | 7629 |
UBC | 7555 |
GBE1 | 7104 |
RPS27A | 5715 |
UGP2 | 4965 |
NHLRC1 | 3783 |
GYG1 | 1970 |
GYS1 | -65 |
EPM2A | -1707 |
GeneID | Gene Rank |
---|---|
PGM1 | 8325 |
UBB | 8115 |
PPP1R3C | 7781 |
UBA52 | 7629 |
UBC | 7555 |
GBE1 | 7104 |
RPS27A | 5715 |
UGP2 | 4965 |
NHLRC1 | 3783 |
GYG1 | 1970 |
GYS1 | -65 |
EPM2A | -1707 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
781 | |
---|---|
set | Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) |
setSize | 113 |
pANOVA | 4.79e-25 |
s.dist | 0.562 |
p.adjustANOVA | 3.19e-23 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RBM8A | 7891 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RBM8A | 7891 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
EIF4A3 | 7020 |
RPL13 | 7009 |
RNPS1 | 6994 |
RPL15 | 6959 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
PPP2CA | 6300 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
GSPT1 | 5769 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
ETF1 | 5555 |
RPL14 | 5533 |
RPS21 | 5369 |
PPP2R1A | 5252 |
RPLP2 | 5242 |
RPL26 | 5239 |
SMG8 | 5235 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
RPL21 | 4774 |
RPL38 | 4758 |
EIF4G1 | 4736 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
NCBP2 | 4271 |
RPL36A | 3707 |
RPS27L | 3593 |
CASC3 | 2433 |
PABPC1 | 2170 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
MAGOH | 1007 |
UPF1 | 792 |
PNRC2 | 710 |
PPP2R2A | 606 |
GSPT2 | 170 |
DCP1A | 82 |
MAGOHB | -83 |
SMG6 | -255 |
UPF2 | -283 |
NCBP1 | -364 |
SMG5 | -3275 |
RPS26 | -3603 |
SMG9 | -4480 |
SMG7 | -5415 |
UPF3B | -5740 |
SMG1 | -6130 |
UPF3A | -6972 |
Nonsense-Mediated Decay (NMD)
783 | |
---|---|
set | Nonsense-Mediated Decay (NMD) |
setSize | 113 |
pANOVA | 4.79e-25 |
s.dist | 0.562 |
p.adjustANOVA | 3.19e-23 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RBM8A | 7891 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
RPS19 | 7955 |
RBM8A | 7891 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
EIF4A3 | 7020 |
RPL13 | 7009 |
RNPS1 | 6994 |
RPL15 | 6959 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
PPP2CA | 6300 |
RPL34 | 6202 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
GSPT1 | 5769 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
ETF1 | 5555 |
RPL14 | 5533 |
RPS21 | 5369 |
PPP2R1A | 5252 |
RPLP2 | 5242 |
RPL26 | 5239 |
SMG8 | 5235 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
RPL21 | 4774 |
RPL38 | 4758 |
EIF4G1 | 4736 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
NCBP2 | 4271 |
RPL36A | 3707 |
RPS27L | 3593 |
CASC3 | 2433 |
PABPC1 | 2170 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
MAGOH | 1007 |
UPF1 | 792 |
PNRC2 | 710 |
PPP2R2A | 606 |
GSPT2 | 170 |
DCP1A | 82 |
MAGOHB | -83 |
SMG6 | -255 |
UPF2 | -283 |
NCBP1 | -364 |
SMG5 | -3275 |
RPS26 | -3603 |
SMG9 | -4480 |
SMG7 | -5415 |
UPF3B | -5740 |
SMG1 | -6130 |
UPF3A | -6972 |
TP53 Regulates Transcription of Death Receptors and Ligands
1302 | |
---|---|
set | TP53 Regulates Transcription of Death Receptors and Ligands |
setSize | 10 |
pANOVA | 0.00252 |
s.dist | 0.552 |
p.adjustANOVA | 0.014 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TNFRSF10D | 8519 |
TNFRSF10C | 8404 |
IGFBP3 | 7172 |
TP53 | 6280 |
TP53BP2 | 5673 |
PPP1R13B | 4190 |
FAS | 3337 |
TMEM219 | 2644 |
TNFRSF10B | 1340 |
TNFRSF10A | 950 |
GeneID | Gene Rank |
---|---|
TNFRSF10D | 8519 |
TNFRSF10C | 8404 |
IGFBP3 | 7172 |
TP53 | 6280 |
TP53BP2 | 5673 |
PPP1R13B | 4190 |
FAS | 3337 |
TMEM219 | 2644 |
TNFRSF10B | 1340 |
TNFRSF10A | 950 |
Transport of connexons to the plasma membrane
1387 | |
---|---|
set | Transport of connexons to the plasma membrane |
setSize | 13 |
pANOVA | 0.000692 |
s.dist | 0.543 |
p.adjustANOVA | 0.00452 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TUBB2A | 8415 |
TUBA4A | 8266 |
TUBA1C | 7408 |
GJA1 | 6327 |
TUBA1B | 6282 |
TUBB4B | 5985 |
TUBAL3 | 5741 |
TUBB2B | 4999 |
TUBA1A | 3673 |
TUBB6 | 3486 |
TUBA8 | 2868 |
TUBB3 | 2464 |
GJB2 | -3751 |
GeneID | Gene Rank |
---|---|
TUBB2A | 8415 |
TUBA4A | 8266 |
TUBA1C | 7408 |
GJA1 | 6327 |
TUBA1B | 6282 |
TUBB4B | 5985 |
TUBAL3 | 5741 |
TUBB2B | 4999 |
TUBA1A | 3673 |
TUBB6 | 3486 |
TUBA8 | 2868 |
TUBB3 | 2464 |
GJB2 | -3751 |
SARS-CoV-2 modulates host translation machinery
1098 | |
---|---|
set | SARS-CoV-2 modulates host translation machinery |
setSize | 49 |
pANOVA | 1.07e-10 |
s.dist | 0.533 |
p.adjustANOVA | 3.48e-09 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS19 | 7955 |
RPS3 | 7856 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPS15 | 7091 |
GEMIN5 | 7041 |
SNRPD2 | 6849 |
RPS18 | 6831 |
RPS28 | 6826 |
SNRPB | 6796 |
RPS13 | 6748 |
RPS12 | 6739 |
RPS29 | 6566 |
RPS17 | 6407 |
RPS10 | 6082 |
GeneID | Gene Rank |
---|---|
RPS19 | 7955 |
RPS3 | 7856 |
RPSA | 7653 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPS15 | 7091 |
GEMIN5 | 7041 |
SNRPD2 | 6849 |
RPS18 | 6831 |
RPS28 | 6826 |
SNRPB | 6796 |
RPS13 | 6748 |
RPS12 | 6739 |
RPS29 | 6566 |
RPS17 | 6407 |
RPS10 | 6082 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
RPS27A | 5715 |
RPS21 | 5369 |
SNRPD1 | 5090 |
RPS16 | 5037 |
RPS20 | 4668 |
RPS14 | 4569 |
SMN1 | 4232 |
RPS27L | 3593 |
GEMIN8 | 3305 |
SNRPE | 3280 |
SNRPD3 | 2994 |
SNRPG | 2011 |
RPS4Y1 | 1834 |
SNRPF | 1507 |
GEMIN6 | 164 |
GEMIN2 | -945 |
DDX20 | -3434 |
RPS26 | -3603 |
GEMIN4 | -3870 |
GEMIN7 | -6480 |
Regulation of expression of SLITs and ROBOs
1051 | |
---|---|
set | Regulation of expression of SLITs and ROBOs |
setSize | 162 |
pANOVA | 4.6e-29 |
s.dist | 0.509 |
p.adjustANOVA | 5.19e-27 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
UBB | 8115 |
PSMB5 | 8014 |
PSMD8 | 7975 |
RPS19 | 7955 |
RBM8A | 7891 |
ELOC | 7884 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
PSMC3 | 7701 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
PSMF1 | 7577 |
UBC | 7555 |
GeneID | Gene Rank |
---|---|
RPL3 | 8213 |
RPLP0 | 8195 |
UBB | 8115 |
PSMB5 | 8014 |
PSMD8 | 7975 |
RPS19 | 7955 |
RBM8A | 7891 |
ELOC | 7884 |
RPS3 | 7856 |
RPL18 | 7818 |
RPL39 | 7733 |
PSMC3 | 7701 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
PSMF1 | 7577 |
UBC | 7555 |
RPL8 | 7546 |
PSMB4 | 7524 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
PSMB7 | 7370 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
EIF4A3 | 7020 |
RPL13 | 7009 |
RNPS1 | 6994 |
RPL15 | 6959 |
PSMD10 | 6932 |
RPL27A | 6925 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
PSMB6 | 6641 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
PSMD14 | 6413 |
RPS17 | 6407 |
PSMD9 | 6357 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
PSMD1 | 6241 |
ELOB | 6230 |
RPL34 | 6202 |
RPS10 | 6082 |
PSMA5 | 6069 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
GSPT1 | 5769 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
ETF1 | 5555 |
RPL14 | 5533 |
PSMC4 | 5408 |
PSMA7 | 5388 |
PSMD4 | 5382 |
RPS21 | 5369 |
SEM1 | 5303 |
PSMD5 | 5248 |
RPLP2 | 5242 |
RPL26 | 5239 |
PSMD13 | 5202 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
PSMA2 | 4818 |
PSMC1 | 4813 |
RPL21 | 4774 |
RPL38 | 4758 |
EIF4G1 | 4736 |
PSMD3 | 4701 |
RPL35 | 4688 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
PSMD2 | 4456 |
PSMC5 | 4430 |
NCBP2 | 4271 |
PSMB8 | 4048 |
PSMB1 | 3958 |
COL4A5 | 3951 |
PSMA1 | 3947 |
LDB1 | 3883 |
PSMD12 | 3831 |
RPL36A | 3707 |
PSMA4 | 3686 |
RPS27L | 3593 |
PSMB3 | 3372 |
PSMB9 | 3286 |
PSME3 | 2733 |
PSME4 | 2643 |
PSME1 | 2547 |
PSMD7 | 2501 |
CASC3 | 2433 |
PABPC1 | 2170 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
RPL9 | 1672 |
DAG1 | 1124 |
MAGOH | 1007 |
PSMB2 | 382 |
GSPT2 | 170 |
MAGOHB | -83 |
RBX1 | -91 |
PSMD11 | -161 |
ROBO1 | -234 |
UPF2 | -283 |
NCBP1 | -364 |
PSMC2 | -702 |
PSMC6 | -1232 |
CUL2 | -1666 |
PSMD6 | -1811 |
SLIT1 | -1896 |
SLIT2 | -2091 |
PSMA3 | -2099 |
PSMA6 | -2513 |
ROBO2 | -2627 |
PSMB10 | -2727 |
LHX4 | -2970 |
PSME2 | -3086 |
HOXA2 | -3107 |
RPS26 | -3603 |
UPF3B | -5740 |
ROBO3 | -5748 |
USP33 | -5940 |
UPF3A | -6972 |
ZSWIM8 | -7463 |
Downregulation of ERBB2:ERBB3 signaling
322 | |
---|---|
set | Downregulation of ERBB2:ERBB3 signaling |
setSize | 13 |
pANOVA | 0.0015 |
s.dist | 0.508 |
p.adjustANOVA | 0.00873 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UBB | 8115 |
NRG2 | 8057 |
UBA52 | 7629 |
RNF41 | 7557 |
UBC | 7555 |
AKT3 | 6434 |
NRG1 | 6015 |
RPS27A | 5715 |
AKT1 | 4206 |
ERBB3 | 1958 |
USP8 | 558 |
ERBB2 | -270 |
AKT2 | -5098 |
GeneID | Gene Rank |
---|---|
UBB | 8115 |
NRG2 | 8057 |
UBA52 | 7629 |
RNF41 | 7557 |
UBC | 7555 |
AKT3 | 6434 |
NRG1 | 6015 |
RPS27A | 5715 |
AKT1 | 4206 |
ERBB3 | 1958 |
USP8 | 558 |
ERBB2 | -270 |
AKT2 | -5098 |
Keratan sulfate biosynthesis
617 | |
---|---|
set | Keratan sulfate biosynthesis |
setSize | 26 |
pANOVA | 9.09e-06 |
s.dist | 0.503 |
p.adjustANOVA | 9.17e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ACAN | 8463 |
CHST1 | 8110 |
CHST6 | 7899 |
OMD | 7855 |
LUM | 7763 |
FMOD | 7680 |
ST3GAL2 | 7591 |
ST3GAL3 | 7565 |
B4GALT5 | 7203 |
PRELP | 6934 |
B4GALT4 | 6913 |
OGN | 6830 |
B4GALT6 | 6664 |
B4GALT2 | 6330 |
CHST5 | 5779 |
B4GALT1 | 4710 |
ST3GAL1 | 4654 |
B4GALT3 | 3792 |
ST3GAL4 | 3706 |
KERA | 2893 |
GeneID | Gene Rank |
---|---|
ACAN | 8463 |
CHST1 | 8110 |
CHST6 | 7899 |
OMD | 7855 |
LUM | 7763 |
FMOD | 7680 |
ST3GAL2 | 7591 |
ST3GAL3 | 7565 |
B4GALT5 | 7203 |
PRELP | 6934 |
B4GALT4 | 6913 |
OGN | 6830 |
B4GALT6 | 6664 |
B4GALT2 | 6330 |
CHST5 | 5779 |
B4GALT1 | 4710 |
ST3GAL1 | 4654 |
B4GALT3 | 3792 |
ST3GAL4 | 3706 |
KERA | 2893 |
SLC35D2 | 1950 |
B3GNT2 | -1337 |
B3GNT7 | -1967 |
B4GAT1 | -2345 |
ST3GAL6 | -4160 |
CHST2 | -5911 |
Membrane binding and targetting of GAG proteins
670 | |
---|---|
set | Membrane binding and targetting of GAG proteins |
setSize | 14 |
pANOVA | 0.00125 |
s.dist | 0.498 |
p.adjustANOVA | 0.00747 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UBB | 8115 |
VPS37B | 7734 |
UBA52 | 7629 |
VPS37A | 7599 |
UBC | 7555 |
RPS27A | 5715 |
UBAP1 | 4820 |
VPS37D | 4542 |
MVB12A | 4044 |
TSG101 | 2732 |
VPS37C | 2725 |
VPS28 | 61 |
NMT2 | -759 |
MVB12B | -776 |
GeneID | Gene Rank |
---|---|
UBB | 8115 |
VPS37B | 7734 |
UBA52 | 7629 |
VPS37A | 7599 |
UBC | 7555 |
RPS27A | 5715 |
UBAP1 | 4820 |
VPS37D | 4542 |
MVB12A | 4044 |
TSG101 | 2732 |
VPS37C | 2725 |
VPS28 | 61 |
NMT2 | -759 |
MVB12B | -776 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins
1259 | |
---|---|
set | Synthesis And Processing Of GAG, GAGPOL Polyproteins |
setSize | 14 |
pANOVA | 0.00125 |
s.dist | 0.498 |
p.adjustANOVA | 0.00747 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UBB | 8115 |
VPS37B | 7734 |
UBA52 | 7629 |
VPS37A | 7599 |
UBC | 7555 |
RPS27A | 5715 |
UBAP1 | 4820 |
VPS37D | 4542 |
MVB12A | 4044 |
TSG101 | 2732 |
VPS37C | 2725 |
VPS28 | 61 |
NMT2 | -759 |
MVB12B | -776 |
GeneID | Gene Rank |
---|---|
UBB | 8115 |
VPS37B | 7734 |
UBA52 | 7629 |
VPS37A | 7599 |
UBC | 7555 |
RPS27A | 5715 |
UBAP1 | 4820 |
VPS37D | 4542 |
MVB12A | 4044 |
TSG101 | 2732 |
VPS37C | 2725 |
VPS28 | 61 |
NMT2 | -759 |
MVB12B | -776 |
E3 ubiquitin ligases ubiquitinate target proteins
336 | |
---|---|
set | E3 ubiquitin ligases ubiquitinate target proteins |
setSize | 43 |
pANOVA | 1.68e-08 |
s.dist | 0.497 |
p.adjustANOVA | 4.03e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UBB | 8115 |
UBE2D2 | 8017 |
UBA52 | 7629 |
UBC | 7555 |
LEO1 | 7512 |
SELENOS | 7504 |
RNF152 | 7303 |
UBE2N | 7174 |
PEX5 | 7026 |
DERL1 | 7024 |
RNF144A | 7012 |
VCP | 6975 |
BCL10 | 6778 |
RAD18 | 6448 |
RRAGA | 6122 |
PCNA | 5826 |
RPS27A | 5715 |
UBE2L3 | 5619 |
UBE2J2 | 5443 |
RNF181 | 5236 |
GeneID | Gene Rank |
---|---|
UBB | 8115 |
UBE2D2 | 8017 |
UBA52 | 7629 |
UBC | 7555 |
LEO1 | 7512 |
SELENOS | 7504 |
RNF152 | 7303 |
UBE2N | 7174 |
PEX5 | 7026 |
DERL1 | 7024 |
RNF144A | 7012 |
VCP | 6975 |
BCL10 | 6778 |
RAD18 | 6448 |
RRAGA | 6122 |
PCNA | 5826 |
RPS27A | 5715 |
UBE2L3 | 5619 |
UBE2J2 | 5443 |
RNF181 | 5236 |
UBE2D3 | 5172 |
CDC73 | 5087 |
PEX13 | 4970 |
UBE2V2 | 4587 |
WAC | 4567 |
H2BC12 | 4348 |
RNF20 | 4107 |
UBE2E1 | 4101 |
PAF1 | 4093 |
PEX2 | 3907 |
PEX14 | 3616 |
UBE2A | 1908 |
PRKDC | 1492 |
UBE2B | 1348 |
PEX12 | 1230 |
RNF40 | 1214 |
RTF1 | 796 |
HLTF | 628 |
PEX10 | 386 |
UBE2D1 | 128 |
SHPRH | -681 |
TMEM129 | -1898 |
CTR9 | -2159 |
Diseases associated with glycosaminoglycan metabolism
304 | |
---|---|
set | Diseases associated with glycosaminoglycan metabolism |
setSize | 38 |
pANOVA | 3.78e-07 |
s.dist | 0.476 |
p.adjustANOVA | 5.33e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ACAN | 8463 |
CHSY1 | 8258 |
CHST6 | 7899 |
BGN | 7889 |
OMD | 7855 |
LUM | 7763 |
PAPSS2 | 7698 |
FMOD | 7680 |
GPC3 | 7664 |
SDC4 | 7646 |
ST3GAL3 | 7565 |
CHST3 | 7378 |
PRELP | 6934 |
OGN | 6830 |
VCAN | 6743 |
DCN | 6593 |
CSPG4 | 6533 |
SLC26A2 | 6018 |
EXT2 | 5603 |
CHST14 | 5060 |
GeneID | Gene Rank |
---|---|
ACAN | 8463 |
CHSY1 | 8258 |
CHST6 | 7899 |
BGN | 7889 |
OMD | 7855 |
LUM | 7763 |
PAPSS2 | 7698 |
FMOD | 7680 |
GPC3 | 7664 |
SDC4 | 7646 |
ST3GAL3 | 7565 |
CHST3 | 7378 |
PRELP | 6934 |
OGN | 6830 |
VCAN | 6743 |
DCN | 6593 |
CSPG4 | 6533 |
SLC26A2 | 6018 |
EXT2 | 5603 |
CHST14 | 5060 |
SDC1 | 4879 |
GPC4 | 4716 |
B4GALT1 | 4710 |
HEXB | 4427 |
GPC1 | 3402 |
B3GALT6 | 3089 |
KERA | 2893 |
HSPG2 | 1665 |
B4GALT7 | 1515 |
GPC2 | 1096 |
B3GAT3 | 998 |
GPC6 | 889 |
AGRN | 119 |
SDC3 | -509 |
HEXA | -2615 |
EXT1 | -3708 |
SDC2 | -5470 |
GPC5 | -5667 |
Chondroitin sulfate biosynthesis
189 | |
---|---|
set | Chondroitin sulfate biosynthesis |
setSize | 16 |
pANOVA | 0.00104 |
s.dist | 0.474 |
p.adjustANOVA | 0.00637 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CHSY3 | 8402 |
CHSY1 | 8258 |
BGN | 7889 |
CHST3 | 7378 |
CHPF | 6806 |
VCAN | 6743 |
DCN | 6593 |
CSPG4 | 6533 |
CSGALNACT2 | 6404 |
CSGALNACT1 | 5386 |
CHST11 | 4243 |
CHST7 | 2503 |
CHPF2 | 116 |
CHST15 | -2561 |
CHST12 | -2644 |
CHST13 | -4730 |
GeneID | Gene Rank |
---|---|
CHSY3 | 8402 |
CHSY1 | 8258 |
BGN | 7889 |
CHST3 | 7378 |
CHPF | 6806 |
VCAN | 6743 |
DCN | 6593 |
CSPG4 | 6533 |
CSGALNACT2 | 6404 |
CSGALNACT1 | 5386 |
CHST11 | 4243 |
CHST7 | 2503 |
CHPF2 | 116 |
CHST15 | -2561 |
CHST12 | -2644 |
CHST13 | -4730 |
Ubiquitin-dependent degradation of Cyclin D
1402 | |
---|---|
set | Ubiquitin-dependent degradation of Cyclin D |
setSize | 50 |
pANOVA | 1.11e-08 |
s.dist | 0.467 |
p.adjustANOVA | 2.86e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UBB | 8115 |
PSMB5 | 8014 |
CCND1 | 7976 |
PSMD8 | 7975 |
PSMC3 | 7701 |
UBA52 | 7629 |
PSMF1 | 7577 |
UBC | 7555 |
PSMB4 | 7524 |
PSMB7 | 7370 |
PSMD10 | 6932 |
PSMB6 | 6641 |
PSMD14 | 6413 |
PSMD9 | 6357 |
PSMD1 | 6241 |
PSMA5 | 6069 |
RPS27A | 5715 |
PSMC4 | 5408 |
PSMA7 | 5388 |
PSMD4 | 5382 |
GeneID | Gene Rank |
---|---|
UBB | 8115 |
PSMB5 | 8014 |
CCND1 | 7976 |
PSMD8 | 7975 |
PSMC3 | 7701 |
UBA52 | 7629 |
PSMF1 | 7577 |
UBC | 7555 |
PSMB4 | 7524 |
PSMB7 | 7370 |
PSMD10 | 6932 |
PSMB6 | 6641 |
PSMD14 | 6413 |
PSMD9 | 6357 |
PSMD1 | 6241 |
PSMA5 | 6069 |
RPS27A | 5715 |
PSMC4 | 5408 |
PSMA7 | 5388 |
PSMD4 | 5382 |
SEM1 | 5303 |
PSMD5 | 5248 |
PSMD13 | 5202 |
PSMA2 | 4818 |
PSMC1 | 4813 |
PSMD3 | 4701 |
PSMD2 | 4456 |
PSMC5 | 4430 |
CDK4 | 4259 |
PSMB8 | 4048 |
PSMB1 | 3958 |
PSMA1 | 3947 |
PSMD12 | 3831 |
PSMA4 | 3686 |
GSK3B | 3440 |
PSMB3 | 3372 |
PSMB9 | 3286 |
PSME3 | 2733 |
PSME4 | 2643 |
PSME1 | 2547 |
PSMD7 | 2501 |
PSMB2 | 382 |
PSMD11 | -161 |
PSMC2 | -702 |
PSMC6 | -1232 |
PSMD6 | -1811 |
PSMA3 | -2099 |
PSMA6 | -2513 |
PSMB10 | -2727 |
PSME2 | -3086 |
Pexophagy
856 | |
---|---|
set | Pexophagy |
setSize | 11 |
pANOVA | 0.00734 |
s.dist | 0.467 |
p.adjustANOVA | 0.0361 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UBB | 8115 |
UBA52 | 7629 |
UBC | 7555 |
PEX5 | 7026 |
EPAS1 | 6770 |
RPS27A | 5715 |
NBR1 | 5401 |
MAP1LC3B | 2819 |
USP30 | 240 |
SQSTM1 | -432 |
ATM | -5149 |
GeneID | Gene Rank |
---|---|
UBB | 8115 |
UBA52 | 7629 |
UBC | 7555 |
PEX5 | 7026 |
EPAS1 | 6770 |
RPS27A | 5715 |
NBR1 | 5401 |
MAP1LC3B | 2819 |
USP30 | 240 |
SQSTM1 | -432 |
ATM | -5149 |
ABC transporters in lipid homeostasis
3 | |
---|---|
set | ABC transporters in lipid homeostasis |
setSize | 12 |
pANOVA | 0.00518 |
s.dist | -0.466 |
p.adjustANOVA | 0.0272 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ABCA5 | -7727 |
ABCA7 | -7587 |
ABCA9 | -6982 |
ABCG1 | -6971 |
ABCD1 | -5219 |
ABCA10 | -5205 |
ABCA3 | -3280 |
ABCA6 | -2941 |
ABCA2 | -2022 |
ABCD3 | -1505 |
PEX19 | 2002 |
PEX3 | 5359 |
GeneID | Gene Rank |
---|---|
ABCA5 | -7727 |
ABCA7 | -7587 |
ABCA9 | -6982 |
ABCG1 | -6971 |
ABCD1 | -5219 |
ABCA10 | -5205 |
ABCA3 | -3280 |
ABCA6 | -2941 |
ABCA2 | -2022 |
ABCD3 | -1505 |
PEX19 | 2002 |
PEX3 | 5359 |
Assembly Of The HIV Virion
89 | |
---|---|
set | Assembly Of The HIV Virion |
setSize | 16 |
pANOVA | 0.00128 |
s.dist | 0.465 |
p.adjustANOVA | 0.00762 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UBB | 8115 |
FURIN | 7913 |
VPS37B | 7734 |
UBA52 | 7629 |
VPS37A | 7599 |
UBC | 7555 |
RPS27A | 5715 |
UBAP1 | 4820 |
VPS37D | 4542 |
MVB12A | 4044 |
TSG101 | 2732 |
VPS37C | 2725 |
VPS28 | 61 |
NMT2 | -759 |
MVB12B | -776 |
PPIA | -3451 |
GeneID | Gene Rank |
---|---|
UBB | 8115 |
FURIN | 7913 |
VPS37B | 7734 |
UBA52 | 7629 |
VPS37A | 7599 |
UBC | 7555 |
RPS27A | 5715 |
UBAP1 | 4820 |
VPS37D | 4542 |
MVB12A | 4044 |
TSG101 | 2732 |
VPS37C | 2725 |
VPS28 | 61 |
NMT2 | -759 |
MVB12B | -776 |
PPIA | -3451 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression
1429 | |
---|---|
set | YAP1- and WWTR1 (TAZ)-stimulated gene expression |
setSize | 11 |
pANOVA | 0.00788 |
s.dist | 0.463 |
p.adjustANOVA | 0.0382 |
Top enriched genes
GeneID | Gene Rank |
---|---|
WWTR1 | 8377 |
TEAD4 | 7887 |
TEAD3 | 7805 |
TEAD2 | 6435 |
YAP1 | 5253 |
RUNX2 | 3669 |
HIPK1 | 3433 |
TBX5 | 2969 |
TEAD1 | 1254 |
HIPK2 | 1055 |
KAT2B | -2826 |
GeneID | Gene Rank |
---|---|
WWTR1 | 8377 |
TEAD4 | 7887 |
TEAD3 | 7805 |
TEAD2 | 6435 |
YAP1 | 5253 |
RUNX2 | 3669 |
HIPK1 | 3433 |
TBX5 | 2969 |
TEAD1 | 1254 |
HIPK2 | 1055 |
KAT2B | -2826 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
734 | |
---|---|
set | NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 |
setSize | 12 |
pANOVA | 0.00633 |
s.dist | -0.455 |
p.adjustANOVA | 0.0315 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IKBKB | -7336 |
MAVS | -6622 |
TRIM25 | -6584 |
CASP8 | -6383 |
CASP10 | -4604 |
IKBKG | -4559 |
RNF135 | -4329 |
IFIH1 | -3538 |
RIPK1 | -1585 |
TRIM4 | -988 |
CHUK | -574 |
FADD | 6108 |
GeneID | Gene Rank |
---|---|
IKBKB | -7336 |
MAVS | -6622 |
TRIM25 | -6584 |
CASP8 | -6383 |
CASP10 | -4604 |
IKBKG | -4559 |
RNF135 | -4329 |
IFIH1 | -3538 |
RIPK1 | -1585 |
TRIM4 | -988 |
CHUK | -574 |
FADD | 6108 |
Cellular response to starvation
180 | |
---|---|
set | Cellular response to starvation |
setSize | 148 |
pANOVA | 2.05e-21 |
s.dist | 0.452 |
p.adjustANOVA | 1.11e-19 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ATF3 | 8509 |
RPL3 | 8213 |
RPLP0 | 8195 |
ATP6V0D2 | 8190 |
EIF2S2 | 8075 |
RPS19 | 7955 |
ATF4 | 7924 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
GeneID | Gene Rank |
---|---|
ATF3 | 8509 |
RPL3 | 8213 |
RPLP0 | 8195 |
ATP6V0D2 | 8190 |
EIF2S2 | 8075 |
RPS19 | 7955 |
ATF4 | 7924 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
RPL36 | 7508 |
RPL5 | 7478 |
RPS5 | 7459 |
RPS6 | 7412 |
RPS8 | 7411 |
LAMTOR5 | 7398 |
LAMTOR1 | 7315 |
ATP6V1H | 7289 |
RPL10A | 7231 |
RPS11 | 7228 |
SEC13 | 7222 |
RPS2 | 7195 |
FAU | 7160 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
RPL29 | 7044 |
RPL13 | 7009 |
RPL15 | 6959 |
RPL27A | 6925 |
ATP6V0C | 6914 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
RPL28 | 6643 |
CEBPB | 6582 |
RPS29 | 6566 |
RPL32 | 6545 |
RPL11 | 6445 |
RPL12 | 6436 |
RPS17 | 6407 |
ATP6V1D | 6384 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
RPL34 | 6202 |
RRAGA | 6122 |
RPS10 | 6082 |
FNIP2 | 6067 |
RPS15A | 6064 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
SH3BP4 | 5819 |
RPS4X | 5817 |
RPS27A | 5715 |
RPL30 | 5661 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
ATP6V1E1 | 5545 |
RPL14 | 5533 |
ATP6V1G1 | 5476 |
LAMTOR2 | 5422 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
RPL35A | 5123 |
RPL27 | 5077 |
RPS16 | 5037 |
RPL21 | 4774 |
RPL38 | 4758 |
BMT2 | 4729 |
RPL35 | 4688 |
RHEB | 4686 |
RPS20 | 4668 |
RPS14 | 4569 |
RPL24 | 4535 |
ATP6V1F | 4187 |
RPL36A | 3707 |
RPS27L | 3593 |
LAMTOR4 | 3299 |
ATP6V1E2 | 3296 |
LAMTOR3 | 3243 |
ATP6V0E1 | 2895 |
CEBPG | 2356 |
ATP6V1B2 | 2323 |
ATP6V1C2 | 2253 |
RPL22L1 | 2027 |
RPS4Y1 | 1834 |
MIOS | 1789 |
RPTOR | 1676 |
RPL9 | 1672 |
ATP6V1A | 1157 |
RRAGB | 1040 |
ATP6V1C1 | 997 |
IMPACT | 597 |
MLST8 | 414 |
SESN1 | 332 |
EIF2S3 | 281 |
RRAGD | -11 |
SEH1L | -225 |
ATP6V0B | -278 |
DEPDC5 | -349 |
TRIB3 | -1153 |
ATP6V0D1 | -1220 |
EIF2AK4 | -1649 |
NPRL3 | -2199 |
ATF2 | -2809 |
ASNS | -2937 |
SESN2 | -3406 |
ATP6V0E2 | -3595 |
RPS26 | -3603 |
MTOR | -3642 |
RRAGC | -3773 |
FNIP1 | -3789 |
ITFG2 | -4266 |
DDIT3 | -5113 |
SZT2 | -5363 |
TCIRG1 | -5371 |
WDR24 | -5420 |
GCN1 | -5596 |
SLC38A9 | -5791 |
WDR59 | -6064 |
NPRL2 | -6403 |
FLCN | -6490 |
KPTN | -6890 |
Regulation of activated PAK-2p34 by proteasome mediated degradation
1048 | |
---|---|
set | Regulation of activated PAK-2p34 by proteasome mediated degradation |
setSize | 48 |
pANOVA | 5.92e-08 |
s.dist | 0.452 |
p.adjustANOVA | 1.22e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UBB | 8115 |
PSMB5 | 8014 |
PSMD8 | 7975 |
PSMC3 | 7701 |
UBA52 | 7629 |
PSMF1 | 7577 |
UBC | 7555 |
PSMB4 | 7524 |
PSMB7 | 7370 |
PSMD10 | 6932 |
PSMB6 | 6641 |
PSMD14 | 6413 |
PSMD9 | 6357 |
PSMD1 | 6241 |
PSMA5 | 6069 |
RPS27A | 5715 |
PSMC4 | 5408 |
PSMA7 | 5388 |
PSMD4 | 5382 |
SEM1 | 5303 |
GeneID | Gene Rank |
---|---|
UBB | 8115 |
PSMB5 | 8014 |
PSMD8 | 7975 |
PSMC3 | 7701 |
UBA52 | 7629 |
PSMF1 | 7577 |
UBC | 7555 |
PSMB4 | 7524 |
PSMB7 | 7370 |
PSMD10 | 6932 |
PSMB6 | 6641 |
PSMD14 | 6413 |
PSMD9 | 6357 |
PSMD1 | 6241 |
PSMA5 | 6069 |
RPS27A | 5715 |
PSMC4 | 5408 |
PSMA7 | 5388 |
PSMD4 | 5382 |
SEM1 | 5303 |
PSMD5 | 5248 |
PSMD13 | 5202 |
PSMA2 | 4818 |
PSMC1 | 4813 |
PSMD3 | 4701 |
PSMD2 | 4456 |
PSMC5 | 4430 |
PSMB8 | 4048 |
PSMB1 | 3958 |
PSMA1 | 3947 |
PSMD12 | 3831 |
PSMA4 | 3686 |
PSMB3 | 3372 |
PSMB9 | 3286 |
PSME3 | 2733 |
PSME4 | 2643 |
PSME1 | 2547 |
PSMD7 | 2501 |
PAK2 | 1643 |
PSMB2 | 382 |
PSMD11 | -161 |
PSMC2 | -702 |
PSMC6 | -1232 |
PSMD6 | -1811 |
PSMA3 | -2099 |
PSMA6 | -2513 |
PSMB10 | -2727 |
PSME2 | -3086 |
The role of GTSE1 in G2/M progression after G2 checkpoint
1329 | |
---|---|
set | The role of GTSE1 in G2/M progression after G2 checkpoint |
setSize | 69 |
pANOVA | 8.45e-11 |
s.dist | 0.452 |
p.adjustANOVA | 2.81e-09 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CDKN1A | 8465 |
TUBB2A | 8415 |
TUBA4A | 8266 |
UBB | 8115 |
PSMB5 | 8014 |
PSMD8 | 7975 |
PSMC3 | 7701 |
UBA52 | 7629 |
PSMF1 | 7577 |
UBC | 7555 |
PSMB4 | 7524 |
TUBA1C | 7408 |
PSMB7 | 7370 |
MAPRE1 | 7099 |
HSP90AB1 | 7067 |
PSMD10 | 6932 |
PSMB6 | 6641 |
PSMD14 | 6413 |
PSMD9 | 6357 |
TUBA1B | 6282 |
GeneID | Gene Rank |
---|---|
CDKN1A | 8465 |
TUBB2A | 8415 |
TUBA4A | 8266 |
UBB | 8115 |
PSMB5 | 8014 |
PSMD8 | 7975 |
PSMC3 | 7701 |
UBA52 | 7629 |
PSMF1 | 7577 |
UBC | 7555 |
PSMB4 | 7524 |
TUBA1C | 7408 |
PSMB7 | 7370 |
MAPRE1 | 7099 |
HSP90AB1 | 7067 |
PSMD10 | 6932 |
PSMB6 | 6641 |
PSMD14 | 6413 |
PSMD9 | 6357 |
TUBA1B | 6282 |
TP53 | 6280 |
HSP90AA1 | 6254 |
PSMD1 | 6241 |
PSMA5 | 6069 |
TUBB4B | 5985 |
TUBAL3 | 5741 |
RPS27A | 5715 |
PSMC4 | 5408 |
PSMA7 | 5388 |
PSMD4 | 5382 |
SEM1 | 5303 |
PSMD5 | 5248 |
PSMD13 | 5202 |
TUBB2B | 4999 |
PSMA2 | 4818 |
PSMC1 | 4813 |
PSMD3 | 4701 |
PSMD2 | 4456 |
PSMC5 | 4430 |
PSMB8 | 4048 |
PSMB1 | 3958 |
PSMA1 | 3947 |
CCNB2 | 3944 |
PSMD12 | 3831 |
PSMA4 | 3686 |
TUBA1A | 3673 |
TUBB6 | 3486 |
PSMB3 | 3372 |
PSMB9 | 3286 |
TUBA8 | 2868 |
PSME3 | 2733 |
PSME4 | 2643 |
PSME1 | 2547 |
PSMD7 | 2501 |
TUBB3 | 2464 |
FKBPL | 1536 |
PSMB2 | 382 |
PSMD11 | -161 |
PSMC2 | -702 |
PSMC6 | -1232 |
PSMD6 | -1811 |
PSMA3 | -2099 |
PSMA6 | -2513 |
PSMB10 | -2727 |
CCNB1 | -2910 |
GTSE1 | -2915 |
PSME2 | -3086 |
CDK1 | -3637 |
PLK1 | -5099 |
HSF1 activation
518 | |
---|---|
set | HSF1 activation |
setSize | 25 |
pANOVA | 0.000104 |
s.dist | 0.449 |
p.adjustANOVA | 0.000819 |
Top enriched genes
GeneID | Gene Rank |
---|---|
HSPA1B | 8461 |
DNAJB1 | 8376 |
HSPA1A | 8314 |
UBB | 8115 |
HSP90AB1 | 7067 |
VCP | 6975 |
HSPH1 | 6800 |
YWHAE | 6747 |
PTGES3 | 6500 |
EEF1A1 | 6422 |
RPA1 | 6273 |
HSP90AA1 | 6254 |
HSF1 | 6136 |
FKBP4 | 6094 |
RPA3 | 5671 |
HSPA1L | 5508 |
SERPINH1 | 3620 |
MRPL18 | 2706 |
DNAJB6 | 751 |
RPA2 | -5 |
GeneID | Gene Rank |
---|---|
HSPA1B | 8461 |
DNAJB1 | 8376 |
HSPA1A | 8314 |
UBB | 8115 |
HSP90AB1 | 7067 |
VCP | 6975 |
HSPH1 | 6800 |
YWHAE | 6747 |
PTGES3 | 6500 |
EEF1A1 | 6422 |
RPA1 | 6273 |
HSP90AA1 | 6254 |
HSF1 | 6136 |
FKBP4 | 6094 |
RPA3 | 5671 |
HSPA1L | 5508 |
SERPINH1 | 3620 |
MRPL18 | 2706 |
DNAJB6 | 751 |
RPA2 | -5 |
HSBP1 | -656 |
DEDD2 | -864 |
HSPA6 | -2762 |
TNFRSF21 | -5590 |
HDAC6 | -6909 |
Translation
1368 | |
---|---|
set | Translation |
setSize | 290 |
pANOVA | 2.82e-39 |
s.dist | 0.447 |
p.adjustANOVA | 4.13e-36 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SSR4 | 8445 |
EPRS1 | 8330 |
RPL3 | 8213 |
RPLP0 | 8195 |
MRPL4 | 8139 |
SSR2 | 8090 |
EIF2S2 | 8075 |
RPS19 | 7955 |
MRPL17 | 7917 |
MRPL42 | 7902 |
EIF3I | 7883 |
EIF4EBP1 | 7864 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
MRPL12 | 7727 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
GeneID | Gene Rank |
---|---|
SSR4 | 8445 |
EPRS1 | 8330 |
RPL3 | 8213 |
RPLP0 | 8195 |
MRPL4 | 8139 |
SSR2 | 8090 |
EIF2S2 | 8075 |
RPS19 | 7955 |
MRPL17 | 7917 |
MRPL42 | 7902 |
EIF3I | 7883 |
EIF4EBP1 | 7864 |
RPS3 | 7856 |
RPL18 | 7818 |
EIF2S1 | 7768 |
RPL39 | 7733 |
MRPL12 | 7727 |
RPSA | 7653 |
UBA52 | 7629 |
RPL4 | 7626 |
RPL19 | 7605 |
RPL10 | 7586 |
RPL18A | 7585 |
RPL8 | 7546 |
EEF1B2 | 7515 |
RPL36 | 7508 |
SRP68 | 7501 |
RPL5 | 7478 |
SRPRA | 7477 |
EEF2 | 7470 |
RPS5 | 7459 |
MRPS24 | 7419 |
RPS6 | 7412 |
RPS8 | 7411 |
EEF1G | 7385 |
MRPL47 | 7372 |
KARS1 | 7371 |
EIF2B2 | 7334 |
EIF3H | 7284 |
MRPL24 | 7262 |
SRP54 | 7238 |
RPL10A | 7231 |
RPS11 | 7228 |
RPS2 | 7195 |
FAU | 7160 |
TARS1 | 7150 |
EIF3G | 7137 |
RPL41 | 7136 |
RPL17 | 7127 |
RPS15 | 7091 |
RPL37 | 7088 |
MRPL11 | 7085 |
RPL29 | 7044 |
MRPS33 | 7016 |
EIF3A | 7011 |
RPL13 | 7009 |
EEF1D | 6985 |
YARS1 | 6970 |
SARS1 | 6962 |
RPL15 | 6959 |
EIF4H | 6951 |
EEF1A1P5 | 6931 |
RPL27A | 6925 |
AURKAIP1 | 6902 |
RPN1 | 6897 |
NARS2 | 6866 |
RPL6 | 6845 |
RPS18 | 6831 |
RPS28 | 6826 |
MRPL51 | 6816 |
CHCHD1 | 6771 |
RPL37A | 6758 |
RPL7A | 6750 |
RPS13 | 6748 |
RPS12 | 6739 |
MRPL2 | 6712 |
MRPS15 | 6674 |
MRPL40 | 6663 |
IARS1 | 6655 |
RPL28 | 6643 |
SSR3 | 6579 |
EIF3C | 6567 |
RPS29 | 6566 |
RPL32 | 6545 |
EIF3L | 6537 |
MRPS22 | 6535 |
DDOST | 6522 |
RPL11 | 6445 |
RPL12 | 6436 |
EEF1A1 | 6422 |
RPS17 | 6407 |
RPL22 | 6352 |
RPL13A | 6349 |
RPL39L | 6344 |
RPL23 | 6332 |
RPLP1 | 6331 |
GADD45GIP1 | 6309 |
SEC11C | 6265 |
RPL34 | 6202 |
RPS10 | 6082 |
SEC61B | 6081 |
RPS15A | 6064 |
MRPL16 | 6029 |
RPS25 | 6009 |
RPS9 | 5958 |
RPS3A | 5952 |
RPS7 | 5915 |
RPS23 | 5904 |
SSR1 | 5894 |
EIF4B | 5889 |
DARS1 | 5879 |
RPL7 | 5858 |
RPS27 | 5857 |
RPS24 | 5845 |
RPS4X | 5817 |
MRPL50 | 5789 |
GSPT1 | 5769 |
MRPL49 | 5719 |
RPS27A | 5715 |
AARS1 | 5686 |
RPL30 | 5661 |
GARS1 | 5647 |
RPL31 | 5636 |
RPL36AL | 5631 |
RPL26L1 | 5604 |
RPL23A | 5596 |
ETF1 | 5555 |
MRPL14 | 5551 |
TUFM | 5550 |
EIF3F | 5549 |
RPL14 | 5533 |
MRPL28 | 5516 |
MRPL53 | 5474 |
MRPL55 | 5444 |
EIF3E | 5427 |
MRPS23 | 5397 |
RPS21 | 5369 |
RPLP2 | 5242 |
RPL26 | 5239 |
MRPL52 | 5237 |
MRPL54 | 5191 |
MRPS16 | 5150 |
RPL35A | 5123 |
MRPS17 | 5092 |
RPL27 | 5077 |
RPS16 | 5037 |
MRPL46 | 4997 |
SEC11A | 4959 |
EIF3D | 4876 |
MRPS12 | 4822 |
RPL21 | 4774 |
RPL38 | 4758 |
EIF4G1 | 4736 |
MRPS7 | 4720 |
RPL35 | 4688 |
SRPRB | 4673 |
RPS20 | 4668 |
MRPL41 | 4605 |
RPS14 | 4569 |
RPL24 | 4535 |
EIF2B3 | 4528 |
MRPL13 | 4512 |
PPA1 | 4507 |
MRPS30 | 4484 |
MRPL34 | 4466 |
MRPS18C | 4431 |
MRPS21 | 4309 |
MRPL37 | 4291 |
TRMT112 | 4285 |
MRPL36 | 4258 |
MRPS2 | 4253 |
MRPS10 | 4250 |
MRPL22 | 4224 |
MTRF1L | 4168 |
CARS1 | 4126 |
MRPL38 | 4116 |
TSFM | 4108 |
MRPL44 | 4075 |
RARS2 | 4036 |
EIF4A1 | 4003 |
MRPL58 | 3959 |
MRPS34 | 3901 |
MRPS6 | 3834 |
AIMP2 | 3773 |
RPL36A | 3707 |
MRPL21 | 3688 |
MRPS11 | 3624 |
RPS27L | 3593 |
LARS2 | 3566 |
MRPS27 | 3541 |
FARS2 | 3536 |
YARS2 | 3527 |
MRPL57 | 3395 |
MRPL15 | 3316 |
MRPS18A | 3295 |
DAP3 | 3291 |
SPCS2 | 3211 |
MRPL23 | 3204 |
MARS2 | 3059 |
RPN2 | 3032 |
MRPS26 | 2957 |
EIF3M | 2905 |
MRPL18 | 2706 |
PPA2 | 2698 |
EEF1E1 | 2660 |
MRPL48 | 2629 |
RARS1 | 2511 |
MRPL9 | 2476 |
FARSB | 2403 |
TRAM1 | 2399 |
HARS1 | 2371 |
MRPL39 | 2351 |
MRPL20 | 2305 |
EIF3J | 2286 |
MRPL33 | 2281 |
SRP72 | 2191 |
EIF4A2 | 2172 |
PABPC1 | 2170 |
EIF3K | 2031 |
RPL22L1 | 2027 |
MTFMT | 1943 |
RPS4Y1 | 1834 |
MRPS31 | 1698 |
SPCS3 | 1674 |
RPL9 | 1672 |
MRPL32 | 1606 |
MRPL3 | 1553 |
MRPS28 | 1513 |
MRPL30 | 1371 |
WARS1 | 1273 |
MRPS36 | 1094 |
EIF3B | 1081 |
SRP14 | 1061 |
MRPS14 | 973 |
MRPS18B | 912 |
SEC61A1 | 892 |
MRPL19 | 890 |
EIF4E | 687 |
MRPL45 | 609 |
CARS2 | 603 |
GFM1 | 602 |
SEC61G | 572 |
MRPS9 | 451 |
EIF5 | 366 |
EIF2S3 | 281 |
APEH | 278 |
GSPT2 | 170 |
IARS2 | 51 |
MRPL43 | 3 |
EIF5B | -22 |
MRPL27 | -117 |
EIF2B4 | -157 |
MRPL10 | -218 |
GFM2 | -260 |
SPCS1 | -729 |
SRP19 | -842 |
EARS2 | -878 |
AIMP1 | -1096 |
SRP9 | -1159 |
FARSA | -1210 |
TARS2 | -1902 |
NARS1 | -1909 |
WARS2 | -2079 |
MRPL1 | -2088 |
EIF1AX | -2134 |
MARS1 | -2232 |
MTIF3 | -2371 |
MRPS35 | -2621 |
MRRF | -2642 |
SARS2 | -3353 |
QARS1 | -3397 |
MRPL35 | -3433 |
RPS26 | -3603 |
PARS2 | -3634 |
ERAL1 | -3685 |
EIF2B5 | -3891 |
DARS2 | -3956 |
LARS1 | -4201 |
EIF2B1 | -4304 |
VARS1 | -4381 |
SEC61A2 | -5327 |
MRPS25 | -5408 |
MTIF2 | -5535 |
AARS2 | -5611 |
PTCD3 | -5666 |
OXA1L | -6182 |
MRPS5 | -6216 |
VARS2 | -6872 |
HARS2 | -7188 |
N6AMT1 | -7350 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.3.2 (2023-10-31)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
##
## locale:
## [1] LC_CTYPE=en_AU.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_AU.UTF-8 LC_COLLATE=en_AU.UTF-8
## [5] LC_MONETARY=en_AU.UTF-8 LC_MESSAGES=en_AU.UTF-8
## [7] LC_PAPER=en_AU.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_AU.UTF-8 LC_IDENTIFICATION=C
##
## time zone: Australia/Melbourne
## tzcode source: system (glibc)
##
## attached base packages:
## [1] stats4 stats graphics grDevices utils datasets methods
## [8] base
##
## other attached packages:
## [1] pkgload_1.3.3 GGally_2.2.0
## [3] beeswarm_0.4.0 gtools_3.9.5
## [5] echarts4r_0.4.5 kableExtra_1.3.4
## [7] topconfects_1.18.0 limma_3.58.1
## [9] eulerr_7.0.0 mitch_1.14.0
## [11] MASS_7.3-60 fgsea_1.28.0
## [13] gplots_3.1.3 DESeq2_1.42.0
## [15] SummarizedExperiment_1.32.0 Biobase_2.62.0
## [17] MatrixGenerics_1.14.0 matrixStats_1.2.0
## [19] GenomicRanges_1.54.1 GenomeInfoDb_1.38.5
## [21] IRanges_2.36.0 S4Vectors_0.40.2
## [23] BiocGenerics_0.48.1 reshape2_1.4.4
## [25] lubridate_1.9.3 forcats_1.0.0
## [27] stringr_1.5.1 dplyr_1.1.4
## [29] purrr_1.0.2 readr_2.1.4
## [31] tidyr_1.3.0 tibble_3.2.1
## [33] ggplot2_3.4.4 tidyverse_2.0.0
## [35] zoo_1.8-12 R.utils_2.12.3
## [37] R.oo_1.25.0 R.methodsS3_1.8.2
##
## loaded via a namespace (and not attached):
## [1] bitops_1.0-7 gridExtra_2.3 rlang_1.1.2
## [4] magrittr_2.0.3 compiler_4.3.2 systemfonts_1.0.5
## [7] vctrs_0.6.5 rvest_1.0.3 pkgconfig_2.0.3
## [10] crayon_1.5.2 fastmap_1.1.1 XVector_0.42.0
## [13] ellipsis_0.3.2 caTools_1.18.2 utf8_1.2.4
## [16] promises_1.2.1 rmarkdown_2.25 tzdb_0.4.0
## [19] xfun_0.41 zlibbioc_1.48.0 cachem_1.0.8
## [22] jsonlite_1.8.8 highr_0.10 later_1.3.2
## [25] DelayedArray_0.28.0 BiocParallel_1.36.0 parallel_4.3.2
## [28] R6_2.5.1 bslib_0.6.1 stringi_1.8.3
## [31] RColorBrewer_1.1-3 jquerylib_0.1.4 assertthat_0.2.1
## [34] Rcpp_1.0.11 knitr_1.45 httpuv_1.6.13
## [37] Matrix_1.6-4 timechange_0.2.0 tidyselect_1.2.0
## [40] rstudioapi_0.15.0 abind_1.4-5 yaml_2.3.8
## [43] codetools_0.2-19 lattice_0.22-5 plyr_1.8.9
## [46] shiny_1.8.0 withr_2.5.2 evaluate_0.23
## [49] ggstats_0.5.1 xml2_1.3.6 pillar_1.9.0
## [52] KernSmooth_2.23-22 generics_0.1.3 RCurl_1.98-1.13
## [55] hms_1.1.3 munsell_0.5.0 scales_1.3.0
## [58] xtable_1.8-4 glue_1.6.2 tools_4.3.2
## [61] data.table_1.14.10 webshot_0.5.5 locfit_1.5-9.8
## [64] fastmatch_1.1-4 cowplot_1.1.2 grid_4.3.2
## [67] colorspace_2.1-0 GenomeInfoDbData_1.2.11 cli_3.6.2
## [70] fansi_1.0.6 viridisLite_0.4.2 S4Arrays_1.2.0
## [73] svglite_2.1.3 gtable_0.3.4 sass_0.4.8
## [76] digest_0.6.33 SparseArray_1.2.3 htmlwidgets_1.6.4
## [79] htmltools_0.5.7 lifecycle_1.0.4 httr_1.4.7
## [82] statmod_1.5.0 mime_0.12
END of report